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Myelodysplastic syndrome (MDS) a clonal disease arising from the mutation of the 
haematopoietic stem cells is characterized by the presence of peripheral blood 
cytopenias, dysplastic haematopoietic differentiation and transformation to acute 
myeloid leukaemia (AML). Defects in the DNA damage repair pathway in MDS and 
AML give rise to chromosomal instability (CI) such as aneuploidy, chromosomal 
translocation and loss of heterozygosity (LOH) a hallmark of human neoplasm. 
Cohesin a multiprotein complex responsible for tethering the sister chromatids 
together until their timely separation in mitosis has been linked with the phenomena 
of chromosomal instability. In this study, second generation sequencing (SGS) was 
performed in a panel of 154 MDS patients to characterize the incidence and 
functional consequences of cohesin mutations in myeloid malignancies. This led to 
the identification of mutations in three components of cohesin ring in 6% (9/154) of 
the patients with maximum number of mutations identified in STAG2. None of the 
patients with cohesin aberrations had a TP53 mutation and all the patients with 
cohesin mutations showed a significant progression free survival. Four of the 
patients showed co-existing mutations in ASXL1 (an epigenetic regulator) and 
SRSF2 (pre-mRNA splicing factor). 
To elucidate the functional consequences of STAG2 mutations and the possibility for 
it to be exploited synthetically as a target for therapeutic intervention two cell lines; 
a myeloid cell line, U937 with a stable knockdown of STAG2 and a urinary bladder 
cell line, UMUC3 with mutated STAG2 were used to study the effect of loss of 
STAG2 on homologous recombination (HR) repair of DNA, cell cycle kinetics and 
viability in response to DNA repair pathway inhibitors such as inhibitors of poly-
ADP-ribose (PARP) and effect on the expression of other members of the cohesin  
 5 
 
complex. Knockdown of STAG2 had no effect on the recruitment of RAD51 a 
marker for HR, cell cycle kinetics and viability in response to treatment with PARP 
inhibitors. Further no effect on the expression of other members of the cohesin 
complex was observed upon knockdown of STAG2. The results from this study 
speculate STAG2 as a candidate which has a role to play in the pathogenesis of MDS 
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1.! Chapter One 
                       INTRODUCTION  
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1.1! Myelodysplastic Syndrome 
Myelodysplastic syndromes (MDSs) are a group of clonal haematopoietic stem cell 
disorders characterized by ineffective haemopoiesis and transformation to acute 
myeloid leukaemia (AML). The sequel of MDS results from underlying cytopenias 
and includes thrombocytopenia, neutropenia and anaemia. The incidence of MDS 
increases with age and the median age at diagnosis is 70-75 years (Scott and Deeg, 
2010). There is increasing evidence that haploinsufficiency, mutations of 
splicesome and epigenetic genes as well as abnormalities in cytokines, the immune 
system and bone marrow stroma all contribute to the development of the full 
spectrum of Myelodysplastic syndromes.  
1.2! Classification 
Over the years, several MDS classification and prognostic scoring system have 
been developed to predict the survival or transition to AML, as the prognosis of 
MDS is highly variable.  (Bennett et al., 1982, Mufti et al., 2008, Tefferi and 
Vardiman, 2009). The French-American-British (FAB) diagnostic schema has been 
largely supplemented by the World Health Organization (WHO) 2001 criteria 
(Table 1.1). The revision included lowering the threshold for the percentage of 
blasts required to make the diagnosis of AML from 30% to 20% thus elimination of 
the MDS subcategory of refractory anaemia with excess blasts in transformation 
(RAEB-T). In addition chronic myelomonocytic leukaemia (CMML) was 
reclassified from a subcategory of MDS to a subcategory of myelodysplastic 
/myeloproliferative disorder. A revised updated version of WHO classification of 
MDS came out in 2016 with a small number of changes. In low risk MDS RCMD-
RS RS has been removed from RCMD to recognize the importance of SF3B1 
mutations. The general term myelodysplastic syndrome has been associated with 
single or multilineage dysplasia as the type of dysplasia and cytopenia are not 
 18 
always concordant. To emphasize the importance of the percentage of blasts that 
dictate therapy in high risk patients the term Refractory anaemia with excess blasts 
1 and 2 have been replaced by myelodysplastic syndrome excess blast 1 and 2.  
 19 
Table 1.1: WHO diagnostic classification of Myelodysplastic Syndrome 
 
The International Prognostic Scoring System (IPSS) was developed by Greenberg 
et al 1997 to provide an improved method for evaluating prognosis in MDS. 






Bone marrow findings 
Refractory anaemia (RA) Anaemia 
No or rare blasts 
Erythroid dysplasia only 
<5% blasts 
<15% ringed sideroblast 
Refractory anaemia with 
ringed sideroblasts (RARS) 
Anaemia 
No blasts 
Erythroid dysplasia only 
≥ 15% ringed 
sideroblasts 
<5% blasts 






No or rare blasts 
No Auer rods 
<1×109/L of 
monocytes 
Dysplasia in ≥10% of 
cells in 2 or more 
myeloid cell lines. 
<5% of blasts in the 
marrow 
No Auer rods 
<15% ringed 
sideroblasts 
Refractory cytopenia with 






No or rare blasts 
No Auer rods 
<1 × 109/L of 
monocyte 
Dysplasia in ≥10% of 
cells in two or more 




No Auer rods 




No Auer rods 




5% to 9% blasts 
No Auer rods 
Refractory anaemia with 
excess blasts-2 
Cytopenias 
5% to 19% blasts 
Auer rods ± 




10% to 19% blasts 





No or rare blasts 
No Auer rods 




No Auer rods 
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and number of cytopenia offered prognostic information and divided patients into 
four risk categories Low, Intermediate-1 (INT-1), Intermediate-2 (INT-2), and High 
(Greenberg et al., 1997) (Table 1.2). 
Table 1.2: IPSS Prognostic Scoring System (IPSS) classification criteria. (a) 
Good, normal, -Y, del (5q), del(20q); Poor, complex (≥ 3 abnormalities) or 
chromosome 7 anomalies; Intermediate, other abnormalities. (b) Age related survival 







Limitations of IPSS was the exclusion of patients with secondary MDS and 
inability to estimate the real time risk as only the variables present at the time of 
diagnosis were included. The IPSS was revised in 2012 to IPSSR. The novel 
components included 5 rather than 3 cytogenetic prognostic subgroups, splitting the 
lower marrow blast percentage value and depth of cytopenias. As compared to 
Score      
Prognostic variable 0 0.5 1 1.5 2 
Bone marrow blasts % <5 5-10  11-20 21-30 
Karyotype Good Intermediate Poor   
Cytopenias 0 to1 2 to3    




0 Low 5.7 9.4 
0.5-1 INT-1 3.5 3.3 
1.5-2 INT-2 1.2 1.1 
≥ 2.5 High 0.4 0.2 
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IPSS, this model defined 5 major prognostic categories rather than four: Very low, 
Low, Intermediate, High, Very high (Table 1.3). 
Table 1.3: IPSS Prognostic Scoring System Revised (IPSSR) classification criteria. 
(a) (Very good, -Y, del(11q); Good, Normal, del(5q), del(12p), del(20q), double 
including del(5q); Intermediate del(7q), +8, +19, i(17q), any other single or double 
independent clones; Poor -7 inv(3)/t(3q)/del(3q), double including -7/del(7q) complex: 
3 abnormalities; Very poor Complex: >3 abnormalities. (b) Age related survival and 






1.2.1! Cytogenetic Abnormalities 
Cytogenetic abnormalities are the major determinants in the pathogenesis, 
diagnosis, and prognosis in MDS and are increasingly becoming the basis of drug 
selection in the treatment of MDS. Chromosomal abnormalities are seen in 50% of 
Prognostic 
variable 
0 0.5 1 1.5 2 3 4 
Cytogenetics Very 
good 
- Good - Intermediate Poor Very 
poor 
BM blast% ≤ 2% - >2%-
<5% 
- 5%-10% ≥10% - 
Haemoglobin 
g/dL 
≥ 10 - 8-< 10 <8 - - - 
Platelets ≥100 50-< 100 < 50 - - - - 
ANC (Absolute 
neutrophil 
count) × 109/L 
≥ 0.8 < 0.8 - - - - - 
Score Risk group Median survival (yr) AML evolution (yr) 
≤ 1.5 Very Low 8.8 NR 
> 1.5-3 Low 5.3 10.8 
> 3-4.5 Intermediate 3.0 3.2 
> 4.5-6 High 1.6 1.4 
> 6 Very High 0.8 0.73 
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patients with primary MDS and 80% of cases with therapy related MDS. 
Cytogenetics plays an important role on the outcome of patients with MDS and 
AML undergoing haematopoietic stem cell transplant. In AML and chronic 
myelogenous leukaemia (CML) balanced cytogenetic abnormalities like reciprocal 
translocation, inversion and insertion are common while unbalanced chromosomal 
abnormalities such as gain or loss of chromosome are common in MDS. 
Cytogenetic abnormalities are important because chromosomal regions contain 
genes that are important in MDS biology and abnormalities such as chromosomal 
deletions show that haploinsufficiency or loss of tumour suppressor genes (TSG) 
are important in MDS pathogenesis. 
1.2.2! Chromosome 5q deletion 
In patients with MDS, deletion of 5q (5q-) is the most common cytogenetic 
abnormality with an incidence of 15% with isolated 5q- being usually associated 
with a favourable prognosis. 5q- deletions are universally heterozygous. Two 
commonly deleted regions (CDRs) 5q33.1 and 5q31 have been found in patients 
with deletion of 5q-. 5q33.1 is the most distal CDR associated with a phenotype 
called 5q- syndrome and is characterized with macrocytic anaemia, relative 
thrombocythemia, female predominance and good prognosis while the proximal 
CDR at 5q31 is associated with therapy-related MDS and is associated with poor 
prognosis (Van den Berghe et al., 1974). Many genes are localised to the deleted 
regions on chromosome 5q. In the last decade significant progress has been made to 
unravel the molecular mechanism of 5q-syndrome. Using a RNA-mediated 
interference (RNAi) based approach in CD34+ cells Ebert et al found 
haploinsufficiency of ribosomal protein S14 (RPS 14) a component of 40S  
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ribosomal subunit located on 5q32/33 CDR to be associated with the development 
of anaemia that characterizes the 5q-syndrome (Ebert et al., 2008). However 
haploinsufficiency of RPS 14 alone does not recapitulate all the features of 5q- 
syndrome and thrombocytosis observed in some patients with 5q-syndrome has 
been linked to deficiency of two microRNA genes miR-145 and miR-146a that map 
within and adjacent to CDR (Kumar, 2009, Starczynowski et al., 2010). Narrowing 
down of the CDR in the 5q- syndrome to 1.5 Mb at 5q32 was made by Boultwood 
et al. In this study reduced gene expression approximating to haploinsufficiency 
was found in CD34+ cells of several candidate genes and included RPS 14, secreted 
protein acidic and rich in cysteine (SPARC) a tumour suppressor protein and casein 
kinase 1 alpha 1 (CSNK1A1) a family of serine threonine kinases which play an 
important role in regulation of hedgehog signalling by governing cell growth and 
patterning in animal development (Boultwood et al., 2002). Further Lia et al 
identified 1-1.5 Mb CDR at 5q31 in AML and advanced MDS, which is different 
from the CDR of 5q- syndrome. The CDR at 5q31 encompasses several genes like 
Early growth response gene (EGR1) a transcriptional factor and Alpha catenin 
(CTNNA1) a putative tumor suppressive gene (TSG) (Lai et al., 2001, Joslin et al., 
2007). Deletions of 5q are not restricted to CDR but encompass both of these 
regions and beyond. NPM1 (Nucleophosmin 1) and APC (Anaphase promoting 
complex) are other genes found outside the CDR and are often lost with deletions of 
5q (Grisendi et al., 2005, Wang et al., 2010). Deletion of some genes may not be 
involved in MDS but could sensitize cells to therapeutic agents like lenalidomide. 
Two cell cycle regulating phosphatases like cell division cycle 25C (CDC25C) and 
protein phosphatase 2 (PP2A) have been implicated in the favourable response to 
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lenalidomide (Wei et al., 2009). 5q- syndrome is also considered as a disease of 









Figure 1.1: Mapping of CDR region on chromosome 5. Location of commonly deleted 
regions (CDR) on long arm of chromosome 5 in humans. Major genes like RPS14 a 
component of 40s ribosomal subunit which is associated with 5q syndrome is located 
on distal arm at position 5q32/33 while the proximal arm contain genes like early 
growth response factor 1 a  transcriptional factor (EGRFR1) and a phosphatase cell 
division cycle 25 (CDC25C). 
 
Two studies carried out showed the involvement of B cells in the development of 
del5q- syndrome (Jaju et al., 2000, Nilsson et al., 2000). One of the three cases of 
5q- syndrome in the study conducted by Jaju et al showed involvement of B cell. 
Work undertaken by Nilsson et al demonstrated that one out of nine patients in his 
cohort had B-cell involvement in all the patients, a minimum of 94% of cells in 
undifferentiated CD34+CD38- were 5q- and in 3 of 5 patients 5q- aberrations were 
found in a large fraction of CD34+CD19+ proB cells suggesting that a lympho 
myeloid is the primary target in 5q- deletions and that 5q- represent an early event 
in MDS pathogenesis. 
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1.2.3! Chromosome 7 and 7q deletions 
Monosomy 7 or interstitial loss of 7q, unlike isolated 5q- is associated with poor 
prognosis. Either in isolation or part of a complex karyotype, about 10% of patients 
carry abnormality of chromosome 7 and this frequency increases to 50% in tMDS 
patients having a history of treatment with alkylating agents (Christiansen et al., 
2004). Several commonly deleted regions have been mapped for chromosome 7q 
deletions (7q21, 7q22, 7q32-33, 7q35-36) but the underlying molecular lesions have 
not been characterised (Asou et al., 2009, Le Beau et al., 1996). EZH2 gene located 
on chromosome 7q36 is found to be mutated in patients with -7/7q deletions and 
alter the epigenetic state of haematopoietic stem cells. Conditional heterozygous 
deletion of a 2.5 kb region in murine hematopoietic stem cells to a region syntenic 
to human 7q22 showed no phenotype indicating that this region does not occupy a 
tumor suppressor gene (Wong et al., 2010).  
1.2.4! Trisomy 8 
Present as a sole abnormality in approximately 8% of the patients, trisomy 8 is the 
only recurrent observed chromosomal amplification. It is seen as an intermediate  
cytogenetic abnormality. The life span of patients with +8 is less than half the 
median expected survival of patients with normal karyotype. However young 
patients with refractory anaemia of short duration, having a sole +8 abnormality and 
carrying HLADR15 respond well to immunotherapy (Sloand et al., 2008). Patients 
with +8 MDS often have expansion of Vβ restricted CD8+ T cells which returns to a 
normal polyclonal distribution after immunosuppressant therapy but bone marrow 
examination shows persistence and even expansion of +8 clone suggesting that the 
immune system targets diseased cells and as a consequence impairs normal 
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haemopoiesis. Trisomy 8 cells show high level of antiapoptotic genes and are 
resistant to irradiation compared to normal cells (Lim et al., 2007). 
1.2.5 Other Chromosomal Abnormalities 
Chromosomal lesions like del Y, 20q-, 3q26 have been found in MDS.  Both –Y 
and 20q are considered to be in the same favourable cytogenetic risk group as 
patients with a normal karyotype. There is no relationship of loss of chromosome Y 
with disease pathogenesis while interstitial loss of 20q does appear to be pathogenic 
not only in MDS but also myeloproliferative disorders and AML (Wiktor et al., 
2000). 19 genes have been deduced from the 20q CDR of patients with MDS and 
AML but none of them is involved in pathogenesis of disease (Bench et al., 2000, 
Wang et al., 2000). Both of the chromosomal lesions are useful for confirming the 
presence of clonal haemopoiesis and response to treatment but neither lesions are 
sufficient to make the diagnosis. Recurrent translocation and inversions of 3q26 
have been associated with poor prognosis in AML and rare cases of MDS. 
Breakpoints typically include MDS1-EVI1 (MECOM) gene locus (Poppe et al., 
2006). 
1.2.6! SNP (Single Nucleotide Polymorphism) Karyotyping 
Various DNA based array technologies have been introduced to facilitate the 
distinction between a normal and malignant genome. Although metaphase 
cytogenetics has been the gold standard and has been reliably used in clinical 
karyotyping, it has its limitations. It is time consuming and technically demanding. 
Its sensitivity is low as it depends on the proportion of clonal cells in the tested 
samples and resolution depends on the location of the lesion with regards to 
banding pattern. The need for cellular proliferation to obtain metaphase spreads is a 
limitation because a significant number shows no cell division. Most importantly 
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metaphase cytogenetics (MC) cannot detect  Acquired somatic Uniparental Disomy 
(AS-UPD) (Tiu et al., 2011). High resolution genome wide techniques such as SNP 
genotyping arrays can detect chromosomal microdeletions and areas of copy neutral 
loss of heterozygosity (CN-LOH) also known as acquired uniparental disomy 
(UPD). The first study using SNP arrays in a cohort of 119 low risk MDS was 
performed by Mohamedali et al in 2007. The study showed greater than 2 Mb of 
UPD in 46% of patients with the most prominent UPD found on chromosome 4 
(Mohamedali et al., 2007). A multicentre international collaboration was formed to 
study the clinical applicability and prognostic significance of combining MC and 
SNP-A in a large cohort of 430 patients with MDS (n=250), MDS/MPN (n=95) and 
sAML (n=85). Combining SNP-A with MC, chromosomal lesions were identified 
in 74% of patients as compared to 44% with MC alone. Survival outcomes (Overall 
survival, progression free survival and event free survival) were poor in patients 
whose chromosomal lesions were detected by combining SNP-A and MC than with 
MC alone. A similar observation in survival outcomes was seen in patients with low 
risk disease when classified according to WHO criteria. Worse overall survival was 
also found in low risk patients with additional SNP defects than with patients with 
no additional defects when classified according to the International Prognostic 
Scoring System (IPSS) (Tiu et al., 2011). Many novel gene mutations have been 
detected by SNP array technology because regions having UPD are associated with 
genes that are often mutated which include TET2 in MDS/MPN, CBL in CMML, 
EZH2 in MDS, CMML and AML.  
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1.3! Genetic Mutations 
Tumorigenesis is a multistep process that involves irreversible genetic alterations in 
the DNA sequence such as mutation, deletion and translocations that contribute to 
progressive transformation of normal cells to malignant cells (Fig 1.2). The term 
epigenetics refers to the heritable component of cellular phenotype that are not 
mediated by changes in the genomic DNA sequence (Bejar et al., 2011a) 
Methylation of cytosine residues and covalent modification of histones are the most 
relevant molecular mediators of the epigenetic state. 
DNA methylation at cytosine that precedes a guanosine in CpG dinucleotide 
represents a crucial epigenetic modification. Methylation occurs at the 5C position 
of pyrimidine ring and is catalysed by DNA methyl transferases (DNMTs) resulting 
in the formation of 5-methyl cytosine. If the deamination of cytosine to form the 
base thymidine is not recognised and repaired, a cytosine to thymidine change 
remains resulting in depletion of CpG dinucleotides. However small (0.5kb to 
several kb) stretches of CpG rich regions termed CpG islands are found in the 
promoter regions of approximately half of the genes and are unmethylated, that 
does not interfere with gene expression. The exception to the unmethylated states of 
CpG island are silenced gene alleles coding for imprinted genes and genes 





Figure 1.2: Point mutations in MDS. Percentage of mutations in genes found in  
different pathways that are involved in the pathogenesis of MDS. A pair of 
genes could show a tendency of either cooccurence or mutual exclusivity. 
Functional redundancy is implied by mutually exclusive gene pair especially if 
they occur in the same pathway. Members of the splicing machinery occur 
exclusive to one another; mutual exclusivity is also seen between TET2 and 
IDH2 although both of them are linked to disordered hypomethylation. On the 
other hand mutations in DNMT3 are found to co-occur with SF3B1 and of 
ASXL1 with EZH1. 
 
The fundamental repeating unit of chromatin is the nucleosome that consists of 146 
bp of DNA wrapped around an octamer of core histone proteins H2A, H2B, H3 and 
H4. The histone tails are subjected to post translational modification that play an 
important role in controlling and maintaining chromatin structure and are also the 
sites of epigenetic modification. Acetylation of histones by histone acetyl 
transferases (HAT) is associated with nucleosome modelling and transcriptional 
activation while deacetylation by histone deacetylases (HDAC) represents 
chromatin condensation and transcriptional repression. Another modification of 
histones is methylation carried by various histone methyl transferases, which can 
act as marker of activation as well as repression.Two critical methylation events 
such as H3K9 and H3K27 methylation on the N-terminus of H3 are markers of 
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transcription silencing and inactivation, whilst methylation of H3K4 is found near 
the open chromatin structures of active genes (Galm et al., 2006). 
1.3.1! Epigenetic modifiers gene mutations 
EZH2 (Enhancer of zeste homolog 2) is a gene involved in epigenetic regulation 
and is mutated in 6% of MDS cases and over 10% of MDS/MPN overlap. EZH2 
gene is located on Chr. 7q36.1 and codes for a histone methyl transferase that forms 
the catalytic subunit of the polycomb repressor complex 2 (PRC2). di and 
trimethylation of lysine 27 on histone 3 catalysed by the PRC2 complex is an 
epigenetic marker for transcriptional repression. In solid tumors, high expression of 
EZH2 is associated with aggressive disease and worst outcomes. EZH2 is often 
mutated in myeloid malignancies resulting in the loss of the catalytic subunit and 
loss of PRC2 function leading to an increase in stem cell renewal and 
differentiation. Truncated mutations occur throughout the gene while missense 
mutations are usually clustered in the C-terminal catalytic SET (suppressor of 
variegation, enhancer of zeste, trithorax) domain, and also in the cysteine-rich and 
SANT (switch-defective protein 3, adaptor 2, nuclear receptor corepressor, 
transcription factor) domains. The mutations are hemizygous (loss of one allele) or 
biallelic (via microdeletions of 7q or UPD) in most cases (Makishima et al., 2010, 
Nikoloski et al., 2010). EZH2 Y641 codon is frequently mutated in follicular and 
diffuse large B-cell lymphomas, but not in MDS. In vitro studies have shown that 
EZH2 mutations found in MDS patients results in loss of function (leading to 
reduced H3K27 trimethylation). EZH2 mutations are associated with poor survival. 
The H3K27 methylation mark recruits DNMT3 to site of de novo methylation 




Mutations in additional sex-comb like-1’ (ASXL1) gene located on chromosome 
20q11.1 have been described in roughly 10% of MDS and MPN, 17% of AML and 
>40% of patients with CMML (Boultwood et al., 2010, Gelsi-Boyer et al., 2009). 
ASXL1 belongs to a three-member family of enhancers of trithorax and polycomb 
proteins (ASXL1, 2, 3). It encodes a chromatin binding protein involved in 
epigenetic regulation and is responsible for recruiting polycomb and trithorax 
complexes to specific loci. ASXL1 protein has two domains, a plant homeo domain 
finger and nuclear receptor box domain and functions as a ligand dependent 
coactivator of retinoic acid receptor. It has been shown to mediate its effect through 
direct interaction either with histone acyl transferases encoded by NCOA1 or 
histone demethylase encoded by LSD1 (Carbuccia et al., 2009). ASXL1 mutations 
are thought to promote myeloid transformation through loss of PRC2 mediated 
myeloid repression (Abdel-Wahab et al., 2012). The vast majority of ASXL1 
mutations found in myeloid malignancies affect the glycine rich exon 12 and are 
frameshift and nonsense mutations resulting in C-terminal truncation of protein and 
loss of C terminal Plant-homeo-domain (PHD) finger. Truncated protein is unable 
to bind methylated histone lysine or interact with chromatin modifiers (Acquaviva 
et al., 2010). 
Progressive multilineage cytopenias and dysplasia with increased numbers of 
haematopoietic stem/progenitor cells characteristics of human MDS is seen in mice 
with haematopoietic deletion of Asxl1. Most of the ASXL1 mutations in myeloid 
patients are seen in its C terminal, resulting in a deletion of PHD protein interacting 
domain creating dominant negative protein that inhibits its wildtype counterpart as 
well as other members of the polycomb multiprotein complex.  
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Ten-eleven translocation gene (TET1) was named as a fusion partner with the 
mixed lineage leukaemia (MLL) gene in t(10;11)(p12;q23) AML (Lorsbach et al., 
2003). It has two other paralogs: TET2 and TET3. TET2 encodes a 2-oxoglutarate 
and Fe (II) dependent deoxygenase that catalyses the conversion of 5-methyl 
cytosine (5mc) to 5-hydroxy methyl cytosine (5hmc). TET enzymes can further 
convert (5hmc) into 5-formycytosine (5fC) and 5-carboxyl cytosine (5caC) (Fig 
1.3). The N-terminal consists of an alpha helix followed by continuous sheets of β 
strands, typical of the double-stranded β helix (DSBH) folds of the 2OG-Fe(II) 
oxygenases. TET1 and TET3 also possesses a CXXC domain, a binuclear zinc- 
chelating domain that is found in chromatin associated protein. 
  
Figure 1.3: DNA methyl transferases (Dnmt) methylate cytosine to 5methyl cytosine 
(5mc). 5mc can be hydroxylated to 5 hydroxy methyl cytosine (5hmC) by Tet family of 
deoxygenases. Process of replication dependent passive demethylation can convert 
5hmC to cytosine due to its poor recognition by Dnmt1. 5hmC can be further oxidized 
to 5 formyl cytosine (5fC) and 5 carboxy cytosine (5caC) by Tet proteins. 5hmC can 
be deaminated to 5 hydroxy methyl uracil (5hmU) by AID/APOBEC deaminases. 
Further TDG (thymine DNA glycosylase) a DNA glycosylases excises 5hmC, 5fC and 







TET2 gene located on chromosome 4q.24 is the most commonly mutated gene in 
MDS. It is found mutated in 20% MDS, 10% of MPN, 30-50% of CMML and 25% 
of secondary AML (Delhommeau et al., 2009, Kosmider et al., 2009, Mullighan, 
2009), TET2 mutations are generally restricted to the C terminal end of the protein 
and result in loss of function. Increase in the level of 5mc and reduction in level of 
5hmc is observed with TET mutations leading to DNA hypermethylation and gene 
silencing (Ko et al., 2010, Ponnaluri et al., 2013, Tang et al., 2009). Crusio et al 
showed that reduced TET2 expression leads to enhanced stem cell function and also 
augments transformation to AML (Moran-Crusio et al., 2011). Decreased 
expression of TET2 has also been found in progenitors, erythoid precursors and 
granulocytes in patients with no detectable mutations suggesting alternative 
mechanism of TET2 deregulation and highlighting the physiological and tumor 
suppressor function of this protein (Langemeijer et al., 2009). 
DNA methyl transferases (DNMTs) mediate the methylation at 5’position of 
cytosine residues in a CpG dinucleotide. DNA methylation is performed by three 
different methylases de novo methylation by DNMT3A and DNMT3B and 
maintenance of methylation by DNMT3. Mutation in DNMT3A was first identified 
in an AML patient with normal karyotype and was subsequently found in 8% of de 
novo MDS. Heterozygous missense mutation that converts arginine to histidine at 
position 882 (R882H) is the most frequent DNMT3A mutation in AML and MDS, 
which reduces the catalytic activity in vitro although it has not been studied in 
combination with wildtype allele (Yamashita et al., 2010). Compound heterozygote 
frameshift and nonsense DNMT3A mutations do occur suggesting that loss of 
function mutations exist. Loss of dnmt3a-/- leads to a competitive growth advantage 
over wildtype in murine dnmt3a-/- hematopoietic stem cells (Challen et al., 2011). 
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Another recurrently mutated gene found in haematological malignancies are Tri 
carboxylic acid cycle (TCA) enzymes. IDH1 and IDH2 were identified as mutated 
oncogenes in a high percentage of glioma and secondary glioma patients (Yan et al., 
2009). Whole genome sequencing of an AML patient sample led to discovery of 
IDH1 mutation in 8% of AML samples (Yoshida et al., 2011). IDH1 and IDH2 
mutations have been confirmed in AML, in MPN at the time of leukaemic 
transformation and in rare cases of MDS (Abdel-Wahab et al., 2010, Kosmider et 
al., 2010, Paschka et al., 2010, Tefferi et al., 2010, Thol et al., 2010).  
IDH1 and IDH2 are homodimeric nicotinamide adenine dinucleotide phosphate 
(NADP+) dependent enzymes that convert isocitrate to α-Ketoglutarate (αKG) and 
reside in cytoplasm and mitochondria respectively. Heterozygous mutations alter 
the functions of the encoded enzymes producing 2-hydroxyglutarate (2HG) instead 
of α-KG which inhibits the functions of many enzymes such as TET family 
members, histone demethylases, and prolyl hydroxylases (Losman and Kaelin, 
2013) (Fig 1.4). Most of the mutations are missense mutations of conserved codons 
(R132 for IDH1 and R140 and R172 for IDH2) and no frameshift or early 
truncations have been identified. Mutations of TET2 and IDH gene appear largely 
exclusive of each other in MDS and AML suggesting that they engage similar 







Figure 1.4: Pathways in MDS encoding epigenetic modifiers and transcriptional 
factors. Trimethylation of lysine 27 on carboxyl terminal tail of histone3 a nucleosome 
component is associated with transcriptional repression. ASXL1 and EZH2 are 
members of polycomb complex protein that maintain the repressive state. DNMT3 is a 
methyl transferase that converts cytosine in CpG islands to 5 methyl cytosine (5mC) 
which is associated with repression. 5mC is converted to 5hmC by TET2 in presence 
of α ketoglutarate (αKG) produced by IDH. 
1.3.2! Mutations in Transcription regulation and cell signalling pathway 
TP53 
TP53 is a tumour suppressor gene located on chromosome 17p13 and its gene 
product p53 is activated by a variety of cellular stresses instigating cell cycle arrest, 
apoptosis and a DNA repair response. Mutations in TP53 although not associated 
with a specific morphological or clinical phenotype are associated with adverse 
disease features. In MDS mutations in TP53 have been described in high risk MDS 
particularly with complex karyotype and therapy-related MDS. Mutations in TP53 
gene occur in 10% of MDS with nearly a third to half of the patients having 
complex karyotype and are associated with poor prognosis after adjusting the IPSS 
subgroup (Bejar et al., 2011b, Kulasekararaj et al., 2013). Mutations in TP53 or p53 
protein expression in del(5q) setting predict poor response to lenalidomide and 















Activation of p53 is important for the erythopoietic defects associated with 
haploinsufficiency for RPS14 (Ebert et al., 2008). Barlow et al created a mouse 
model for 5q- syndrome and showed that segmental haploidy of a region between 
Cd74 and Nid67 syntenic to a region within the CDR of 5q-syndrome containing 
the gene RPS14 resulted in macrocytic anaemia a key feature of 5q- syndrome. The 
bone marrow of these mice showed a prominent dysplasia within the erythroid and 
monolobulated megakaryocyte lineage, decrease in erythroid and myeloid 
progenitor cells which was accompanied by an increase in p53 positive cells and 
increase apoptosis of bone marrow cells proving the evidence that 
haploinsufficiency of RPS14 in 5q- causes ribosome disorganised biogenesis. 
Deletion of p53 in Cd74/Nid67 deficient mice ameliorated thrombocytopenia and 
reduction in number of progenitor cells supporting the evidence that ribosomal 
stress leads to activation of p53 (Barlow et al., 2010). A leading hypothesis suggests 
that ribosomal haploinsufficiency leads to accumulation of free ribosomal proteins 
due to disrupted ribosomal biogenesis that binds to MDM2 a negative regulator of 
p53 which results in activation of p53 leading to apoptosis and cell cycle arrest 
(Dutt et al., 2011).  
 
RUNX1 
RUNX1 (also known as AML1 or CBFA2) is the second most commonly mutated 
gene in MDS and was identified as a translocation partner to ETO (now called 
RUNX1T1) in cases of t(8:21) in AML. It encodes for one of the two heterodimeric 
subunits of the human core transcription factor (CBF). RUNX1 translocations are 
more common in AML as compared to MDS, however point mutations are found in 
de novo MDS (7 -15%) and at a higher frequency in therapy related MDS. In both 
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MDS and AML, RUNX1 mutations are markers of poor prognosis (Chen et al., 
2007, Steensma et al., 2005).  
A proximal Runt homology domain (RHD) essential for both DNA binding and 
distal transactivation domain (TAD) essential for protein protein interaction and 
recruitment of cofactors is found in RUNX1 protein. Missense mutations are found 
in the Runt domain, whilst nonsense and frameshift mutations are found throughout 
the length of the protein and disrupt the transactivation domain (Fig 1.5). This 
distinction may be physiologically relevant since Runt domain mutations with 
impaired DNA binding can function in a dominant negative manner. RUNX1 
activity will be reduced by these mutations as compared to loss of function mutation 
by one allele. 
 
Figure 1.5: Localisation of various domains found in RUNX1 protein.The RUNX1 
protein has two domains the proximal RUNT1 domain responsible for DNA binding 
and the distal transactivation domain (TAD) responsible for protein protein 
interaction. Missense mutations are found in the Runt domain while nonsense and 
frameshift mutations are found throughout the length of the protein. 
  
Germ line mutations in RUNX1 cause familial platelet disorder a rare human 
disease with an inherent susceptibility to develop acute myeloid leukaemia 
suggesting that this gene may act as a tumor suppressor gene in this setting (Song et 
al., 1999). Runx1 knockout mice die without achieving complete haematopoiesis 
few days after birth (Dowdy et al., 2010). Excision of Runx1 in the adult 
haematopoietic compartment of these mice leads to extramedullary haematopoiesis, 
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lymphoid defects, expansion of myeloid progenitor pool and inefficient platelet 
production but do not succumb to AML (Growney et al., 2005). 
RAS 
The RAS proto-oncogene belongs to small GTPase family and exists in three 
different isoforms N-RAS, K-RAS and H-RAS. In MDS NRAS the most common 
mutation is present in 10-15% of patients while 1-2% having KRAS mutations. 
Considered in isolation these mutations are associated with poor prognosis and 
progression to AML. RAS proteins are GTPases that act as signal switch molecules 
in controlling signalling pathways involved in cell proliferation and cell survival. 
Ras proteins are normally tightly regulated by guanine nucleotide exchange factors 
(GEFs) promoting GDP dissociation and GTP binding and GTPase-activating 
proteins (GAPs) that stimulate the intrinsic GTPase activity of Ras to switch off 
signalling. The RAS signalling pathway is constitutively activated by RAS 
mutations in exon 12, 13 and 61 resulting in an increase in intracellular RAS GTP 
which in turn activates various pathways like the BRAF mitogen- activated and 
extracellular signal-regulated kinase (MEK), extracellular signal-regulated kinase 
(ERK) cascade which determines proliferation and becomes deregulated in certain 
cancers. (Schubbert et al., 2007). 
C.CBL 
The CBL gene is located on chromosome 11q23.3 and its gene product is a tyrosine 
kinase associated ubiquitin ligase that negatively regulates signalling through these 
receptors by targeting them for degradation. In CMML and in patients with juvenile 
myelomonocytic leukaemia it is mutated in 15% of cases, but in MDS it is found in 
fewer than 5% of patients. CBL mutations result in increased receptor tyrosine 
kinase (TK) levels and phosphorylation of STAT5, which are believed to mediate 
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hypersensitivity of these mutant cells to a wide variety of growth factor and 
cytokines (Sanada et al., 2009, Sargin et al., 2007). CBL mutations are biallelic, 
which suggests that CBL is a tumour suppressor gene and loss of wildtype is 
advantageous. However most of the CBL mutations are localised in the N- terminal 
region in exons 8 and 9 leaving the rest of the protein intact suggesting a gain of 
function. Frameshift and early truncation mutations are uncommon. The common 
CBL mutations are known to encode a dominant negative protein that inhibits the 
function of the wildtype and its homolog CBLB (Fig 1.6).  
Figure 1.6: Schematic representation of the domain architecture of C.CBL 
protein.The C.CBL consists of a highly conserved N-terminal region that is comprised 
of a tyrosine kinase binding domain (TKB) consists of 4 helix, a calcium binding EF 
domain, a variant SH2 domain linked with the RING finger domain. The C-terminal 
consists of a proline rich stretches multiple serine and phosphorylated tyrosine sites 
and an ubiquitin associated UBA domain and leucine zipper. 
 
Modest cytokine hypersensitivity is seen in mouse cells deficient for CBL that is 
greatly enhanced by the introduction of a mutant CBL gene perhaps due to the 
inhibition of partially compensatory CBLB activity (Rathinam et al., 2008). In 
MDS CBL mutations are found to be exclusive of several other commonly mutated 
genes including FLT3, KIT NPM1, CEBPA, PTPN11 and NRAS. 
 
JAK2 
Activating mutations of JAK2 (Janus Kinase 2) form a part of diagnostic criteria for  
polycythaemia vera and are found in roughly half of the patients with 
thrombocythemia and primary myelofibrosis. JAK2 is a nonreceptor tyrosine kinase  
that transduces the signal from several cytokine receptors including the 
erythropoietin (Epo), G-CSF, and thrombopoietin (Tpo) receptors. Depending on 
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the receptor to which it is attached it can activate a large number of signalling 
pathway involved in cytokine mediated cell survival, proliferation and 
differentiation, Only the common mutation V617F has been reported in MDS and is 
found in 5% of unselected patients and does not have any prognostic significance 
(Steensma and Tefferi, 2008). However, MDS/MPN (Myeloproliferative neoplasm) 
crossover syndrome RARS-T is an exception where JAK2V617F is found in 50% of 
patients. Cases of wildtype JAK2 RARS have been defined in which 
thrombocythemia occurs only at the time of acquisition of V617F mutation 
(Malcovati et al., 2009). Given the high rate of JAK2 mutation in MDS/MPN there 
appears to be a cooperating advantage between those abnormalities responsible for 
the ring sideroblast phenotype and the constitutive activation of JAK2. The nature 
of this interaction is not yet understood. 
1.3.3! Splicing mutations 
Whole genome sequencing identified mutations in a completely new class of genes 
involved in mRNA splicing. SF3B1 was the first gene to be identified, which was 
particularly mutated in 68% of cases with MDS subtype refractory anaemia with 
ringed sideroblast (RARS) (Papaemmanuil et al., 2011). All the mutations appeared 
to be heterozygous mutations and were clustered from exon 12 to 15 of the gene. 
K700E accounted for 59% of the variants observed. Several other hotspots for 
amino acid mutations E622, R625, H622, K666, I704 were also observed. All the 
mutations identified were found in the fourth, fifth, and sixth HEAT domains 
localised in the C-terminal. Transcriptome profiling suggested that SF3B1 mutation 
was associated with downregulation of essential mitochondrial gene network. 
Further patients with SF3B1 had overall longer survival and no deleterious effects 
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than patients without SF3B1 mutations. Since SF3B1 mutations could readily be 
identified in peripheral blood as well as ring sideroblast in bone marrow the study  
proposed the use of SF3B1 as a screening for patients for MDS. It is also found to 
be recurrently mutated in chronic lymphocytic leukaemia (CLL) and at low 
frequencies in solid tumors (Wang et al., 2011). In a parallel study Yoshida et al 
identified mutations in multiple components of the RNA splicing machinery, 
SF3B1, SRSF2, U2AF1 (U2AF35), ZRSR2, using whole exome sequencing in 57% 
of MDS patients. Most of the mutations were mutually exclusive and affected genes 
involved in 3’ splice site recognition step of pre mRNA processing inducing 
abnormal RNA splicing and haemopoiesis. In case of U2AF35 mutations were 
found clustered at two highly conserved amino acids positions S34 or Q157, SRSF2 
mutations exclusively occurred at position P95 while most of the SF3B1 mutations 
were found at position at K700 and to a lesser extend involved K666, H662 and 
E622 while in case of ZRSR2 they were widely distributed throughout the region. 
Gene set enrichment assay (GSEA) analysis disclosed an enrichment of genes 
involved in nonsense mediated decay (NMD) pathway among the significantly up 
regulated genes in mutant U2AF35-transduced HeLa cells. Most of the mutations 
identified in SF3B1, SRSF2 and U2AF1 to date are missense mutations affecting 
invariant positions suggesting a gain of function or change of function.  In the case 
of ZRSR2 missense nonsense and frameshift mutations have been reported 
suggesting loss of function (Papaemmanuil et al., 2013, Thol et al., 2012). 
Splicesome mutations have been found to co-occur with mutations in epigenetic 
modifiers in MDS. Mutations in SF3B1 has been found to co-occur with mutations 
in DNMT3A the methyl transferase, TET2 mutations co-occur with mutations in 
SRSF2 and ZRSR2 and U2AF1 has been associated with ASXL1 or TET2. 
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Splicing factor mutations were found in 38% of cases in a cohort of 154 MDS 
patients in a study carried out by Mian et al. SF3B1 mutations were found in 80%  
of cases with RARS /RCMD/RS and showed beneficial prognostic impact on 
overall survival. Mutations in SRSF2/ U2AF1 occurred in advance forms of 
diseases like RAEB and CMML and coexisted with mutations in NRAS, FLT3 and 
RUNX1 with known oncogenic mutations (Mian et al., 2013). Subsequently the 
same group showed that SF3B1 mutations arise from haematopoietic stem cell 
compartment thereby providing a therapeutic target (Mian et al., 2015). 
1.3.4! Cohesin mutations 
The cohesin complex which is involved in holding the sister chromatids together, 
post replicative DNA repair, transcriptional regulation is found to be mutated in 
MDS and other myeloid malignancies. Cohesin mutations actually fall into two 
categories, truncation and frameshift mutations reported in STAG2 and RAD21 and 
missense mutations reported in SMC1A and SMC3. While most evidence for 
cohesin mutations in myeloid leukaemia has come from AML, cohesin mutations 
have also been found in related myeloid malignancies. In 2010, a comparative 
genomic hybridisation identified loss of one copy of RAD21 in one patient with 
chronic myelomonocytic leukaemia and complete loss of STAG2 in another patient 
with de novo acute myeloid leukaemia in 167 myeloid disease samples. These 
initial studies provided important hints that mutations in cohesin complex have a 
role to play in tumorigenesis (Rocquain et al., 2010). The first report of somatic 
cohesin mutations in AML was identified in SMC3 gene in a cohort of 200 patients 
at a frequency of 3% (Ding et al., 2012). Subsequently this result was confirmed 
and extended by TCGA (The Cancer Genome Atlas) identifying mutations in each 
of the cohesin subunit (SMC1A, SMC3, RAD21 and STAG2) at a frequency of ~3% 
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and a cumulative cohesin mutations frequency of 13% (13/200) in adult denovo 
AML. All the mutations were mutually exclusive of one another. Kon et al (Kon et 
al., 2013) and Thota et al (Thota et al., 2014) determined the frequency of cohesin 
mutations in both de novo and secondary AML (as well as in other types of myeloid 
malignancies). In both the studies AML harboured the most frequent mutations in 
core cohesin subunits. Kon et al identified mutations and deletions of the cohesin 
subunits in 13% (16/120) of de novo AML and 8% (3/37) of secondary AML in a 
mostly mutually exclusive manner. In contrast Thota et al identified a higher 
frequency of cohesin mutations in secondary AML samples (20%; 30/149) than in 
de novo AML (11%; 32/301). In both the studies most of the mutations were 
identified in STAG2 followed by RAD21 and then SMC3. Further evidence of 
cohesin’s involvement in myeloid malignancies came from the work of Haferlach 
showing that approximately 15% of patients with MDS harbour mutations in 
cohesin complex. STAG2 and SMC1A were associated with poor survival outcomes 
that strongly suggested that cohesin mutations were central to development and 
prognosis of MDS (Haferlach et al., 2014)(Walter et al., 2012). Cohesin mutations 
have also been associated with pathogenesis of DS-AMKL (Down syndrome acute 
megakaryoblastic leukaemia). Genome profiling and whole exome sequencing in a 
cohort of Transient abnormal myelopoiesis (TAM), DS-AMKL and non-DS-AMKL 
revealed that DS-AMKL emerged from a pre-existing TAM clone (already having 
an underlying constitutive trisomy 21 and GATA1 mutation) after acquisition of 
additional mutations with major mutational targets (53%) in members of the 
cohesin complex  (Yoshida et al., 2013). 
 
One of the members of the cohesin complex STAG2 located on X chromosome has 
been found to be mutated in a large variety of cancers. Solomon et al reported 
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STAG2 to be mutated in 21% Ewing’s sarcoma and 19% of melanoma and 
glioblastoma. Loss of STAG2 in this study, however, was associated with 
chromosomal instability (Solomon et al., 2011). In another study, truncated 
mutations in STAG2 in 36% of papillary non-invasive urothelial carcinoma and 
16% of invasive urothelial carcinomas of bladder were detected. Tumours with 
STAG2 mutations were also shown to have concurrent p53 overexpression or 
mutations (Solomon et al., 2013). The highest incidence of STAG2 mutations has 
been reported in bladder cancer (24.7%) (Taylor et al., 2013). Most of the mutations 
in this study were inactivating mutations (missense, frameshift, splicing) leading to 
loss of protein function. Interestingly, the mutations in this study were not 
associated with chromosomal instability, such as loss of whole chromosomes 
(aneuploidy) (Taylor et al., 2013). In another study, Martinez et al predicted STAG2 
as a tumour suppressor gene that was found to be mutated in 12 of 77 urinary 
bladder tumors (15.6%). Similarly to previous studies, loss of STAG2 was not 
associated with aneuploidy and had a better prognosis in both NMIBC (Non muscle 
invasive bladder cancer) and MIBC (muscle invasive bladder cancer) (Balbas-
Martinez et al., 2013). Loss of expression of STAG2 has also been found in 27% 
gastric cancers, 23% of colorectal cancers (CRC) and 30% prostrate carcinomas 
(PCA) (Kim et al., 2012). STAG2 inactivation cooperated with KRAS mutation as an 
early event in the progression and evolution of human pancreatic ductal 
adenocarcinoma (PDA) (Evers et al., 2014). Mutual coexistence of STAG2 and 
TP53 was found to be associated with worst prognosis in a study to reveal 
secondary mutations that contribute to disease progression. Data from this study 
suggested that STAG2 and TP53 co-operate towards genomic instability in an 
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aggressive disease like Ewing’s sarcoma. Mutual exclusivity was also found 
between STAG2 and CDKN2A lesions (Tirode et al., 2014). 
The pathophysiology of MDS and its progression to AML involves cytogenetic, 
epigenetic and genetic aberrations. Data arising from whole genome sequencing 
(WGS) have shown that the progression of MDS to AML is complex. Further 
second generation sequencing have shown more tantalizing results like the 
occurance of small clones of MDS related genes in individuals who are either 
healthy or have mild cytopenias with no definitive signs of MDS. Better 
understanding of the molecular landscape of MDS has important clinical 
implications. The discovery of mutations in members of the cohesin complex has 
opened a new field that needs to be unravelled in the pathogenesis of MDS so a part 
of my thesis will focus on the occurrence and clinical correlation of cohesin 
mutations in MDS patients. 
1.4! Cohesin Complex 
The chromosomes are at the very heart of all genetic processes. Accurate 
chromosomal segregation at mitosis is essential for the maintenance of genomic 
integrity. Sister chromatids need to be tightly coupled from the time of generation 
in S phase until metaphase, so as to undergo appropriate segregation at anaphase. 
The cohesin complex plays a pivotal role in the establishment of the cohesion 
between sister chromatids both during mitosis as well as meiosis. Cohesin belongs 
to the conserved group of protein complexes that are dedicated to chromosome 
biology. It has now been recognised that the cohesin complex also plays pivotal 
roles in maintaining the genomic integrity of the cell by holding sister chromatids 
together during post replicative DNA repair, and through its regulation in gene 
transcription. 
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Defects in the cohesin complex have been associated with severe developmental 
diseases collectively termed as “cohesinopathies” examples of which include 
Cornelia de Lange Syndrome (CdLS), Roberts Syndrome (RBS)/ SC phocomelia 
(SC) and Warsaw breakage syndrome (Mannini and Musio, 2011). 
1.4.1! Architecture of Cohesin complex 
The cohesin complex is composed of four subunits, SMC1, SMC3, (RAD21, Mcd1, 
Scc1) kleisin and stromalin (SA, Scc3, STAG1/2) proteins which are conserved 
across the species from yeasts to mammals. The structural organisation of 
individual components have been well characterized in budding yeast and the 
complex shows structural homology with cohesin from other species with sequence 
conservation among the subunits, as well as biochemical and electron microscopic 
similarities (Dorsett, 2011). 
Smc1 and Smc3 are members of the structural maintenance of chromosome (SMC) 
group of chromosomal ATPases that are conserved from bacteria to humans. Most 
prokaryotes have only one Smc protein which form a homodimer, while there are 
six Smc proteins in eukaryotes (Smc 1-6) which form a heterodimer. Each Smc 
subunit is self-folded by anti-parallel coiled coil interactions, so that the N and the 
C terminal come together creating a rod shaped molecule with an ATP binding 
cassette (ABC)-like head domain at one end and hinge domain at the other end. 
Each head domain contains a N-terminal walker A box and a C-terminal walker B 
box (Ivanov and Nasmyth, 2005, 2007).  
Although various models have been proposed as to how the cohesin holds the sister 
chromatids together, such as ring (embrace model), the two ring model, multimeric 
bracelet and multimeric rod shaped model, the ring model is accepted widely where 
by the hinge domain of Smc1 and Smc3 are tightly associated with each other while 
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the ATPase head domain are physically connected by RAD21 (Scc1, Mcd1) to form 
a close tripartite ring with an outer diameter of 40nm. ATP binding to the ATPase 
domain is essential for binding of RAD21/Scc1/Mcd1 with the Smc1/ Smc3 
heterodimer (Weitzer et al., 2003). The fourth unit of the complex Scc3 or 
STAG1/2 binds to RAD21. The sequence of this protein has HEAT repeats that are 
responsible for protein protein interaction. The cohesin complex consists of various 
other regulatory subunits like PDS5, WAPL and sororin that play a role in loading 












Figure 1.7: Structure of the Cohesin complex. The cohesin complex consists of a 
heterodimer of SMC1 and SMC3 which fold upon themselves in the hinge region to 
form antiparallel coiled coil arms with the amino and carboxy termini coming 
together in head domains that contain ABC-type ATPases. Cohesin forms a ring like 
structure with RAD21 bringing the SMC head domains together. STAG2 binds to 
RAD21. Pds5, Wapl and Sororin are other regulatory factors responsible for loading 
and unloading of cohesin. The cohesin complex has critical roles in sister chromatid 
cohesion.  
1.4.2! Cohesin Loading and Establishment 
The cohesin complex is loaded at the end of mitosis in telophase in higher 
eukaryotes, but at the end of G1/S boundary in Sacchromyces cerevisiae (budding 
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yeast) by a protein complex kollerin consisting of adherin proteins (Scc2, Mis4, 
NIPL, Nipped B) and Scc4 (Mau-2). Scc2 are HEAT repeat proteins that physically 
interact with cohesin. Kollerin binds to the chromosome and along with ATP 
hydrolysis is required by the Smc proteins for topological binding with the sister 
chromatids. The mechanism by which cohesin is loaded by Scc2-Scc4 on the 
chromosome is poorly understood. Experiments by Nasmyth and co-workers have 
predicted that a preformed ring associates with the chromatin and that the DNA 
enters the ring from the hinge region. The energy requirement for ring opening is 
derived from the bending of the hinge domain towards the ATPase head resulting in 
ATP hydrolysis (Gruber et al., 2006). In budding yeast (Sacchromyces cerevisiae), 
cohesin is loaded at CAR sites (Cohesin associated regions) that fall within the 
intergenic regions and are distinct from the Scc2-Scc4 loading sites. Although the 
notion that cohesin first binds to Scc2-Scc4 sites and then is translocated to CARs 
site is argued by evidences suggesting that the loading site can lie within the CARs 
site suggesting a direct deposition of the complex. Orthologs of Scc2 and Scc4 have 
been found in fission yeast, drosophila and mammals. A major fraction of mouse 
and human cohesin sites have been found in the vicinity of the transcriptional 
insulator, CTCF (CCCTC binding factor required for transcriptional repression) 
with a preference for regions in the vicinity of transcribed genes. How cohesin is 
loaded at these sites is not clear. Cohesin needs to be relocated from its site of 
loading to permanent positions and Nasmyth and co-workers have reported that 
ATP hydrolysis responsible for association of cohesin to chromatin is also 
responsible for its translocation (Hu et al., 2011). 
It has also been shown that the association of cohesin with the chromosome is not 
enough for pairing of sister chromatids. For this chromosome- associated cohesion, 
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cohesin must attain a “pairing competent state” which is acquired by the acetylation 
of the Smc3 protein on Lysine112 and Lys113 by Eco1/Ctf7 (establishment factor) in 
budding yeast. In mammals two orthologs (Esco1 and Esco2) also regulate cohesion 
at Lys105 and Lys106 Reviewed in (Nasmyth, 2011). Eco1/Ctf7 interacts physically 
with the sliding clamp Proliferating cell nuclear antigen (PCNA) as well as with the 
clamp loader replication factor C (RF-C) further suggesting its role in linking 
cohesin to DNA replication (Kenna and Skibbens, 2003). Other replication 
associated proteins include an “alternative” RF-C component containing 
Chromosome transmission fidelity protein 8 (Ctf8), Chromosome transmission 
fidelity protein 18 (Ctf18), sister chromatid cohesion protein (Dcc1), Chromosome 
transmission fidelity protein4 (Ctf4) that associates with DNA polymerase α and the 
Chl1 helicase (close homolog of L1) (Bermudez et al., 2003, Hanna et al., 2001, 
Mayer et al., 2001, Skibbens, 2004). It remains unclear how the establishment of 
cohesin is coupled to replication at a mechanistic level and Losada et al have 

























Figure 1.8: Regulation of cohesin dynamics during Interphase. (a) Scc2 promotes 
loading of cohesin onto the parental chromatid before DNA replication. It may also be 
involved in transient unloading or mobilization of cohesin. Scc2 could mediate these 
functions by facilitating disengagement of the SMC head domains of cohesin. Two 
confirmations of cohesin, with engaged and disengaged head domains, are represented 
in green and orange respectively. (b) Speculative models for the establishment of 
cohesion during DNA replication. The replication machinery (yellow oval) could 
simply pass through the cohesin ring (model 1). Alternatively, passage of the 
replication fork could impose a conformational change in cohesin. The altered cohesin 
complex may return to the original conformation (model 2) or may generate a novel 
cohesive structure (model 3). Model 4 proposes that the replication forks push the 
cohesin complexes so that they accumulate at termination sites. Replication of the 
remaining short stretch of DNA could be facilitated by specialized factors such as the 
alternative RF-C. Subsequent action of the transcriptional machinery could then 
relocate cohesin from the termination sites to regions of convergent transcription 
(Losada et al 2003). 
 
The acetylation by Eco1/Ctf7 counteracts the effect of the anti-establishment 
cohesion factor, releasin formed by Pds5 (BimD or Spo76) and wing associated 
protein (Wap1, Wpl1, Rad61) and release of Pds5 from the releasin complex. 
Vertebrate’s cells have two Pds5 like proteins (PDS5A and PDS5B) and are 
associated with maintenance of cohesin. Studies in mouse and human cells have 
shown that cohesin complexes that include SA1 (cohesin-SA1) and SA2 (cohesin-
SA2) mediate sister chromatid cohesion at telomeres and centromeres. PDS5A and 
PDS5B which can bind to either cohesin-SA1 or cohesin-SA2 both contribute to 
telomere and arm cohesion whereas PDS5B is specifically required at centromeres 
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(Losada, 2014).  Irr1/Scc3 is the third member of the anti-establishment complex 
and has been demonstrated as one of the stable components of cohesin complex. 
Acetylation also recruits Sororin (Dalmatian) proteins in vertebrates and drosophila 
that prevents cohesin from disengagement by displacing WAPL from PDS5 
although WAPL remains attached to cohesin. Hos1 in yeast and HDAC8 (Human 
deacetylase 8) in human deacetylates Smc3 in preparation for the next cycle of 
mitosis (Borges et al., 2010, Nasmyth, 2011). 
1.4.3! Regulation of Cohesin 
Timely dissolution of cohesin is important for proper segregation of chromosomes. 
In vertebrates, the bulk of cohesin removal occurs in prophase and is mediated by 
the phosphorylation of STAG2 (SA2) by polo like kinase 1 (PLK 1) and sororin by 
aurora kinase B (AURB) and cyclin dependent kinase 1 (Cdk1), however some of 
the cohesin remains attached at the centromere protected by Shugoshin like proteins 
(SGO1) and is finally removed before the onset of anaphase. SGO1 interacts with 
phosphatase PP2A and recruits PP2A to the centromere and this recruitment is 
believed to keep STAG2 in a dephosphorylated state preventing removal of cohesin 
from the centromere. WAPL and PDS5 are also essential for removal. It is thought 
that the phosphorylation of STAG2 causes changes in cohesin, which facilitates the 
dissociation of cohesin by WAPL and opening of the ring. Apart from the prophase 
pathway, the centromeric/pericentric cohesin in higher eukaryotes and bulk of the 
cohesin in yeast is removed by cleavage of RAD21/Scc1 by separase. Till the onset 
of anaphase, activity of separase is inhibited by its association with securin. In 
vertebrate cells separase is additionally inhibited by Cdk1 phosphorylation and its 
binding to Cdk1 subunit cyclin B. Activation of APC/C (Anaphase Promoting 
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Complex/cyclosome) by Cdc20 leads to ubiquitin mediated degradation of securin 




Figure 1.9: Cell Cycle regulation of Cohesin. Cohesin is loaded onto chromatin in 
early G1 phase by the Nipped B like protein (NIBPL)-MAU2 heterodimer. Binding of 
PDS5 and Wings apart-like protein homologue (WAPL) to cohesin through RAD-21 
and stromal antigen (SA) causes its unloading. DNA exits the complex through the 
interface created by SMC3 and amino terminal of RAD21. During DNA replication 
loading of cohesin on sister chromatids is promoted by acetylation of SMC3 by 
ESCO1 and ESCO2 acetylase (Ac) in the amino terminal of SMC3 at position K105 
and K106. This acetylation causes recruitment of sororin which bounds to PDS5 and 
displaces WAPL although WAPL remains attached to complex. In prophase most of 
the cohesin dissociates from the sister chromatids which is caused by the 
phosphorylation of SA-subunit by polo-like kinase 1 (PLK1) and of sororin by aurora-
kinase B (AURB) and cyclin dependent kinase 1 (CDK1) however some of the cohesin 
remains attached at the centromere and is prevented from dissociation by the 
concomitant action of shugoshin1 (SGO1) and protein phosphatase (PP2A). The 
remaining cohesin is removed at the beginning of the anaphase by the cleavage of 
RAD21 by separase. The cohesin complex released during mitosis can be recycled in 





1.5! Functions of Cohesin 
1.5.1! DNA Repair/ DNA damage checkpoint regulation 
The earliest evidence that cohesin is involved in DNA double strand break (DSB) 
repair came from the results in S. pombe where a cohesin mutant was rendered 
sensitive to γ radiation (Birkenbihl and Subramani, 1992). In fact the role of cohesin 
in DNA DSB repair was established before its involvement in sister chromatid 
cohesion. Scc1 depleted in the DT-40 chicken cell line, cell lines derived from 
breast cancer patients with impaired RAD21 and depletion of RAD21 from HeLa 
cells confirmed that cohesin is important for repair in higher eukaryotes.  
It was first shown by Yokomoris group that cohesin is recruited to laser induced 
DNA damage sites in human cells in an MRE11, RAD50 dependent manner (Kim 
et al., 2002). The enrichment of cohesin at DNA DSB was also confirmed by 
Koshland and Sjogren groups in yeast and it was found that damage induced 
cohesion was not restricted at the DSB but spread throughout the genome in G2 after 
genome duplication (Strom et al., 2007, Unal et al., 2007). This damage-induced 
cohesion (DI) was controlled by DNA damage response factors like Mec1, Tel1, 
Mre11, ϒH2AX and cohesin regulators (Scc2, Eco1, and Smc6) and was 
independent of replication. Further work done by Koshland and others found that in 
response to a DSB, Chk1 phosphorylates Scc1 at Serine (S83). This 
phosphorylation augments the acetylation by Eco1 at two positions, Lys84 and 
Lys210. The acetylation counteracts the effect of Wap1 in establishment of 
cohesion. Furthermore Smc3 acetylation by Eco1 was uniquely required for S phase 
cohesion and not for DI cohesion. So far evidence for DI cohesion has only been 
observed in yeast. Several lines of evidence show that DI cohesion might be a 
conserved mechanism in higher organisms. Sororin was found to be required for 
efficient DSB repair during G2 in sororin depleted HeLa cells and decreased inter-
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sister chromatid distance was observed after DSB in DT40 chicken cells consistent 
with the establishment of DI cohesion. ChIP (chromatin immunoprecipitation) 
followed by deep sequencing (Chip-seq) revealed that ionising radiation (IR) 
triggered an Esco-1 dependent increase in acetylation of Smc3 and genome wide 
reinforcement of cohesin binding at pre-existing sites. (Kim et al., 2010, Wu and 
Yu, 2012). 
Cohesin has also been found to be involved in intra S phase checkpoint in human 
cells. In response to DNA damage, ATM and ATR phosphorylated Smc1 at two 
serine residues S957 and S966 and this phosphorylation was found to be important 
for intra S phase checkpoint. Smc3 was also found to be phosphorylated at S1083 
(Luo et al., 2008). How the phosphorylation of cohesin activates intra S phase 
checkpoint remains unclear. Cohesin has also been implicated in G2/M DNA 
damage checkpoint in human cells. Depletion of Scc1 by RNAi led to defective 
recruitment of 53BP1 to DNA damage foci and weaker Chk2 activation. Cohesin 
was also found to be required in Chk2 activation in G1 prior to replication (Watrin 
and Peters, 2009). 
Cohesin’s role in DSB repair is attributed to the fact that it can hold the sister 
chromatids together. This is important in terms of HR (Homologous 
Recombination) where the intact sister chromatid is held in close proximity with the 
broken DNA and can be used as template. A four- fold reduction of Scc1 or Smc3 
decreased survival in response to radiation and also increased recombination 
between homologues leading to loss of heterozygosity (Covo et al., 2010). Cohesin 
may also regulate the choice of repair between HR and NHEJ pathway (Schar et al., 
2004). 
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1.5.2! Gene Regulation 
Cohesin regulates eukaryotic gene expression but the mechanism is poorly 
understood. The first evidence that cohesin is involved in gene regulation came 
from studies in Drosophila where the Scc2 ortholog Nipped-B was found to act as a 
modulator for the enhancer/promoter interaction at the cut and Ubx (Ultrabithorax 
gene) (Rollins et al., 1999). Evidence that cohesin has a gene regulatory role in 
vertebrates came from the work in zebra fish where the expression of runx1 (Runt - 
related transcription factor 1) and runx3 genes were abolished in early embryos 
mutant for rad21. Cohesin also regulates gene expression in post mitotic tissue. In 
Drosophila, a mutational screen found SMC1 to be important for pruning of post 
mitotic neurons. 
Cohesin associates with CTCF (CCCTC binding factor), which is an integral 
component of the c-myc insulator element MINE that separates transcriptionally 
active c-myc from the chromatin that bears features typical for heterochromatin. 
Several studies revealed that much of the cohesin co-localizes genome wide with 
CTCF. The fact that CTCF forms loops has already been confirmed by chromosome 
conformation capture (3C) assay. Dependence of CTCF based long range 
interaction on cohesin was first demonstrated for the mouse Interferon gamma locus 
(lfng) (Hadjur et al., 2009). In association with CTCF, cohesin mediates looping at a 
number of other genes including β globulin gene, X chromosome inactivation and 
HoxA locus in mice. At the β globulin locus, depletion of NIPBL or cohesin 
prevents the activation of globulin gene and formation of loops (Wang et al., 2011).  
Wendt et al showed that 89% of CTCF sites overlapped with Scc1, and Scc1 is 
required along with CTCF for genomic imprinting at the Igf2/H19 locus (Wendt et 
al., 2008). In another study, Rubio et al using a proteomic approach showed that 
STAG1 (Scc3/SA1) subunit of cohesin interacts with CTCF at c-myc insulator 
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elements and CTCF recruits cohesin to the ICR (Imprinted Control Region) of the 
Igf2/H19 locus in an allele specific manner. 
Studies undertaken have uncovered two distinct cohesin binding sites that maybe 
involved in the gene regulation function of cohesin. Strong cohesin binding sites 
that coincide with CTCF such as the imprinting region where long term integrity 
and topology of the loops are important may require cohesin along with CTCF as a 
positioning partner. In contrast, numerous weak cohesin sites map to active 
promoters and enhancers where cohesin is colocalized with NIPBL(Merkenschlager 
and Odom, 2013). CTCF/cohesin binding sites (CBS) were found as mutational 
hotspot in a study to unravel mutational signature pattern at non -coding cancer 
genome. The findings provided clues to a number of predicted factors that 
contribute to CBS mutations. CBS mutations arise under abnormal conditions and 
tend to occur in late and special replicating regions such as the origin of replication. 
A preferential mutational signature T.A>C.G and T.A> G.C was observed at CBS 
sites which varied in gastrointestinal and mutated TP53 tumor types. Their work 
identified a new and unexpected class of cancer associated mutations that require 
vigorous effort to find its cause and consequences (Katainen et al., 2015). 
Cohesin co-localises with estrogen receptor α in the MCF-7 cell line and with liver 
specific transcription factor HNF4A (Hepatocyte Nuclear Factor 4) in a hepatic cell 
line. Although the functional significance of cohesin binding in MCF-7 is not 
known, depletion of cohesin prevents estrogen responsive transition of breast cancer 
cells from G0/G1 indicating that cohesin influences the physiological estrogen 
response. 
In mouse embryonic stem cells, cohesin and the mediator complex mediate long 
range interaction between enhancers and the transcription factors at the promoter 
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regions of pluripotent genes such as Oct4 (Octamer binding transcription factor4), 
Sox2 (Sex determining region Y– box 2) and Nanog that contribute to pluripotency 
and self-renewal by activating their own transcription and other genes involved in 
early development. Depletion of cohesin, mediator or Nipbl has same effect on 
embryonic stem cell as loss of Oct4 suggesting that they are important for 
maintaining expression of key pluripotency transcription factors (Dorsett, 2011, 
Rhodes et al., 2011). However recent study has shown that cohesin depletion does 
not affect the expression of most of the pluripotent genes. Chromatin conformation 
capture (3C assays) revealed that the enhancer promoter interaction around 
pluripotent genes still remained strong even after 24hr of RAD21 depletion 
however induce DNA damage or DNA damage accumulation due to proliferation 
can affect gene expression (Gupta et al., 2016). 
In concert with Polycomb group (PcG) silencing proteins cohesin restrains gene 
expression. Restraint genes coding for transcription factors like the invected-
engrailed or Enhancer of split [E (spl)-C] are expressed at low to moderate levels in 
Drosophila. Such genes are bivalent having both the H3K27me3 (H3 lysine 27 
trimethyl) methylated silent mark as well as H3K4me3 (H3 lysine 4 trimethyl) 
modification associated with transcriptionally active genes. Reduction of cohesin or 
polycomb strongly increases transcription of genes targeted simultaneously by 
cohesin and polycomb. Notably more than half of the 200 genes that increase in 
expression in mouse embryonic stem cells with cohesin knockdown are bivalent 
which maybe an important mechanism of gene regulation by cohesin in embryonic 
stem cell (Dorsett, 2011; Dorsett, 2012; Kagey, 2010). 
In Saccharomyces cerevisiae, cohesin binds the heterochromatin region at the 
centromeric and telomeric regions and interacts with the protein that binds to these 
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regions. Cohesin is involved in the establishment and maintenance of the 
boundaries at HMR (Hidden mat right) silent mating locus. Mutations in SMC1 
component of cohesin allow the SIR (Silent Information Regulator) silencing 
proteins to spread beyond the boundary causing silencing of the adjacent region 
(Dorsett and Strom, 2012, Rubio et al., 2008). 
A study was undertaken to compare the distribution of cohesin in two different 
tissues (cortex and pancreas) in mouse and to study the effect on transcriptional 
regulation and chromatin architecture. Chromatin contacts were studied at 
protocadherin (Pcdh) and Regenerating islet-derived gene locus. Complete ablation 
of cohesin had a very reduced effect on chromatin contacts in the Pcdh clusters 
between the wildtype and SA1 null embryos in brain. In contrast to Pcdh the Reg 
locus seems to be sensitive to decrease in cohesin levels. Impaired homeostasis of 
the pancreas due to altered expression of the Reg genes made SA1 heterozygous 
mice more prone to pancreatic cancer (Cuadrado et al., 2015). In fission yeast Swi-6 
ortholog of heterochromatin protein 1 (HP1) has been found to be responsible for 
association of cohesin with heterochromatin regions which leads one to speculate 
that expression of genes at this loci is affected by accumulation of cohesin at these 
loci. 
1.5.3! Chromatin remodelling 
Using a comprehensive protein interactome Panigrahi et al found cohesin interacts 
with chromatin remodelers like Chromodomain helicase DNA binding protein, 
(CHD4), the histone methyl transferase (SETD3), linker histone H1 and its 
chaperone Nucleosome assembly protein 1-like 1 (NAP1L1)(Panigrahi et al., 2012). 
Cohesin associates with chromatin remodeller SNF2h on chromosome arms in vivo. 
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These observations predict a role for SNF2h in mediating association of cohesin 
and chromatin (Hakimi et al., 2002).  
1.5.4! Centrosome duplication 
Cohesin is involved in faithful centrosome duplication. Evidence for this comes 
from studies on separase that was found to be responsible for centrosome 
duplication and centriole disengagement. Furthermore in HeLa cells depletion of 
RAD21 causes premature separation of centrioles. A splice variant of shugoshin 
(sSgo1) has been found to be required for protection of centrioles in mammalian 
cells. Work done by Schockel et al have shown that ectopic activation of separase or 
depletion of shugoshin (Sgo1) results in both premature sister chromatid separation 
and centriole disengagement in human cells (Schockel et al., 2011). Clarke and co-
workers have also reported the importance of cohesin subunits (Rad21, Smc1 and 
Smc3) in bipolar mitosis suggesting that the cohesin ring is involved in maintaining 
the spindle pole integrity (Diaz-Martinez et al., 2010). 
1.6! Cohesin and Meiosis 
Meiosis- specific cohesin complexes consist of two structural maintenance of 
chromosomes (SMC1α/ SMC1β and SMC3) the α-kleisin subunit (Scc1/Rad21) 
which is replaced by Rec8 in yeast and metazoans, Rad21L in mammals and C(2)M 
in Drosophila and SA subunit STAG3. It has been observed that meiotic cohesin is 
involved in other cellular functions and not in sister chromatid cohesion. 
1.6.1! Programmed Double strand break repair (PDSB) 
At meiosis, cohesin is involved in programmed DSB repair required in the 
generation of chiasmata, a structure formed due to reciprocal exchange between 
non-sister chromatids. This differs from mitosis where repair is activated to 
maintain the genomic integrity against perturbation and involves recombination 
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between sister chromatids. The difference might have evolved due to the 
recruitment of a different kleisin subunit Rec8 in meiosis as compared to 
(Scc1/Rad21/Mcd1) in mitosis. Apart from its role in PDSB (Programmed Double 
strand break repair) Rec 8 might be involved in creating PDSBs as it has been found 
to colocalize with Spo11, the enzyme responsible for creating PDSB in yeast 
(Kugou et al., 2009). Also co-purification of Rec8 from different organisms with 
Rad51/Dmc1 which coats ssDNA required for strand invasion during PDSB repair 
also argues for involvement of Rec8 in events downstream of PDSB formation 
(Katis et al., 2010). 
1.6.2! Pairing of Homologous Chromosomes 
During meiosis I, pairing of homologous chromosomes takes place through the 
formation of the synaptonemal complex (SC). Cohesin proteins (Smc1, Smc3, 
STAG3) have been found to recruit recombination proteins such as Dmc1 (DNA 
meiotic Recombinase1) and Msh4 (Mut S protein homolog 4) on the chromosomes 
and can promote synapsis even in the absence of axial elements that are required for 
formation of the synaptonemal complex. Rad21L, a meiotic specific kleisin subunit 
is involved in initiating synapsis and recombination between homologs. Deficiency 
of Rad21L in male mice leads to failure in completing synapsis and eventually leads 
to azoospermia and infertility, whilst in female mice, absence of Rad21L leads to 
age related sterility (Herran et al., 2011). Even deficiency of Pds5 which is an 
accessory protein required for maintenance of cohesin has found to lead to failure in 
pairing and formation of synaptonemal complex, but no defects in sister chromatid 
cohesion. A recent study was conducted to assess genetic interactions between 
Stag3 and the α-kleisin subunits RAD21L and REC8 by constructing double 
knockout mouse model of Stag3, RAD21L and Stag3 and REC8 and compare them 
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(a)                                         (b) 
to REC8 and RAD21L double mutants. Stag3 Rad21L were found to be essential 
for axis formation between the chromosomes while Stag3 and REC8 were the main 
complex responsible for centromeric cohesion The ratio of centromere to chromatin 
signal was high for RAD21L single mutant suggesting that RAD21L is essential for 
chromocenter clustering unlike RAD21L, Rec8 double mutant (Ward et al., 2016). 
1.6.3! Monoorientation of sister kinetochore during meiosis 1 
One of the feature of meiosis 1 is that the sister kinetochore of each homolog are 
attached to the same spindle pole during metaphase 1(monoorientation) (Fig 1.10). 
It has been observed in S.pombe, Oryza sativa (rice) and Arabidopsis that during 
meiosis1 mutated/null Rec8 leads to biorientation of sister kinetochores as well as 
SCC defects (Chelysheva et al., 2005, Watanabe and Nurse, 1999). Interestingly in 
higher eukaryote (mice) Rad21 (mitotic homolog) is also expressed and plays a role 
in monoorientation. Consistent with this both Rad21 and shugoshin (Sgo2) have 
been involved in sister kinetochore association during meiosis 1 in mouse 
spermatocyte. 
           
 Figure 1.10: Kinetochore orientation by cohesin in meiosis. (a) A bivalent linked at 
the chiasmata (red arrow) by cohesin. Cohesin orients sister kinetochore towards the 
same pole of the spindle while homologous kinetochore are oriented towards the 
opposite pole in meiosis I (b) One of the two chromosomes derived from bivalent in 
meiosis II. Pool of cohesin around centromere helps in bipolar orientation of sister 
kinetochore in meiosis II. 
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1.7! Cohesinopathies 
Cornelia de Lange Syndrome (CdLS) is the most common dominantly inherited 
congenital malformation disorder occurring in 1 in 10,000 live births. In 65% of the 
Cornelia de Lange probands it occurs due to a heterozygous mutation in the NIPBL 
gene located at 5q13 chromosome and the severe clinical features arise due to 
deletions or truncations in NIPBL (Dorsett and Krantz, 2009). As mutations in 
NIPBL account roughly for only more than half of CdLS, genetic screens was 
conducted to look for mutations in other genes with similar functions in a large 
cohort of CdLS cases without NIPBL mutations, which led to the identification of 
5% of cases with a missense or small inframe deletion in SMC1A X linked gene, 
(Borck et al., 2007, Musio et al., 2006)<1%  mutations in SMC3 (Deardorff et al., 
2007). Since then mutations in other cohesin genes like RAD21 and HDAC8 have 
been identified (Deardorff et al., 2012).   
Roberts syndrome (RBS) and SC phecomelia are homozygous or compound 
heterozygous autosomal recessive disorder caused by a mutation in ESCO2 that 
encodes a member of the acetyl transferase family (Schule et al., 2005). Mutations 
in ESCO2 either cause complete loss of protein or loss of acetyl transferase activity. 
Mutations in ESCO1 have not been reported, as they are lethal. SC phecomelia is a 
milder form of Roberts syndrome in terms of physical defects and mental 
retardation. 
Although mutations in cohesin and cohesin associated genes cause these two 
syndromes the underlying etiology for these two syndromes can be different 
(Skibbens et al., 2013). Most CdLS patient cells do not show any defects in 
chromosomal segregation but rather exhibit gene dysregulation. Direct evidence to 
support this altered gene regulation comes from the study of transcriptional 
regulation of HOXD gene in mammals which is responsible for proximal-distal limb 
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patterning. Expression of HOXD gene, which is found to be reduced in CdLS 
patients, is found to be controlled by cohesin which brings the transcriptional 
control element located 200 kb away close to the transcriptional start site (Dorsett, 
2009, Spitz et al., 2003). Gene dysregulation has also been observed due to 
mutation in cohesin loader in drosophila and zebra fish (Muto et al., 2011). Mice 
heterozygous for a mutation in Nipbl showed characteristics of CdLS. These 
phenotypes arose despite a decrease in Nipbl transcript levels of only approximately 
30%, implying extreme sensitivity of development to small changes in Nipbl 
activity. Further gene expression profiling demonstrated that Nipbl deficiency leads 
to modest but significant transcriptional dysregulation of many genes including the 
protocadherin beta (Pcdhb) genes required for cell surface diversity generation in 
nervous system (Kawauchi et al., 2009). Consequently Horsfield et al has shown 
that mutation in Rad21 leads to developmental delay in zebrafish due to reduced 
expression of runx1 and run3 genes (Horsfield et al., 2007). 
In a study to address how ESCO2 brings about RBS, early embryonic lethality was 
observed in mice deficient in ESCO2 in contrast to human patients with RBS. The 
reason behind this disparity has not been resolved. Deletion of both the copies of 
ESCO2 in mice embryonic fibroblasts (MEF) led to chromosome missegregation 
and apoptosis. In a study conducted by Wheelan et al ESCO2 was found to be 
important for cohesion at heterochromatin regions. In collating these results it has 
been proposed that developmental defects observed in RBS/ SC phecomelia may be 
due to cohesin dependent gene expression changes in heterochromatin regions 
(Whelan et al., 2012). In another study by Bose et al with budding yeast bearing 
mutations analogous to human cohesinopathies (eco-1W216G and smc1-Q843Δ) 
showed defects in ribosome biogenesis and protein translation but no defects in 
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chromosome segregation (Bose et al., 2012). Detailed analysis showed that both the 
mutants produce less ribosomal RNA that is expected to constrain ribosome 
biogenesis. Thus these results demonstrate that cohesin can regulate gene 
expression and cause disease ethology by altering general translational efficiency. 
Recently a new cohesinopathy called Warsaw breakage syndrome has been 
identified which is caused by a defect in DDX gene (also known as CHLR1) a 
member of XPD helicase and could be a novel partner of cohesin pathway probably 
involved in DNA repair and holding the sister chromatids together (van der Lelij et 
al., 2010). 
Enrichment of SMC1A was found at dysregulated genes in Cornelia de Lange 
Syndrome (CdLs) cell lines. Mutant cohesin impaired the occupancy of both Pol II 
and transition to the Pol II elongating form providing a molecular mechanism for 
the typical altered transcription profile observed in CdLs (Mannini et al 2015). 
More recently STAG2 was found to be a dosage sensitive gene, copy number gains 
of which was responsible for causing a novel cohesinopathy with Intellectual 
disability, behavioural problems and other clinical presentations. A large number of 
genes were dysregulated due to STAG2 copy number gains one of which among 
them was oligophrenin1 (OPHN1) that is highly expressed in the brain and 
important for regulation of dendritic morphogenesis and synaptic plasticity. OPHN1 
is located on chromosome Xq12q13.1 and duplication encompassing OPHN1 is 
associated with global developmental delay, autism (Kumar et al., 2015). 
1.8! Cohesin as targets for therapeutic intervention 
Overexpression of SMC1A has been found in triple negative breast cancer and 
supports the idea that in normal cells SMC1A biosynthesis is tightly regulated and 
that an imbalance in the amount of this protein may directly affect the cell survival 
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and other cellular functions. Inhibition of SMC1A showed more than three fold 
increased sensitivity in both BRCA wildtype and mutated triple negative breast 
cancer (TNBC) cell lines including basal-like and mesenchymal stem-like subtypes 
to PARP-inhibitor ABT-888 (Yadav et al., 2013).  Further studies carried out 
showed loss of SMC1A associated with reduced proliferation and induction of 
apoptosis in colorectal and lung cancer cells. In particular associated loss of SMC1A 
mRNA and protein in colorectal cell line increased chemo sensitivity to oxiplatin in 
HT-29 cells (Li et al., 2016, Zhang et al., 2013). 
Mutant high expression of RAD21 was found in tumorigenic cell line as compared 
to normal and immortalized breast cancer cell lines. Down regulation of RAD21 in 
breast cancer cell lines MCF-7 and T-47D had a significant effect on proliferation 
and viability, and further showed increased cytotoxicity to two DNA damaging 
agents etopside and bleomycin. The data from this study speculated RAD21 as a 
new target for breast cancer that could be used as an adjuvant to enhance the 
antitumor activity of traditional chemotherapeutic and radiation treatments (Atienza 
et al., 2005). A study conducted by Gelot et al demonstrated that cohesin complex 
prevents end joining of distal ends in S/G2 phase by suppressing both classic and 
alternate end joining C-NHEJ and A-EJ pathway. Further whole exome sequencing 
of RAD21 depleted SV40 fibroblast led to an increase in sequence insertion, 
duplication and deletion (Gelot et al., 2016). An investigation carried out by Yun et 
al found that reduction of cohesin decreased amplified copy number at genes 
APIP/PDHX/CD44 in chromosomal unstable gastric cell lines and also of c-my 
existing at both HSR (homogenously stained regions) and DM (double minute) in 
chromosomal instable cell lines. Knockdown of RAD21 decreased the recruitment 
of pre-replication complex at amplified genes and reduced the copy number of 
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amplified genes. Reduction in expression of cohesin also sensitized cells to DNA 
damaging agents like cisplatin and PARP inhibitors. In summary they predicted 
cohesin to be responsible for maintaining high copy number in cells with 
chromosomal instability (Yun et al., 2016). 
Mutations in STAG2 and STAG3 (meiotic counterpart of SA proteins) have been 
found to confer resistance to B-Raf proto-oncogene, serine threonine kinase 
inhibitors (BRAFi) in melanoma. A study undertaken by Shen et al showed an 
increase in basal levels of phosphorylated (p)-ERK in these cells due to a significant 
decrease in ERK phosphatase called dual phosphatase specificity 6 (DUSP6) upon 
knockdown of STAG2. The promoter region of DUSP6 was found to contain a 
CTCF binding site which is responsible for controlling gene expression which was 
affected upon knockdown of STAG2 however restoration of DUSP6 in the 
background of STAG2 silenced shRNAs in melanoma cells enhanced the ability of 
BRAFi to inhibit ERK activities. Taken together their results strongly suggested 
that loss of STAG2 inhibits CTCF mediated expression of DUSP6 leading to 
reactivation of MEK-ERK signalling in BRAFi-treated melanoma (Shen et al., 
2016). 
Inhibition of HDAC8 that is responsible for deacetylation of SMC3 by inhibitor 
PCI-34051 did not influence recruitment of estrogen receptor α at SOX4 and IL-2 
genes but rather influenced cell cycle progression and survival. At higher doses of 
inhibitor the cell barely made into S phase and there was an alteration in the 
characteristic shape and cell viability was lost after 48hr of drug treatment 
(Dasgupta et al., 2016). 
Genomic integrity is maintained by the co-ordinated activity of DNA damage 
response pathways, cell cycle checkpoints and alterations in transcriptional 
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regulation. The fate of genomic integrity can be threatened by deleterious double 
strand breaks that can lead to chromosomal rearrangements and apoptosis. Single 
agent PARP inhibitors have been exploited synthetically in various types of cancer 
especially in the area of breast and ovarian cancer however using PARP inhibitors 
in the context of cohesin mutations in myeloid malignancies needs to be explored. 
1.9! DNA double strand repair Pathway 
Of the many types of lesions that exist within a cell, DNA double-strand breaks 
(Bothmer et al.) are the most dangerous, continually threatening genomic integrity. 
DSBs are either created by endogenous sources that include, errors in DNA 
metabolism (e.g. replication across single- strand nicks and replication fork 
collapse), endogenous nucleases, programmed genome rearrangements and reactive 
oxygen species. Numerous DSBs of exogenous origin, both natural (e.g. cosmic 
rays, terrestrial background radiation, certain viruses) and man-made (e.g. weapons 
of mass destruction and diagnostic and therapeutic procedures) threaten the 
genome. 
1.9.1! Challenges faced by Double-Strand-Break Repair Systems 
Some of the requirements for an effective DSB repair include 
a.! Sensitivity: Rapid detection and repair of DSB before a catastrophic event 
i.e. cell death (apoptosis); unregulated cell division leading to tumor 
formation occurs. 
b.! Specificity: The repair system should be able to detect only DSBs but no 
nick, abasic sites; mismatches or interstrand crosslinks that require distinct 
repair systems. 
c.! High fidelity: The ability to repair DSBs without causing any collateral 
damage. 
 68 
d.! The ability to repair a variety of DNA ends including those produced by 
certain forms of irradiation and reactive oxygen species that are not directly 
ligatable. 
e.! The ability to coordinate the timings of repair with the physiological state of 
cell. 
Typically cells uses two main mechanisms for DSBs repair homologous 
recombination (HR) which occurs in S phase and classical non-homologous end 
joining (C-NHEJ) which is dominant in G1 and sub S phases. Various alternate 
error prone pathways like alternate end joining (alt EJ) and single strand annealing 
(SSA) exist as well but contribute towards genomic rearrangement and oncogenic 
transformation. Members of the Phosphotidylinositol-3kinase-related kinases 
(PIKK) through their ability to phosphorylate a large number of substrates play 
important role in different stages of DSB signalling. These kinases are Ataxia-
Telangiectasia-Mutated (ATM) and DNA-dependent Protein Kinase catalytic 
subunit (DNA-PKcs) critical for signalling of DSBs while Ataxia- Telangiectasia 
and Rad3 Related (ATR) is involved in response to DNA single strand breaks 
(SSBs) and stalled replication forks (Bartek and Lukas 2007), (Jazayeri et al., 
2006). In mammalian system MRE11/RAD50/NBS1 (MRN) and Ku 70/80 sensors 
of DSBs that also aid in processing of DNA ends recognise DSBs and recruit ATM 
and DNA PKcs to site of DSBs (Carson et al., 2003, Difilippantonio et al., 2005, 
Mordes and Cortez, 2008). Homologous recombination (HR) repair is tightly 
coordinated with cell cycle progression, which is in large part governed by cyclin-
dependent kinases (CDKs). CDK-mediated phosphorylation of C-terminal 
interacting protein (CtIP) and Nijmegen Breakage Syndrome 1 (NBS1) appears to 
be essential for MRN-mediated DNA-end resection (Limbo et al., 2007, Sartori et 
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al., 2007). MRN complex interacts with the N-terminal of ATM and recruits it to 
DSBs. It is also required for activation of ATM. ATM exists as inactive dimers or 
multimers in undamaged cells however auto phosphorylation in trans leads to its 
dissociation into active monomers. Serine(S) S1981 was the first auto 
phosphorylation site to be identified (Bakkenist and Kastan, 2003). Additional 
phosphorylation sites have been documented at S367 and S1893 that may contribute 
to activation process. Active ATM then promotes recruitment of C-terminal 
interacting protein (CtIP) to damaged sites where it interacts with and stimulates the 
nuclease activity of nuclease meiotic recombination 11 (MRE11) to initiate strand 
resection and generate short tracts of ssDNA. ATM substrates are rapidly 
phosphorylated after activation of ATM and include structural maintenance of 
chromosome-1 (SMC1), (Nijmegen breakage syndrome 1) NBS1, checkpoint 
kinase 2 (CHK2), p53BP1, breast cancer early onset-1 (BRCA1) mediator of DNA 
damage checkpoint protein-1 (MDC1) and γ-H2AX (Lavin, 2008). In response to 
DNA damage ATM, ATR and DNA-PKcs phosphorylates H2AX a histone H2A 
variant on its serine 139  (γ-H2AX) (Rogakou et al., 1998) MDC1 recognizes γ-
H2AX and binds to it through its BRCT domain which further promotes 
accumulation and retention of active ATM and MRN complexes to γ-H2AX 
containing chromatin surrounding the sites of DNA damage (Stewart et al., 2003). 
In undamaged cells MDC1 exists in a complex with MRN however following ATM 
activation MDC1 and its interacting MRN complex are recruited to γ-H2AX. End 
resection occurs in two phases: an initial phase called end clipping and a second 
phase called extensive resection. The initial phase involves MRE11 and CtIP which 
removes a limited number of bases (20 bp in mammalian cells and 100-300 bp in 
yeast) Reviewed in (Ceccaldi et al., 2016). The second phase involves extensive end 
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resection by helicase and endonuclease (BLM, CtIP, EXO1, DNA2, WRN) 
generating 3’ overhangs (Sturzenegger et al., Symington and Gautier, 2011). Upon 
DNA damage the eukaryotic ssDNA binding protein replication protein A (RPA) 
initially competes with RAD51 for single strand binding, however RPA also has a 
pro recombinogenic role once RAD51 is loaded on ssDNA it favours presynaptic 
formation by eliminating secondary structures and by protecting DNA ends from 
degradation (Chen et al., 2013). RAD51 paralogs BRCA2 and RAD52 favour RPA 
displacement, RAD51 nucleofilament formation and strand exchange activity (Fig 
1.11 b). BRCA2 is the main mediator of RAD51 nucleofilament formation and 
strand exchange that it does through a series of eight evolutionary conserved motifs 
called BRC repeats. BRCA2 BRC domains promotes ssDNA binding of RAD51 by 
disrupting self assembled RAD51 oligomers and favouring one to one binding of 
RAD51 monomers. BRCA2 binding also stabilizes ATPase activity of RAD51 
thereby supporting the ssDNA binding activity of RAD51. In a second step the 
BRCA2 C terminal domain binds to RAD51 oligomers in the context of the 
RAD51-ssDNA helix and thus promoting nucleofilament growth and participating 
in strand invasion. This gives rise to D-loop intermediates where the 3’end of 
invading strand primes DNA synthesis using the homologous chromosome as a 
template. The invading strand is disengaged after DNA synthesis and annealed with 







Figure 1.11: Pathways to repair DNA Double Strand Breaks (DSBs). Selection of the 
pathway to repair DSBs primarily depends on end resection. If end resection is 
blocked then repair of DSBs occurs through NHEJ pathway (A) that involves binding 
of Ku70/80 and DNA-PKcs to broken ends. DNA-PKcs phosphorylate a large number 
of substrates like Artemis, XRCC4, DNA Ligase IV, followed synapsis of broken ends 
and ligation followed by end processing and DNA ligation. Once resection has 
occurred repair takes place through HR (B) that involves binding of RAD51 
(recombinase) to resected ends followed by strand invasion using the intact strand as 
template. After DNA synthesis has occurred the invading strand is disengaged 
followed by ligation with the broken ends and results in localized conversion without 
crossovers. 
 
Classical NHEJ is initiated by Ku70/80 end binding which protects broken ends and 
causes the recruitment of catalytic subunit of DNA-dependent protein kinase 
(DNA-PKcs) (Fig 1.11 a) (Jacobs et al., 2011). Ku initially interacts with the distal 
termini of DSB and protects them from end resection (Downs and Jackson, 2004). 
Recruitment of DNA-PKcs translocates Ku inwards by about one helical turn 
allowing interaction of DNA-PKcs 10bp upstream at both termini (Yoo and Dynan, 
1999). DNA-PKcs upon binding causes phosphorylation of a large number of 
substrates including Ku, Artemis, XRCC4, Ligase IV and XLF (XRCC4 like factor) 
followed by synapsis of DNA ends and recruitment of end processing and ligation 
enzymes (Neal and Meek, 2011). Phosphorylation of DNA-PKcs either trans-auto 
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phosphorylation (Chan et al., 2002) or phosphorylation by ATM promotes its 
dissociation from DNA end.  DNA ends in classical NHEJ that have a 5’phosphate 
and a 3’OH group can be ligated directly, however complex ends produced by 
reactive oxygen species or irradiation cannot be ligated directly and hence 
additional enzymes are required to process these termini for ligation. Artemis, a 
nuclease processes free ends for more efficient ligation during cNHEJ (Moshous et 
al., 2003). Once the endonuclease activity of Artemis is activated by DNA-PK, the 
complex is required to remove single stranded DNA overhangs containing damaged 
nucleotides.XRCC4 has been shown to interact with polynucleotide 
kinase/phosphatase (PNKP) that phosphorylates 5’ OH group and dephosphorylates 
3’-phosphate termini providing the correct end groups for DNA ligation. Extension 
of the DNA ends requires a particular DNA polymerase that fills in the end at or 
near the site of DNA damage. Four classes of DNA polymerase have been 
recognised in eukaryotes A, B, X and Y families (Burgers et al., 2001). Three 
members of the pol X family have been associated with mammalian NHEJ. pol λ, 
pol µ and terminal deoxynucleotidyl transferase (TdT) which all share the BRCT 
(BRCA1 C-terminal) domains essential for complex formation between the polX 
members and core cNHEJ factors at DNA ends (Ramsden, 2011). The final step of 
joining the DNA ends in cNHEJ pathway is carried out by DNA XRCC4, Ligase IV 
and XLF complex. Ligase IV has a N-terminal catalytic domain and interacts with 
the α helix of XRCC4 via a region between the two C-terminal BRCT domains. 
Binding of XRCC4 stabilizes and stimulates the activity of Ligase IV (Wu et al., 
2011). 
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1.9.2! Synthetic lethality 
The term Synthetic Lethality was coined by Calvin Bridges in 1922. The concept 
arises from the genetic studies done in Drosophila where loss of one gene function 
is tolerated by overreliance on another gene in a redundant pathway. Synthetic 
lethality occurs when the gene from the redundant pathway is also deleted or its 
product inhibited. Although conventional chemotherapy has been used to treat 
cancer its range and effectiveness has largely been restricted due to its side effects. 
The growing capability of cancer cells to resist chemotherapeutic drugs is one of the 
major drawbacks besides inability to distinguish between normal and malignant 
cells. Also overdosage of drug and immunosuppression has harmful side effects. 
The use of targeted therapy helps to overcome the drawbacks of conventional 
chemotherapy. Targeted therapy stops growth of cancer cells by interfering with 
specific target molecules responsible for carcinogenesis and tumor growth. The use 
of PARP inhibitors especially in the field of ovarian and breast cancer has 
revolutionized the field of targeted therapy. 
1.10! PARP 
Poly (ADP-ribose) polymerases (PARPs) also known as ADP-ribosyltransferases 
(ART) are members of a small family of proteins that play important roles in 
biology (Bock and Chang, 2016). Humans express 17 of these enzymes that 
catalyse the post translational modification of target proteins, a process termed 
PARylation (Luo and Kraus, 2012, Rouleau et al., 2010). PARP1 is the most 
abundantly present isoform and plays crucial role in DNA repair, epigenetic 
modulation of chromatin, regulation of genomic stability, modulation of cellular 
energy pools, the regulation of transcription and a distinct form of cell death called 
parthanatos (De Lorenzo et al., 2013). 
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New directions in poly(ADP-ribose) polymerase biology 
FEBS Journal 
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1.10.1! Structure of PARPs 
Members of the PARP family are characterized by the presence of a conserved 50 
amino acid sequence found in the C-terminal domain that is highly conserved in  
eukaryotes and is also known as the PARP signature (Virag and Szabo, 2002). 
Outside of this domain, PARP enzymes are quite diverse and based on the presence 
of well characterized protein domains are grouped into subfamilies (Fig 1.12). 
PARPs utilize these domains to target them to specific cellular locations, to identify 
target proteins and to regulate the enzymatic activity of catalytic domain. 
 
Figure 1.12: The PARP family. The 17 Human PARPs. PARP1 the mostly widely 
studied PARP enzyme has an N terminal DNA binding domain that contains zinc 
finger binding motif, the central automodification domain, with a BRCT motif and a 
C-terminal catalytic PARP domain that is present in most of the PARP enzymes. 
PARP 13.2 does not contain the PARP domain. (Bock and Chang 2016) 
 
PARP1, a highly abundant nuclear enzyme discovered 50 years ago activated by 
DNA damage, plays an essential role in single strand base repair (SSBR) (Chambon 
et al., 1963). PARP2 has structural similarity and overlapping function with 
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PARP1.The catalytic activity of PARP1 increases by 10-500 fold after it is recruited 
to DNA damage sites, resulting in the synthesis of protein conjugated long ADP- 
ribose polymers. PARP enzymes use nicotinamide adenine dinucleotide (NAD+) as 
a cofactor and transfer the ADP-ribose moiety to form mono or polyADP-ribose 
chain (pADPr) on proteins like histones, topoisomerase1, and DNA protein kinases. 
However, the bulk of pADPr is attached to PARP1 itself resulting in the recruitment 
of over a hundred other proteins, one of which is XRCC1 (X-ray cross-
complementation group 1) that acts as a scaffold for DNA polymerases and ligase 
components of base excision repair machinery (BER) for both short and long patch 
repair (El-Khamisy et al., 2003). Formation of pADPr reduces the affinity of 
PARP1 and histones for DNA providing a mechanism for removing PARP1 from 
the damaged site and local modulation of chromatin compaction. Further polymer 
synthesis is also antagonized by two enzymes that hydrolyse pADPr, poly (ADP-
ribose glycohydrolase) (PARG) and possibly ADP-ribose hydrolase 3 (ARH3) 
(Rouleau et al., 2010). 
Apart from SSBR, PARP1 is also involved in several other biological processes. 
Rapid recruitment of Ataxia telangiectasia-mutated (ATM) to sites of DNA DSBs is 
dependent on pADPr synthesis suggesting that PARP1 acts as a facilitator of 
homologous recombination DSB repair. Haince et al envisaged a model were 
parylation of modified proteins or PARP1 itself facilitates the phosphorylation of 
ATM downstream targets i.e. p53, SMC1A and γH2AX (Haince et al., 2008). 
PARP1 competes with Ku in preventing high fidelity repair and promote mutagenic 
repair by alternate non-homologous end joining (Alt- NHEJ). DSB repair of the 
AID- induced genetic lesions generated during immunoglobulin gene conversion 
are repaired by Alt-NHEJ (Paddock et al., 2011).  
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PARP1 is involved in chromatin modulation and regulating the composition of 
chromatin. Binding of PARP1 to nucleosomes in the absence of NAD+ leads to 
compaction of nucleosomal arrays into high order structures that are refractory to 
invitro transcription. Presence of saturating amounts of NAD+ leads to  
automodification of PARP-1, de-compaction of chromatin and restoration of 
transcription (Kraus, 2008). PARP1 plays a role in altering chromatin composition 
by excluding Histone H1 from the promoters of some PARP-1-regulated genes 
possibly by competing with it to bind to nucleosomes. 
PARP1 acts as a promoter specific co-regulator (either a coactivator or corepressor) 
for a number of sequence specific DNA binding transcriptional regulators such as 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) nuclear 
receptors, Oct-1, specificity protein 1 (Sp1) and others. In most cases, the DNA 
binding motif of PARP is responsible for recruitment of PARP-1 to relevant target 
promoters. PARP-1 can also act as a promoter specific exchange factor that 
promotes the release of inhibitory transcription factors and the recruitment of 
stimulatory factors during signal-regulated transcriptional response (Kraus, 2008). 
Parp1-/- showed hypersensitivity to DNA damaging agents particularly alkylating 
and ionising agents (Shall and de Murcia, 2000). Gene expression profiling in 
Parp1-/- mouse cells and breast cancer cell lines treated with PARP1 short-hairpin 
RNAs (shRNAs) reveal that PARP1 loss or down regulation alters the expression of 
many genes involved in cell cycle control and stress response such as p53 (Frizzell 
et al., 2009, Simbulan-Rosenthal et al., 2000). Among the upregulated genes from 
Parp1-/- fibroblasts were genes involved in the extracellular matrix or cytoskeletal 
proteins that have been reported to play roles in cancer initiation and progression, 
whilst being associated with normal or premature aging. Collectively these 
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observations implicate PARP1 in transcription as well as multiple aspects of DNA 
damage response. 
1.10.2! PARP Inhibitors 
The development of competitive inhibitors of PARP catalytic activity has become 
an area of active research and much recent excitement in PARP field. The focus is 
to develop specific, potent, effective and safe PARP inhibitors that may be used as 
research tools and for clinical therapies. The idea of synthetic lethality to target 
cancer was first highlighted by Hartwell (Hartwell et al., 1997) and colleagues and 
subsequently championed by Kaelin (Kaelin, 2005).The most pertinent example of  
synthetic lethality to treat cancers comes from tumor specific loss of tumor 
suppressor genes BRCA1 and BRCA2 in ovarian and breast cancer (Lord et al., 
2015). BRCA1 and BRCA2 were originally identified as familial breast and ovary 
cancer predisposition genes. PARP1 is involved in the repair of SSBs during BER 
and inhibition of PARP1 leads to the accumulation of SSBs that are converted to 
DSB after replication or stall replication forks. Stalled replication forks and DSB, 
are generally repaired by DNA recombinase RAD51 dependent homologous 
recombination that requires BRCA1 and BRCA2. In the absence of BRCA1 and 
BRCA2, DSB and replication forks cannot be restarted and collapses causing 
persistent chromatid breaks. The repair of these breaks by alternate error prone 
pathways results in the accumulation of large number of chromatin breaks and 
aberrations leading to loss of viability (Fig 1.13). 
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Figure 1.13: Concept of Synthetic Lethality according to BRCA status. External or 
Internal insults to genomic integrity results in the formation of SSBs. XRCC1 (X-ray 
repair cross complementing protein1) which forms a multimolecular complex with 
PARP1 is involved in base excision repair (BER) of SSBs. When exposed to PARP 
inhibitors SSBs accumulate which convert to DSBs and subsequent collapse of 
replication fork. In cells with intact BRCA these breaks are repaired by homologous 
recombination repair pathway leading to DNA repair and cell viability. Cancer cells 
with dysfunctional BRCA are deficient in HRR pathway and when exposed to PARP 
inhibitors DSBs accumulate leading to cell death. 
 
In 2003, two groups demonstrated the potential of using PARP1 inhibition as a 
targeted synthetic lethal approach to treat BRCA –mutant cancers on the basis of 
this model (Bryant et al., 2005, Farmer et al., 2005). 
3-aminobenzamide (3-AB) was the first PARP inhibitor (PI) to be developed, but it 
lacked the requisite potency and selectivity to be used as a research tool or in the 
clinic. All PARP inhibitors have an amide pharmacore and are catalytic inhibitors 
competitive to NAD+. PARP inhibitors do not prevent binding of PARP1 to DNA 
but inhibit synthesis of pADRr polymer and DNA repair. They may further hamper 
repair as first suggested by Satoh and Lindahl by preventing the dissociation of 
PARP1 and thus physically preventing access of repair proteins. However, another 
mechanism of PARP-1 inhibition involving the trapping of DNA/PARP-1 
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complexes has been proposed where PARP-1 inhibitors (olaparib, velaparib, 
talazoparib) binds to the catalytic domain of PARP-1 and causes an allosteric 
conformational change in PARP-1, stabilizing the reversible association of PARP1 
with DNA which results in persistence complexes at SSBs and conversion of SSBs 
into DSBs in HR deficient cells causing cell death (Murai et al., 2012, Murai et al., 
2014).  
1.10.3! PARP as chemo and radiosensitizers 
PARP inhibitors (PARPi) have also been found to increase the cytotoxicity of DNA 
methylating agents, topoisomerase poisons and ionising radiations (IR) in 
combination. Several studies have investigated chemosensitization by second and 
third generation PARP inhibitors. In one of these studies, PARP inhibitor NU1025 
was found to potentiate DNA strand breakage and cytotoxicity induced by 
topoisomerase I inhibitor camptothecin. Lack of PARP activation prevented 
enhancement of etopside mediated cytotoxicity or DNA strand breakage by PARP 
inhibitor NU1025. This differential effect between topoisomerase I and II inhibitors 
could either be cell specific or due to the differences in the nature of DNA strands 
breaks formed by the two topoisomerase inhibitors The results from this 
investigation paved way for the use of PARP inhibitors in combination with 
topoisomerase I inhibitor in anti cancer therapy(Bowman et al., 2001). 
In another study, the PARPi, PD128763 and NU1025 were found to potentiate the 
DNA strand breakage and cytotoxicity induced by temozolomide, Both the 
inhibitors were found to be 40 and 50 fold more potent than 3 aminobenzamide 
(3AB) and benzamide (BZ) and could be used in micro rather than millimolar 
concentration (Boulton et al., 1995). 
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PARP is responsible for the repair of various types of DNA damage caused by 
radiotherapy. Radiosensitization by PARPi may be caused by the accumulation of 
SSBs that are converted to DSBs during replication as is supported by increased 
sensitivity of S-phase cells to IR by PARP inhibitor 4-amino-1, 8-napthalamide 
reviewed in (Curtin, 2014). 
1.10.4! PARP Trials 
In 2005, the first phase I clinical trial began that established preliminary clinical 
evidence of efficacy of using PARP inhibitors to treat BRCA mutant cancers. In an 
initial accelerated dose escalation phase, the maximum dose of PARP inhibitor 
olaparib (AstraZeneca/KuDOs) was well tolerated in 12/19 patients with BRCA1/2 
mutated breast, ovarian and prostrate cancer with an objective response rate (ORR) 
of 47% and disease control rate (DCR) of 63%. Further myelosuppression and 
nervous system side effects were much milder than those elicited by standard 
chemotherapy (Kilburn and Group, 2008) A retrospective analysis showed that 
platinum sensitive patients showed the most favourable response to olaparib with a 
response rate of 69%. 
On the basis of the promising results of phase I trials, two phase II trials in chemo-
refractory breast and ovarian cancer used olaparib at two doses of 400mg and 
100mg twice a day. The ovarian cancer cohort showed an effective response rate of 
33% while a response rate of 41% [median progression free survival (PFS) of 5.7 
months] was observed in breast cancer cohort with 400-mg twice a day (Audeh et 
al., 2010, Tutt et al., 2010). Progression-free survival (PFS) is defined as the time 
from random assignment in a clinical trial to disease progression or death from any 
cause. 
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Two additional phase II studies by Germon et al (Gelmon et al., 2011) and 
Ledermann et al (Ledermann et al., 2012) (commonly referred to as study 19) in 
sporadic advanced ovarian and triple negative breast cancers (TNBC) were 
initiated. In the Gelmon study, the presence or absence of BRCA mutation was used 
as a selection criteria and patients received 400mg of olaparib twice a day, 
sustained antitumor response which correlated with prior platinum sensitivity was 
seen even in the absence of BRCA mutation in the ovarian cohort while in the 
breast cancer cohort despite reduction in tumor and higher frequency of disease 
stabilization no sustained response was achieved either in BRCA mutated or non 
mutated group. The Ledermann study assessed the utility of olaparib as a 
maintenance therapy in high grade serous ovarian cancer (HGSOC) after showing 
an initial response to platinum. The PFS for germline or somatically occurring 
BRCA1 and BRCA2 was 11.2 months versus 4.3 months for patients who received 
placebo.  
The approval of Olaparib in 2014 for the treatment of BRCA deficient ovarian 
cancers validated PARP-1 as an anticancer target and established its clinical 
importance in cancer therapy. Around nine PARP inhibitors are currently active in 
various clinical trials which show potent activity (IC50 in the nM range) but 
nonselective inhibition of PARP-1 and PARP-2 (Wang et al., 2016). 
Varied PARP activity was also found in a cohort of 109 Chronic Lymphocytic 
Leukaemia (CLL) patients. Parp activity correlated with PARP1 protein expression, 
however no association was found between PARP activity and p53 status or ATM 
loss, Binet stage, IGHV mutational status or survival but significant correlation was 
found between Bcl-2 (antiapoptotic factor) and Rel A (an NF-κB subunit). Further 
culturing of CLL cells on an irradiated monolayer showed sensitivity to potent 
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PARP inhibitor talazoparib at nM concentrations independent of p53, ATM or HRR 
status and hence suggested PARP1 as a therapeutic target in CLL by PARP 
inhibitors (Herriott et al., 2015). 
A substantial amount of work in the field of PARP has been done by Gaymes et al 
from our group. Initial work carried out by him proposed that chromosomal 
instability disorders like Fanconi anaemia and Blooms syndrome which show 
increase propensity to transform to leukaemia could be targets for PARPi therapy 
due to DNA repair defects. The data also suggested that PARPi can target cells with 
defects in DNA repair and signalling molecules rather than sole defects in 
homologous recombination. The chromosomal unstable cell lines showed 
sensitivity to PARPi and increase in non homologous end joining activity and 
proposed that increase non homologous end joining and loss of HR competency 
make chromosomal instability syndromes sensitive to PARP inhibitors (Gaymes et 
al., 2008). Subsequent study conducted by him showed that PARP inhibitors cause 
cell cycle arrest and increase apoptosis in primary leukaemic samples and 
leukaemic cell lines. The effect of PARP inhibitors were potentiated by the use of 
histone deacetylase inhibitors (HDAC) and supported the feasibility of phase I 
clinical trial alone or in combination in AML and high risk MDS (Gaymes et al., 
2009). Further another study showed that microsatellite instability (MSI) is caused 
due to defects in the mismatch repair genes (MMR) and MSI dependent mutations 
in DNA repair genes like MRE 11 and CtIp confer sensitivity to PARP inhibitors 
(Gaymes et al., 2013). 
Lastly work carried out by another group in our department showed that recessive 
transcriptional factors in AML like AML ETO and PML RARA showed strong 
sensitivity to PARP inhibitors as compared to MLL-fusions which were insensitive 
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to PARP inhibitors and found Hox-A9 responsible for the differential effect. In 
activation of Hox9 in AML1 ETO and PML RARA made them insensitive towards 
PARP inhibitor olaparib. Combined use of PARPi along with Hox-A9 inhibitor 
achieved selective killing of otherwise PARPi resistant MLL leukemic cell line 
revealing a novel venue to overcome Parp resistance in AML (Esposito et al., 2015) 
A large number of inhibitors have been developed against common mutations in 
AML. 5-azacytidine and 5-aza2deoxycytidine (decitabine) are hypomethylating 
agents which have been found to reverse aberrant DNA hypermethylation leading to 
restored expression of critical tumour-suppressor genes and have been used against 
DNMT3 mutations (Challen et al., 2011). Synthetic lethality has also been reported 
between IDHI/2 mutations and inhibitors of BCL in AML and are being used in 
clinical trials 
Lastly work done by Gaymes et al in our group has shown that 15-20% of 
leukaemic  patient sample cells  in his cohort were  sensitive to PARP inhibitors. 
Identification of cohesin mutations in myeloid malignancies as target for 
therapeutic intervention will help in the selection of suitable candidates for PARP 
inhibitor treatment so a part of my work will be focussed to unravel this possibility. 
Hence the aim of this study is  
To determine the prevalence of occurance of cohesin mutations in a cohort of MDS 
patients and co-relate this with other genetic mutations, survival, response to 
therapy. 
To determine the functional consequences of knockdown of STAG2 in a myeloid 
cell line. Exploiting STAG2 as a target for therapeutic intervention through 
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Rabbit anti-SMC1A 1:500 ab21583 abcam 
Rabbit anti-SMC3 1:1000 ab9263 abcam 
Mouse anti-RAD21  05-908 Millipore 
Mouse anti-STAG2 (J-12) 1:500 sc-81852 
Santa Cruz 
Mouse anti-STAG1 (LL-16) 1:200 sc-81851 
Santa Cruz 
Rabbit anti-RAD51 (H-92) 1:50 sc-8349 
Santa Cruz 
Mouse anti-Phospho-γH2AX 1:50 JBW 301 
Millipore 
β-Actin 1:4000 ab8580 abcam 





HRP-conjugated anti-mouse antibody 1:3000 Sigma 
HRP-conjugated anti-rabbit antibody 1:3000 Sigma 
Anti mouse IgG FITC 1:200 Sigma 
Anti rabbit IgG TRITC 1:200 Sigma 
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2.1.2! PCR, Gel Electrophoresis and Sequencing Materials 
Agarose, molecular biology grade /electrophoresis grade Sigma 
BigDye Terminator v3.1 cycle sequencing kit Applied 
Biosystems 
BigDye XTerminator purification kit Applied 
Biosystems 
Ethidium Bromide Sigma 
Filtered and unfiltered tips Star labs 
Gel cleaning kit QIAEX II, gel extraction kit Qiagen 
GoTaq ®colourless Master Mix Promega 
Nuclease free Water Sigma 
O’Gene Ruler ladder mix (0.1 µg/µl) Fermentas 
6x Orange DNA loading dye Fermentas 
50XTris Acetate EDTA buffer (TAE buffer) Sigma 
2.1.3! DNA and RNA extraction reagents 
  
2.1.4! Cloning Reagents 
Chloroform Sigma 
DNeasy blood and tissue kit Qiagen 
Ethanol Sigma 
2-Propanol (Iso-propanol) Sigma 
RNase free water Qiagen 
TRizol Invitrogen 
BactoAgar Becton Dickson 
Bacto Yeast Extract Becton Dickson 
Carbenicillin solution 100mg/ml in 50% ethanol (10 ml) Bioline 
GenElute ™ HP Plasmid Maxiprep Kit Sigma 
One Shot ® Mach1™ T1R chemically competent E.coli Invitrogen 
Sodium Chloride (NaCl) Sigma 
Tryptone enzymatic digest Sigma Aldrich 
Wizard ® Plus SV Miniprep DNA purification kit Promega 
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2.1.5! Tissue culture reagents 
Dimethyl sulfoxide (DMSO) Sigma 
Eagles Minimum Essential Medium (EMEM) ATCC 
70% Ethanol (Fixing cells) Haymankimia 
Fetal Bovine serum Sigma 
Neubauer Improved Haemocytometer VWR International 
Penicillin/Streptomycin solution PAA 
Phosphate Buffered Saline (PBS) PAA 
Roswell Park Memorial Institute Medium (RPMI- 1640) Thermo Fisher 
Scientific 
Trypan Blue 0.4%, 0.85% NaCl Lonza 
 
TrypLE ™ Express Enzyme Thermo Fisher 
Scientific 
2.1.6! Transfection reagents 
Amaxa cell line nucleofector kit V Lonza 
Ingenio cuvettes Cambridge Bioscience 
Ingenio electroporation solution Mirus 
Ingenio pipettes Cambridge Bioscience 
Polybrene Sigma 
Puromycin Sigma 
2.1.7! Plastic and glass ware 
15 and 50 ml falcon tubes VWR International Limited 
25, 75 and 175cm2 ventedtissue culture flasks VWR International Limited 
5ml, 15ml, 25ml serological pipettes VWR International Limited 
6, 12, 24, 96 well plates VWR International Limited 
10µl, 200µl and 1ml filter tips Star labs 
Coverslips BDH coverslips 
Cryovials Greiner bio-one 
1.5ml microcentrifuge eppendorf tubes Star labs 
Poly lysine coated slides Sigma 
Syringe filters 0.22 and 0.45µm Millex 





2.1.9! Cell lines 
 
2.1.10! cDNA synthesis and qPCR reagent 
FastStart Universal Probe Master mix Roche Diagnostics 
MicroAmpTM Fast Optical 96 well reactions plate with 
Barcode 
Life Technologies 
Optical cap Roche Diagnostics 
qPCR primers Integrated DNA 
technologies 
SuperScript® VILO TM cDNA Synthesis kit Life Technologies 
 
2.1.11! Western Blot reagents 
Spectra Multicolor Broad Range Protein Ladder Thermo Scientific Fisher 




Dithiothreitol (DTT) Sigma 
Nitrocellulose Membrane GE Healthcare 
Expression plasmid Plasmid description Manufacturer 
GIPZ STAG2 shRNA Generation of lentivirus Thermo Fisher 
pMDG, p8.9 Generation of lentivirus Dr David Darling 
pLKO Generation of lentivirus AddGene 
Retroviral p-GFP-V-RS Origene 
Cell line Source Provider 
HEK293-T Human Embryonic Kidney Dr David Darling 
U-937 Histiocytic Lymphoma Dr Terry Gaymes 
UM-UC3 Urinary bladder ATCC 
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Non fat dried milk (Marvel) Sainsbury 
Nupage (4-12%) Bis-Tris gel Life Technologies 
Nupage® LDS Sample buffer (4X) Life Technologies 
Nupage ®Transfer buffer (20X) Life Technologies 
Nupage ®Tris-Acetate SDS Running buffer 
(20X) 
Life Technologies 
Tween 20 Sigma 
2.1.12! Protein Estimation Reagents 
Bovine Serum Albumin (BSA) Fisher Scientific 
Radio Immunoprecipitation Assay (RIPA) lysis buffer BioRad 
Phenyl methane sulfonyl fluoride (PMSF) BioRad 
Sodium orthovanadate BioRad 
Protease Inhibitor cocktail solution Bio-Rad 
Alkaline Copper Tartarate solution Bio-Rad 
Dilute Fooling Reagent Bio-Rad 
Solution S Bio-Rad 
 
2.1.13! Cell viability and cell cycle reagents 
7-Aminoactinomycin D (7-AAD) BioLegend 
Cell based Assay Annexin V Binding buffer Cayman 
Fluorescein isothiocyanate (FITC) Sigma 
FITC Annexin V BioLegend 
Propidium Iodide (PI) Sigma 











2.1.15! Drugs used 
 
2.1.16! Buffers, solutions and media 
Blocking solution for western blots: 5% w/v marvel milk powder was dissolved in 
PBST 
 
Blocking solution for Immunocytochemistry: 1% (w/v) BSA was dissolved in PBS.    
 
Cell cycle staining solution: 400µl of propidium iodide, 50µl of FITC and 100µl of 
1 mg/ml RNAse A. Made upto 10ml in PBS. 
 
10X DNA loading dye: 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol, 
30% (v/v) glycerol. Made up in dH2O and stored at room temperature. 
 
Eagle’s Minimum Essential Medium: 10% heat inactivated Fetal Bovine Serum 
(FBS), 100 U/ml penicillin and 100 µg/ml streptomycin was added and stored at 
4°C. 
 
2X HEBS: 0.28M NaCl, 0.05M HEPES, 1.5mM Na2HPO4, pH 7.0. Made up in 
dH2O, filter sterilized and stored at 4°C. 
DAPI (4’, 6-diamidino-2-phenylindole) Sigma 
Goat serum Sigma 
Mounting medium Merck 
4% Paraformaldehyde Sigma 
BMN-673 Biomarin 
Cisplatin Sigma 
AZD 1152 –HQPA Aurora-kinase B inhibitor Sigma 
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Freezing medium for cell culture: 10% DMSO, 90% FBS. Made prior to use and 
stored at -20°C. 
 
Luria-Bertani (LB) Broth: 1% (w/v) bactotrytone, 0.5% (w/v) yeast extract, 1% 
NaCl, 2 ml NaOH for 1 litre LB. 
 
Luria-Bertani (LB) plates containing selective antibiotics: 1.5% (w/v) agar was 
added to LB broth and then autoclaved. The solution was cooled to 50°C followed 
by the addition of appropriate antibiotic and then mixed in a hood. The antibiotic 
containing LB agar was then poured into 100 mm dishes allowed to solidify and 
then stored at 4°C until further use. 
 
Penicillin/ Streptomycin: The 100X stock solution was aliquoted into 5 ml falcon 
tubes. 
2.2! Protein Extraction 
Whole cell protein extracts were prepared using Radio-Immuno Precipitation Assay 
(RIPA) with cell lysis buffer (50mM Tris-HCl pH 8, 150mM NaCl, 1% NP-40, 1% 
Sodium deoxycholate, 0.1% SDS) containing 1mM PMSF (phenyl methyl 
sulphonyl fluoride), sodium orthovanadate and cocktail protease inhibitors (Bio-
Rad). 100µl of freshly prepared ice-cold RIPA lysis buffer was used to lyse the cell 
pellet and was incubated on ice for 30min with intermittent vortexing. Cellular 
debris was pelleted  (7500 × g, 5min, 4°C) and the protein supernatant was 
transferred to a fresh tube. Protein lysate was stored at -20°C. 
2.2.1! Protein Assay 
Protein concentration was measured using the DCTM protein assay (Bio-Rad), a 
detergent compatible colorimetric assay following detergent solubilisation. Based 
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on the well-documented Lowry method, the assay is based on the reaction of the 
protein with an alkaline copper tartarate solution and Folins reagent. Copper 
tartarate treated protein causes the reduction of Folins reagent by loss of oxygen 
atoms that results in a quantifiable blue colour change proportional to protein 
concentration. Comparison to a standard curve enables the protein concentration to 
be measured. Reaction was performed according to the manufacturer’s microplate 
assay protocol. Serial dilution of Protein standard II (bovine serum albumin) 1.4 – 
0mg/ml was used to create a standard curve. 5µl of protein lysate or standard was 
first mixed with 25µl of reagent A (Bio-Rad) and then 200µl of reagent B (Bio-Rad) 
followed by incubation at room temperature for 15 min. Colour change was 
measured by absorbance at 750nm and protein concentration calculated against the 
standard curve. 
2.2.2! Western Blotting 
Western Blot was used to identify specific proteins in cell lysates under denaturing 
and reducing conditions. Polyacrylamide gel electrophoresis (PAGE) was used to 
size separate protein before transfer and immobilisation onto nitrocellulose 
membrane. The membrane was blocked in 5% milk powder made in PBS Tween 
for 1 hr followed by probing with a primary antibody specific to the protein under 
investigation overnight on a roller at 4°C. Detection was achieved using secondary 
antibody conjugated with horseradish peroxidase (HRP) and enhanced 
chemoluminescence reagents a mixture of luminol and hydrogen peroxide. In the 
presence of hydrogen peroxide HRP catalyses oxidation of luminol exciting it to 
emit light, which can be detected using X-ray, film. 
Pre cast gels (4-12% Bis-Tris Gel) (Invitrogen) were used to separate proteins. 
Protein samples (15 µg) were prepared by adding sample buffer to a concentration 
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of 1X and 1µl (10%) of DTT (dithiothreitol) followed by heat denaturation at 100°C 
for 5-10 min. 10µl of sample was loaded alongside a size standard protein ladder 
and gel were run at 170V for 1hr in 1X running buffer (25mM Tris, 0.2M glycine, 
0.1% SDS). Post electrophoresis the stacking gel was trimmed from the lower 
resolving gel and discarded. To transfer the proteins from the gel a corresponding 
size of nitrocellulose membrane (GE Healthcare) was placed on top of the gel, 
which was then sandwiched between, two filter cards of same size one on each side 
and three nylon pads soaked in running buffer. Extra care was taken not to create or 
avoid any bubbles between the layers. Proteins were transferred from the gel onto 
the membrane at 20V in 1X transfer buffer for 1hr. After 1hr the nylon pads were 
again soaked in transfer buffer and transfer was continued again for 1hr. After the 
transfer was complete the membrane was incubated in blocking solution (milk 
powder) for 1hour to reduce nonspecific antibody binding after which an 
appropriate dilution of primary antibody was made in blocking solution and added 
to the membrane. The membrane was kept on roller at 4°C overnight. Next day the 
membrane was washed three times in 0.1% PBST (Phosphate Buffer Saline Tween) 
five min each before incubating in an appropriate concentration of secondary 
antibody again made in blocking solution for 1hr at room temperature. After 1hr the 
membrane was again washed three times in PBST before developing with 5 ml of 
ECL solution (GE Healthcare) for 5min. The membrane was wrapped in plastic and 
secured in a developing cassette for X-ray film exposure. 
2.3! RNA Extraction 
1×106 cells were pelleted and resuspended in 1ml TRIzol® (Invitrogen) followed by 
vigorous vortexing. TRIzol® reagent is a monophasic solution of phenol, guanidine 
isothiocyanate and other proprietary components which facilitate the isolation of 
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RNA. TRIzol® reagent maintains the integrity of the RNA due to the highly 
effective inhibition of RNase activity while disrupting cells and dissolving cell 
components during sample homogenisation. The pellets were either stored at -80°C 
or the samples were processed immediately by incubating for 5min at room 
temperature. 20 µl of chloroform were added to the homogenised samples and then 
centrifuged at 12,000×g for 15min at 4°C separating the homogenate into a clear 
upper aqueous layer (containing RNA), an interphase and a red lower organic layer 
containing the DNA and proteins. The separated aqueous layer was transferred to a 
fresh microcentrifuge tube, 500µl of 2-propanol was added to precipitate RNA and 
then the mixture was incubated at room temperature for 10min. The samples were 
centrifuged at 12,000×g for 10 min at 4°C. The supernatant was discarded and the 
pellet was washed with 1ml of 75% (v/v) ethanol vortexed and then centrifuged 
again at 7500×g for 5 min. The supernatant was discarded and the RNA pellet was 
air-dried for 30 min. The pellet was resuspended in 20 µl of RNase free water and 
the concentration was determined using a spectrophotometer (Thermo Scientific™ 
Nanodrop). 
 
SuperScript VILOTM cDNA synthesis kit (Cat No: 117540450) was used to reverse 
transcribe 100-1000 ng of total RNA according to manufacturer’s protocol (Table 
2.1). Incubation was carried on the above mix at 25°C for 10 min and then at 42°C 
for 60min. The reaction was terminated for 5min at 85°C. The cDNA samples were 
stored at -20°C. The cDNA samples were diluted to 10ng accordingly depending on 





Table: 2.1 cDNA synthesis master mix 
Reagent Volume 
10X Superscript Master Mix 2µl 
RNA (upto 1µg)  
Water to 10µl 
 
2.3.1! Quantitative Real Time PCR (q-RT PCR) 
FastStart Universal Probe Master mix and probes from Universal Probe Library 
(Roche Diagnostics) were used to perform Quantitative Real time PCR. The probe 
finder assay design software available on Roche website was used to design target 
specific primer sequences and the matching universal library probe. Each sample 
was run in triplicate to avoid variations (Table 2.2). 
Table 2.2: Preparation of Real-time PCR master mix 
Reagent Volume 
FastStart Universal Probe Mastermix 10µl 
cDNA 5µl 




The thermo cycling conditions on the StepOnePlus Real-Time PCR (Applied Bio systems) 
(Table 2.3). 
 
Table 2.3: qPCR Cycling Conditions 
Temperature Time No of cycles 
50°C 2 min 1 cycle 







The 2-ΔΔCT was used to calculate relative changes in gene expression determined from real 
time quantitative PCR experiments using GAPDH and TUBULIN as housekeeping genes. 
Amount of target= 2-ΔΔCT 
ΔΔCT = ΔCT target - ΔCT calibrator/wildtype 
ΔCT = CT target - CT GAPDH or TUBULIN 
Where CT is the threshold cycle. 
 96 
2.4! Cell culture 
2.4.1! Culturing of cell lines 
Suspension cell line U-937 was cultured in RPMI medium supplemented with 10% 
(v/v) FBS and 1% (v/v) penicillin/streptomycin. Cells were maintained at a cell 
density between 1×105-2×106 cells /ml and media was replaced every 3-4 days. 
Adherent cell line UMUC3 was cultured in UMEM media with 10% (v/v) FBS and 
1% (v/v) penicillin/streptomycin in a ratio of 1:4 to 1:10. Media renewal was 
carried 2 to 3 times per week by discarding the culture media and rinsing the cells 
with PBS to remove all traces of serum that contain trypsin inhibitor. 5-6ml of 
TrypLETM Express (1X) Phenol Red was added to the flask and the flask was left in 
the incubator for 5-15 min for cells to detach. TrypLETM Express cleaves peptide 
bonds on the C terminal sides of lysine and arginine and is a direct replacement for 
trypsin. Its exceptional purity increases specificity and reduces damage to cells that 
can be caused by other enzymes present in some trypsin extracts. To neutralize the 
trypsin UMEM was added in larger volume and the cells were then spun down at 
300×g for 5 min. Supernatant was removed and cells were resuspended in desired 
volume after counting the cells. 
2.4.2! Cell counting 
Cells were mixed with trypan blue in a 1:10 ratio to distinguish between live and 
dead cells. Trypan blue is a vital stain that is not absorbed by healthy viable cells. 
When cells are damaged or dead, trypan blue can enter the cell allowing dead cells 
to be counted. This method is sometimes referred as dye exclusion method. 50µl of 
cell suspension was resuspended in 400µl of media and then 50µl of trypan blue 
was added to it and loaded on the haemocytometer (Neubauer cell counting 
chamber, depth 0.1µl) to count the cells. Cells that were healthy and not stained 
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were counted from four corner squares and the following calculation was used to 
determine concentration of cells per ml. 
 
Cells/ml= Average of cells in four corners× dilution factor ×104 
 
2.4.3! Cryopreservation of cells 
Adherent cell line after trypsinization as described in section 2.4.1 and suspension 
cell line were spun at 300 × g for 5 min and then resuspended in 1 ml of freezing 
media and stored in cryovial tubes (UMEM freezing media for adherent cell line 
and RPMI freezing media for suspension cell line at a density between 1-5×106 cells 
/ml). The tubes were placed in cryo freezing container (Nalgene, Mr Frosty) 
overnight and then transferred into liquid nitrogen next day. 
2.5! Cell Cycle Analysis 
2.5.1! Cell cycle staining 
3×105 cells were pelleted at 300 ×g for 5min and then washed with PBS. The cells 
were then fixed using 1 ml of ice cold 70% ethanol (v/v) while continuously 
vortexing and the cells were stored at -20°C. For cell cycle analysis the cells were 
centrifuged again at 300 ×g for 5min and the ethanol was removed. The pellet was 
air dried for 15min to remove traces of ethanol and then 400µl of staining solution 
Refer to section 2.1.16 was used to resuspend the pellet followed by incubation for 
30 min at 37°C and running the sample on a FACS Canto II machine (Becton-
Dickinson). 
2.5.2! Cell cycle analysis by flow cytometry 
DNA analysis is the second most important application of Flow cytometry (Flow 
cytometry a basic introduction). By measuring the DNA content of individual cells 
information, can be obtained about their ploidy, which is of particular relevance in 
 98 
tumours, and for a population the distribution of cells across the cell cycle. Flowjo 
software (Flow jo LLC) was used to analyse data. Various gating strategies were 
used to include only single viable cells eliminate debris, dead cells and clumps to 
produce a histogram plot that gives the percentage of cells in each phase of cell 
cycle and to ascertain whether knockdown of a particular gene has any effect on 
any phase of cell cycle. 
2.6! Annexin V Staining 
Apoptosis or programmed cell death is a normal physiological process for removal 
of unwanted cells. In apoptotic cells, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the 
plasma membrane, thereby exposing PS to the external cellular environment. 
Annexin V is a 35-36 kDa Ca2+ dependent phospholipid-binding protein with high 
affinity for PS and binds to expose apoptotic cell surface PS. Annexin V can be 
conjugated to fluorochromes while retaining its high affinity for PS and thus serve 
as a sensitive probe for flow cytometric analysis of cells undergoing apoptosis. 7-
aminoactinomycin D (7AAD) is a viability staining solution and can penetrate the 
membrane of dying cells and stain them to discriminate between dead and live cells 
and in an apoptotic assay it is used to distinguish between apoptotic and necrotic 
cells. 
2.5×10 5 cells were added to a FACS tube. The cells were washed with 1ml of PBS 
and then spun down at 500×g for 5min.The supernatant was removed and cells were 
resuspended in either 50µl of buffer, Annexin V, 7AAD or both followed by 
incubation for 15min at room temperature in the dark and then topped up with 
250µl of 1X FACS buffer before reading the sample on the canto machine. 
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2.7! Immunocytochemistry 
3×105cells of log phase STAG2 deficient cells were seeded in a 24 well plate in 1ml 
of media. 1µl of 100 µM BMN-673, was added to deficient as well as control cells 
and cells were incubated in the drug for 24hr. After 24hr the cells were spun down 
at 300 ×g for 5 min and then resuspended in 300µl of PBS. 150µl of cell 
suspensions were cytospin on a poly-lysine coated glass slides at a speed of 300×g 
for 5min. The cell pellet was allowed to dry and circled using a Dako-pen. The cells 
were fixed using 4% paraformaldehyde for 15min and then washed three times each 
with PBS for 5min. 0.1% Triton X 100 (v/v) in PBS was used to permeabilize the 
cells for 5 min maximum followed by three washes with PBS for 5min and then 
blocked using 5% sheep or goat serum in 1% BSA in PBS for half an hour. The 
slides were washed briefly and then incubated in 50µl of primary antibody (RAD51, 
phospho-γH2AX) made in 1% BSA in PBS for 60min. The slides were washed 
twice with PBS for 10 min and then incubated in 200µl of secondary antibody anti-
IgG –FITC/TRITC for 60min in the dark and then washed again twice with PBS. 
The slides were then incubated with a drop of DAPI (50-100µg/µl) diluted 1:1000 
in PBS for 5min at room temperature and then was washed again for 10min in PBS. 
The slides were dried at room temperature for 5min and then were mounted using 
vectashield. 
2.8! siRNA 
siRNA SMARTpool (Cat no: 10735) from Thermo Scientific was used to target 
STAG2. Scrambled siRNA of similar construct was used as a control. The results 
obtained from using SMARTpool siRNA were validated using siRNA from Santa 
Cruz Biotechnology (catalogue no sc-62970). 
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2.9! Retroviral siRNA 
Four retroviral shRNA against STAG2 were obtained from Origene 
(Cat no: T1336253, T1336254, T1336255 and T1336256). 
2.10! Transfection of cells 
2.10.1! Transfection by Nucleofection 
After harvesting and counting the cells 2×106 cells were resuspended in 100µl 
nucleofection solution. 1µg of shRNA or 100nM of siRNA was added to the cells. 
The cell suspension was transferred to a nucleofector cuvette and the cuvette was 
placed in a nucleofactor device after selecting the appropriate programme for cell 
type (W-001 for U-937). 500µl of media was added to cuvette immediately and the 
cell suspension was gently resuspended using a Pasteur pipette and transferred to a 
6 well tissue culture plate. The transfected cells were topped up with 1ml media and 
samples were collected after every 24hr for 3 days. 
2.11! Lentivirus short-hair pin RNA (LVshRNA) virus particleproduction 
Six shRNAs were used to knockdown STAG2 of which four GFP labelled STAG2 
lentiviral RNAs (Cat no: V2LHS-198853, V2LHS-207886, V3LHS-391825 and 
V3LHS-391830) were obtained from Fisher Scientific and two shRNAs (Cat no: 
3782 and 1221) were obtained from Addgene. HEK 293T (Human Embryonic 
Kidney) cells were seeded at a density of 1.1 × 108 cells for 1000cm2 layer flasks 
[T1000 flasks, Millipore] using DMEM (10% FCS, 1% Pen/Strep) media and 
transiently co-transfected with three plasmids pMDG (envelope plasmid encoding 
VSVG), p8.9 (gag, pol) and the shRNA against STAG2. 
The pool of plasmids containing pMDG (135 µg), p8.9 (315 µg) and shRNA (450 
µg) were diluted to a total volume of 11.25 ml with dH2O. 11.25 ml of 0.5M CaCl2 
was added to the mixture. 22.5 ml of 2× HEBS was added to the mixture dropwise 
while vortexing and incubated for 30 min. After 30min pools of plasmids were 
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diluted in 150 ml DMEM added to 293T cells and the cells were incubated for 16 hr 
at 37°C and 5% CO2. The media was replaced with fresh DMEM after 24 hr and 
incubated for 24 hr further. After 48hr the supernatant was collected and filtered 
through a 0.45µm filter and concentrated at 10,000 × g overnight at 6°C. The 
supernatant was removed and pellet was air-dried for half an hour and resuspended 
in 500µl of RPMI-1640 medium and stored at -80°C. 
2.11.1! Lentiviral transduction 
Cells were seeded at a density of 4×105 cells in 1 ml of RPMI in a 24 well plate. 
Viral particles (12 µl) along with 4µg/ml of polybrene were added. After 48hr the 
cells were topped with 1 ml of fresh media and 2µg /ml of puromycin was added for 
selection. After 4 days the cell were transferred into a T-25 flask and maintained for 
14 days under puromycin selection. 
2.12! Cloning 
2.12.1! Transformation in DH5α-T1 E.coli 
Transformations were performed using chemo-competent DH5α- T1 cells (Life 
Technologies). The cells were thawed on ice for 4-5min and then 1µl of DNA was 
added, mixed by flicking the tube and then incubated on ice for 30min. The cells 
were heat shocked at 42°C for 30 seconds and then immediately placed on ice for 
2min. 500µl of S.O.S media (Invitrogen) was added to the cells and then incubated 
at 37°C for 1hr with continuous shaking for cells to recover. After 1hr 100µl of 
cells were plated on LB agar plates containing ampicillin (100µg/ml). 50 µl of cells 
were diluted in 50µl of LB and were plated on a second plate, plates were dried in 
the hood and then placed upside down in a 37°C incubator. 
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2.12.2! Miniprep: Alkaline Lysis Method 
Pure Yield ™ Plasmid Miniprep system (Promega) was used to isolate plasmid 
DNA from bacterial colonies. Bacterial colonies were picked from LB plates and 
inoculated in 5ml LB broth containing appropriate antibiotic. The bacterial cultures 
were grown at 37°C in Innova 4300 incubator shaker. The turbid culture was 
pelleted at 2340 × g (Rotanta 460R Hettich centrifuge) for 10min and resuspended 
in 100µl of PBS. Cells were lysed using 100µl of cell lysis buffer and mixed by 
inverting the tube several times. The reaction was neutralized by adding 350µl of 
ice-cold neutralization solution (4-8°C) and mixed thoroughly by inverting. The 
mixture was centrifuged at full speed in a microcentrifuge for 3min and the 
supernatant was transferred to a Pure Yield TM Minicolumn. The minicolumn was 
placed in a collection tube and centrifuged at 13000rpm for 15secs. The flow-
through was discarded and 200µl of Endotoxin Removal Wash was added and 
centrifuged for 13000 rpm for 15secs. The column was washed with 400µl of 
column wash solution and again centrifuged at 13000 rpm for 30sec. The DNA was 
eluted by transferring the minicolumn into a 1.5 ml microcentrifuge tube and 
incubating at room temperature with 30µl of elution buffer followed by 
centrifugation at 13000 rpm for 15secs. The eluted DNA was stored at -20°C. 
2.12.3! Maxiprep: Gen Elute HP Plasmid Maxi Prep 
Maxiprep was used to produce DNA in bulk. A single colony was inoculated in 5ml 
LB broth containing appropriate antibiotic and was incubated for 5-6 hrs at 37°C as 
previously mentioned. After 5-6 hours the starter culture was diluted into 150 ml 
LB broth with appropriate antibiotic and grown overnight. The bacteria was 
pelleted by centrifugation at 5000 × g for 10 min and supernatant was discarded. 
The pellet was completely resuspended in 12 ml of Resuspension/RNASE A 
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solution by pipetting up and down and vortexing. 12 ml of lysis solution was added 
to the suspension and mixed immediately by gently inverting six to eight times. The 
mixture was then allowed to stand for 5 min until it became clear and viscous and 
then neutralized by adding 12 ml of chilled Neutralization solution and inverting 
again which resulted in the formation of white aggregate. 9 ml of binding solution 
was added to the white aggregate and the solution was immediately poured into the 
barrel of the filter syringe and allowed to sit for 5 min. In the meantime a GeneElute 
HP Maxiprep Binding Column was placed in a 50 ml collection tube. 12 ml of 
Column Preparation solution was added to the column and spun in a swinging 
bucket rotor at 3000 × g for 2 min. The eluate was discarded. The filter syringe 
barrel was held over the binding column and pressed gently to expel half of the 
clear lysate into the column. The lysate was spun in a swinging bucket rotor at 3000 
× g for 2 min. The eluate was discarded and the rest of the eluate was added to the 
column and process was repeated. The column was washed with 12 ml of Wash 
Solution1 and spin in a spin bucket rotor at 3000 × g for 2 min. The eluate was 
discarded. The column was washed with 12 ml of Wash solution 2 and spun in a 
swinging bucket rotor at 3000 × g for 5 min. The binding column was transferred 
into a clean 50 ml tube. 3 ml2 of elution solution was added to it and was then 
centrifuged in a swinging bucket at 1000 × g for 5 min. 
2.13! Patients Samples 
154 MDS patients were selected for mutational screening for STAG2. Patients with 
MDS seen at Kings College Hospital from June 2004 to June 2011 were enrolled in 
this study. All patients provided written informed consent in accordance with 
National Research Ethics Protocol (KCLPR060 PR029). 
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2.14! DNA Techniques 
2.14.1! DNA Extraction 
DNA was extracted from patients sample using QIAamp DNA purification kit 
(Qiagen) as per the manufacturers instructions. Bone marrow mononuclear cells 
were resuspended in 200µl PBS and 20µl protease and then lysed using 200µl of 
cell lysis buffer (AL buffer) followed by plus- vortexing. Incubation at 56°C for half 
an hour was followed by addition of 200µl 75-100% ethanol. The mixture was 
applied to a QIAamp Mini spin column and washed with 500µl of AW1 and AW2 
buffer before eluting the DNA in 100µl EB (Elution buffer). 
2.14.2! Determination of DNA concentration 
DNA concentration was determined using the Thermo Scientific Nanodrop (ND-
8000; Nanodrop) spectrophotometer. The spectrophotometer has an absorbance 
range from 220-750nm. The absorbance spectrum of DNA was measured at 260nm. 
2µl of DNA sample was placed on the nanodrop and light absorbed by the sample 
was measured against the blank (EB buffer). Absorbance ratio at 260/280 is a good 
representative of purity. Ratio of less than 1.8 indicates protein contamination while 
more than 1.95 suggests RNA contamination. DNA samples with absorbance ratio 
around 1.8 were used for sequencing. 
2.14.3! DNA Amplification 
REPLI-g Midi Kits (Qiagen) was used to amplify DNA as per the manufacturer’s 
instructions from CD34+ of 154 MDS (Myelodysplastic Syndrome) patients. 
Briefly, DNA was diluted using 1X T.E (Tris- EDTA) buffer (100ng in 5µl). 2.5µl 
of the diluted sample was taken in a microcentrifuge tube and 2.5µl of D1 buffer 
prepared according to (Table 2.4) was added, vortexed and then incubated at room 
temperature for 3min. 
 105 




Reconstituted Buffer DLB 
(500µl H2O + DLB buffer) 
9µl - 
Stop solution - 12µl 
Nuclease Free Water 32µl 68µl 
Total Volume 41µl 80µl 
 
Neutralization of the sample was achieved by adding 5µl of buffer N1 (refer table 
2.4) followed by brief vortexing and centrifugation. A 40µl mastermix containing 
the REPLI-g DNA polymerase (1µl), REPLI-g Reaction buffer (29µl) and 
Nuclease- free water (10µl) was added to 10µl of denatured DNA. An isothermal 
amplification reaction was carried out at 30°C for 16hrs and the polymerase was 
then inactivated by heating at 65°C for 3min, yielding approximately 40µg of DNA. 
The amplified product was stored at -20°C. 
2.14.4! Checking Amplified DNA 
The amplified DNA was diluted 1 in 50 using 1X TE buffer and then was run on a 
2% Tris Acetate EDTA (TAE) agarose gel at 120V for half an hour to check 
amplification. 
2.15! Primer Design 
The DNA Sequence of STAG2 was obtained from the Ensemble website and 
primers were designed using Prime 3 software, creating a PCR product size ranging 
between 250-350bp. A buffer region of at least 50bp was allocated on either side of 
the amplicon to enable accurate sequencing of the target. Universal tags (aUSF and 
aUSR) were incorporated into the primers at the 5’ end. All the primers were 
ordered from IDT (Integrated DNA Technology). Sequence for all the primers is 
listed in the appendix. 
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2.15.1! Primer Testing and PCR optimisation 
 The lyophilized primers were spun down and DNase, RNase free water was added 
as recommended by IDT to make a stock solution of 100µM. All primers were 
tested using unamplified control genomic DNA (10ng/µl) using PCR reaction 
mixture and programme shown in (Table 2.5) and analysed on 1.5% TAE agarose 
gel alongside ladder (GeneRuler Thermo Scientific SM0331). Samples were run at 
120V for 20min in 1X TAE buffer. Amplified DNA samples from 154 MDS 
patients were used for Next generation sequencing of the STAG2 gene. The first 
round PCR reaction and cycling conditions are shown in Table 2.5. 




A second round of PCR was performed using (0.9µl) of amplified product from the 
first round of PCR using primers obtained from Sigma Life Science (0.75µl). These 
primers were targeted to the aUS primers and had sequences at the 5’ and 3’ end to 
hybridise with the DNA capture beads in addition to the forward and reverse strands  
for sequencing. The primers also had a 10 base long MIDs (Multiplex Identifiers) 
(Catalogue number: 05144507001) to identify individual patients. The programme 




Cycles Temperature Time Steps 
1 94°C 5 min Enzyme Activation 
35 94°C 35 secs Denaturation 
62°C 40 secs Primer Annealing 
72°C 45 secs Elongation 




Promega Go Taq 5µl 
Primer (5µM) 0.5µl 
DNA (10ng/µl) 1µl 
H2O 3.5µl 
Total 10µl 
(a)                                                (b) 
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Table 2.6: 2nd round of PCR programme for 454 Sequencing 
Cycles Temp Time Steps 
1 94°C 5min Enzyme Activation 
8 94°C 35secs Denaturation 
60°C 40secs Primer Annealing 
72°C 45secs Elongation 
1 72°C 15min Inserting the missing nucleotides 
 
Post- PCR amplified amplicons were quantified using picogreen dye (Invitrogen) 
on the Rotor-Gene 6000 Multiplexing System (Corbett Research). All the 
amplicons per patient were equalized in concentration, based on the picogreen 
measurement by diluting 1µl of DNA in 50µl of 1X Tris-EDTA buffer (Life 
Science Technologies). The tubes were then run on the Corbett rotor gene alongside 
six double stranded DNA concentrations of 2 ng/µl, 1 ng/µl, 0.5 ng/µl, 0.25 ng/µl 
and 0.125 ng/µl. The data was analysed using the Rotor-gene software. After the 
concentration was equalised, all the amplicons per patient were pooled together and 
a further picogreen measurement was performed to equalize the concentration of all 
the patient samples before pooling. 
2.15.2! Gel extraction and purification 
The libraries were loaded on a 1.8% TAE agarose gel and electrophoresis was 
carried out at 160V for 40min. The band was excised from the gel and gel 
purification was carried out using QIA quick Gel Extraction Kit (Qiagen). Briefly, 
500µl of buffer QG was added to the gel slice and was incubated at 50°C until the 
gel was completely dissolved by vortexing every 2min. 10µl of 3M sodium acetate 
and 100µl of 100% isopropanol were added to increase the yield of DNA. 400µl of 
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sample was applied to QIAquick column. The column was washed with 500µl of 
QG buffer and 750µl of PE buffer to remove traces of agarose and salts etc. The 
DNA was eluted using 30µl of Buffer EB (Elution Buffer) in DNase, RNase free 
microcentrifugetubes. 
2.15.3! Bead Purification 
Agencourt AMPure XP magnetic beads (Beckman Coulter, USA) were used to re-
purify the DNA again obtained from gel purification. 1.5µl of beads were added for 
every 1µl of the sample, vortexed and incubated at room temperature for 10min. 
The sample was then placed on Magnetic Particle Concentrator (MPC) and the 
supernatant was discarded. The beads were washed twice with 70% ethanol and 
then dried out at room temperature for 15min. Beads were resuspended in 40µl of 
warm 30°C water and left at room temperature for 10min to elute the DNA. The 
DNA sample was then put back on the Magnetic Particle Concentrator and the 
supernatant was then collected.  
2.15.4! Library Preparation 
A third picogreen measurement and gel electrophoresis was carried out to confirm 
the final concentration. The concentration was then converted to 1×107 molecules/µl 
by adding the appropriate amount of molecular grade water.  
2.15.5! Sequencing 
The GSFLX Titanium LV emPCR Kit (Lib-A) from Roche Applied Sciences was 
used to perform the emulsion PCR on purified amplicons. Live and mock 
amplification mix and the capture bead wash buffer were prepared as indicated in 









Table 2:.8: (a) Mock Amplification mix (b) 1X capture bead wash buffer 
 
 
DNA capture beads A (with forward primer) and B (with reverse primer) were 
vortexed and centrifuged at 5000×g for 1min. The supernatant was discarded and 
beads were washed twice with 1ml of 1X capture bead wash buffer. After three 
washes 50-60µl of supernatant was left behind to prevent beads from drying.  
2.15.6! Emulsion PCR 
12µl of the purified library at concentration of 1× 107 molecules/µl was added to 
capture beads A and B and kept in the fridge. Two cups of oil emulsions were 
Reagent Volume 
Molecular Grade Water 1200µl 
emPCR additive 1500µl 
5X amplification mix 780µl 
Amplification primer A or B 230µl 
emPCR Enzyme mix 200µl 
Ppiase 5µl 
Total 3915µl 
Reagent Volume  
5X Mock Amplification 
Mix 
2000µl 
Molecular Grade Water 8000µl 
Total 10000µl 
Reagent Volume  
10X Capture Bead Wash 
Buffer 
1000µl 
Molecular Grade Water 9000µl 
Total 10,000µl 
(a)                                                                     (b) 
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installed on the TissueLyzer and shaken for 2min at 28Hz. 5ml of 1X Mock 
Amplification mix was added to each cup and cups were further shaken for 5min at 
28Hz to facilitate micelle formation. Next 3.9ml of Live Amplification mix was 
added to respective capture beads + DNA library solution. Live Amplification mix 
A + DNA library + capture beads A were added to one emulsion cup and solution 
with capture beads B was added to other cup and then each cup was put back on 
Tissue Lyzer for 5min at 12Hz and then solution from each cup was dispensed into 
96 well plate (100µl per well) using multistep dispenser pipette. Emulsion PCR 
(Table 2.9) (Fig. 2.1) was carried overnight as indicated. 
 
Table 2.9: Emulsion PCR conditions  
 
Cycles Temperature Time Steps 
1 94°C 4min Enzyme activation 
50 94°C 30secs Denaturation 
58°C 4min 30secs Primer Annealing 
68°C 30secs Elongation 
 10°C ∞ On hold 
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Figure 2.1: Schematic representation of Emulsion PCR. (Image taken from Roche 
emPCR Method manual Oct 2009). 
 
Adaptors are ligated to DNA fragments for use in subsequent purification, 
quantification, amplification and sequencing steps by PCR. The library is attached 
to DNA capture beads. Each bead carries a unique single stranded library fragment. 
Beads are emulsified with amplification reagents in water and in oil mixture to trap 
individual beads in amplification microreactors. The entire emulsion is amplified to 
create millions of clonally copies of each library fragment on each bead. The 
emulsion is broken down while the amplified fragments remain bound to specific 
beads. 
2.15.7! Vacuum Assisted Emulsion Breaking 
Post-PCR emulsions were broken using the GSFLX Titanium emPCR breaking kit 
and breaking reagents (Lot 93874520). The breaking kit (Fig 2.2) was attached to 
the vacuum source in a fume hood and the emulsions were rinsed with 3 times 
100µl of 100% isopropanol. The capture beads A and B were mixed at this stage 
and then spun at 1000 × g for 10min. The supernatant was discarded and pellet was 
washed with 40ml of Enhancing Fluid XT, two times with 100% isopropanol two 
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times, 100% ethanol and again with Enhancing Fluid by centrifuging at 1000 × g 
for 5min. The pellet was transferred to microcentrifuge tubes and washed twice 
with 1ml of Enhancing fluid at 4000 × g for 1min. 
 
Figure 2.2: Assembled set-up for vacuum assisted emulsion breaking and bead 
recovery. (Image taken from Roche emPCR Method manual Oct 2009). 
 
2.15.8! DNA Library Bead Enrichment 
After the final wash supernatant was removed and 1ml of fresh Melt solution 
(500µl of 5M NaOH and 19.5ml of Molecular Grade Water) was added, vortexed 
and incubated for 2min at room temperature. The supernatant was discarded and 
1ml of Melt solution was added again. The Melt solution was washed using 1ml of 
Annealing buffer XT twice and spun at 3200 × g for 2min. The pellet was 
resuspended in 45µl of annealing buffer and 12.5µl each of enrichment primer A 
and B was added (from GSFLX Titanium MV emPCR Kit) and kept on a heat block 
at 65°C for 7-8 min and then was subsequently kept on ice for 2 min to stop the 
reaction. The pellet was then washed twice with 1ml of enhancing fluid and spun at 
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3200 × g for 2min to remove residual primers. The pellet was then resuspended in 
800µl of Enhancing Fluid (XT). 
2.15.9! Preparation of Enrichment Beads 
 The tubes containing the Enrichment beads were vortexed and placed on a 
Magnetic Particle Concentrator (MPC). The supernatant was then discarded and 
beads were washed twice with 1ml of enhancing fluid. After the final wash, 320µl 
of enhancing fluid was added to the beads and 80µl of enrichment beads were added 
to the pellet resuspended in enhancing fluid from previous step. The tubes were 
secured with autoclave tapes and placed on a rotor for 15min, pooled in 15ml glass 
tubes and placed again on the MPC. The beads were washed with 3-4ml of 
enhancing fluid 15 times till a clear supernatant was obtained.  
2.15.10 Collection of Enrichment Beads 
Enriched beads were resuspended in 1.5ml Melt solution (prepared earlier), 
vortexed and placed back on the MPC and left for 5min. The supernatant was 
collected and the denaturation step was performed again to get maximum yield. The 
Melt solution was washed twice with 1ml annealing buffer and centrifuged at 3200 
× g for 2min. The pellet was resuspended in 1ml of annealing buffer. 
2.15.11 Determine Bead Enrichment 
Table 2.10: Coulter Counter Z1 models settings for bead counting 
3µl aliquot of the beads were counted using Beckham Coulter Z1 particle counter. 
% Bead Enrichment = (Number of Enriched Beads/35 × 106 beads/cup) × 100 
Parameter Dual Threshold (µm) 
Upper Size 25 
Lower Size 15 
Count Mode Between 
Aperture 100µm Upper Size 100 
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2.15.12 Sequencing Primer Annealing 
 25µl of sequencing primer A [from GSFLX Titanium LV emPCR Kit] + 25µl of 
sequencing primer B was added to the pellet in annealing buffer and was placed on 
a heat block at 65°C for 7-8min. The reaction was stopped by placing the tube on 
ice for 2min. The library was washed three times with 800µl of annealing buffer, 
spun at 3200 × g for 2min and then was stored in the fridge in 1ml of annealing 
buffer. 
2.15.13 Preparation of Bead Buffer 2 (BB2) 
Bead wash buffer (200ml) was placed on ice for 10min. 1.2ml of the Supplement 
CB and 34µl of Apyrase was added to make the Bead Buffer 2 (BB2) Table 2.11. 
 




2.15.14 Preparation of DNA Bead Incubation Mix (DBIM) 
Bead Preparation [Titanium Sequencing Kit XLR70] 
1.! Packaging beads were washed three times with 1ml of BB2 and spun at 
10,000 × g for 5min. 550µl of BB2 was added and the beads were left on 
ice. 
2.! Enzyme and PPiase beads were vortexed for 30sec each and then placed on 
the MPC. Each tube was washed three times with 1ml of BB2. Enzyme 
beads were left in 1ml of BB2 while PPiase beads were left in 500µl of BB2 
and left on ice. 
3.! DNA + Control Beads: The libraries were thawed overnight and the next 
day, spun and 2 ml of annealing buffer was added. The library was 
BB2(µl) Polymerase Cofactor (µl) DNA Polymerase (µl) Total (µl) 
1570 150 300 2020 
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measured again using the bead counter. The appropriate volume of DNA 
library beads (2 million beads per region) were separated and 20 µl of DNA 
control beads was added / region along with 1ml of DBIM/ region and 
placed on the rotor for 15 min. 
2.15.15 Layer Preparation 
Layers 1, 3 and 4 were prepared according to table in falcon tubes and placed on ice 
(Table 2.12). 
 
Table 2.12: Dilution of beads for layer preparation 
 












2500 1300 ----- 3800 
Layer 4 
PPiase Beads 
3340 ----- 460 3800 
 
2.15.16 Assembling the Bead Deposition Device (BDD) 
The Roche Pico Titre Plate Kit was washed and assembled as per manufacturers 
instructions as indicated in the (Fig 2.3) by placing the PTP device onto the BDD 
base and aligning the notched corner. 
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Figure 2.3: Assembling the BDD. (Image taken from Roche sequencing method 
manual Oct 2009). 
 
1.9ml of each layer was loaded on the PTP plate through the loading ports and 
centrifuged at 1620 × g for 5min. Previous layer were aspirated before adding 
subsequent layers. After the last layer was aspirated out the plate was removed from 
the gasket and loaded on the 454 sequencer. 
 
2.15.17 Run Requirements 
One maintenance wash and two pre-washes were carried out before the run. The 
PTP cartridge along with the camera faceplate were cleaned and the sequencing kit 
reagent LR70 required for the run were loaded on the machine as per the 
manufacturer’s instructions. 
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2.16! Sanger Sequencing 
Sanger Sequencing was carried out on skin and T cells to confirm that STAG2 
mutations found in six patients were not constitutional polymorphisms. Amplicons 
in which mutations were detected were amplified using respective primers and the 
PCR programme described in (Table 2.5). The PCR products were cleaned using 
ExoSAP-IT from Affymetrix (6µl sample + 3µl ExoSAP). The programme used is 
described in (Table 2.13).  
Table 2.13: Exo-Sap –IT clean-up programme 
 
The concentration of the amplified DNA was measured and 10-20ng of DNA was 
used for Step PCR to incorporate the dye into the DNA sequence (Table 2.14 and 
2.15). 
Table 2.14: Step-PCR reaction mixture 
 
Reagents Volume (µl) 
5X Sequencing Buffer 2 
Big dye 0.5 
5µM Universal Primer 
(aUSF) or (aUSR) each 
1 














Time Temperature Steps 
15min 37°C ExonucleaseI removes leftover primers 
15min 80°C Shrimp Alkaline Phosphatase removes dNTPs 
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Table 2.15: PCR Programe 
 
Purification of the PCR products was carried out using 45µl of the Big Dye 
XTerminator and 5µl of  the SAM solution (Applied Bio systems). The mixture was 
vortexed on a plate mixer for 30min followed by centrifugation for 2min at 1000 × 
g. Sanger Sequencing was carried out using an ABI 3130x genetic analyser and the 
DNA sequences were visualized for mutations using SeqScape Software (v2.5) and 
analysed using Sequencing Analysis Software (Applied Bio systems, Foster City 
CA). 
2.17! MiSeq Amplicon Sequencing 
The same cohorts of patients used for sequencing of STAG2 were used to sequence 
other three members of the cohesin complex SMC1A, SMC3, RAD21. The same 
methodology was applied as for the 454 sequencing up until the first round of PCR. 
After the first round of PCR, all the amplicons for three genes from four patients 
were run on 1.5% agarose gel and from the intensity of the bands the concentration 
of DNA was adjusted. The amplicons for all the genes for all the patients were 
Cycle No Temperature (°C) Time Cycles Comment 
1 95 1min × 1 Enzyme Activation 
2 95 10secs  
×15 
Denaturation 
55 5secs Primer 
Annealing 
60 1.15min Elongation 
3 95 10secs  
× 5 
Denaturation 
55 5secs Primer Annealing 
60 1.30secs Elongation 
4 95 10secs  
× 5 
Denaturation 
55 5secs Primer Annealing 
60 2min Elongation 
5 4 ∞  On hold 
1 
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pooled together and gel and bead purification was performed as mentioned in 
section (2.15.2 and 2.15.3) followed by picogreen measurement to obtain a 
concentration of 0.2 ng/µl for Nextera PCR.  
2.17.1! Tagmentation of Input DNA 
During this step input DNA was tagmented (tagged and fragmented) by the Nextera 
XT transposome. The Nextera XT transposome simultaneously fragments the input 
DNA and adds adaptor sequence to the ends allowing amplification by PCR in 
subsequent steps. 
2.17.2! Preparation 
The Amplicon Tagment Mix (ATM), Tagment DNA Buffer and input DNA were 
removed from -20°C storage and thawed on ice. Neutralize Tagment Buffer (NT) 
needs to be at room temperature and was visually inspected to ensure that there is 
no precipitate. If there was precipitate it was vortexed until all particulates were 
resusupended. After thawing, all the reagents were adequately mixed by gently 
inverting the tubes 3-5 times followed by a brief spin in a microcentrifuge.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
2.17.3! Make NTA 
A new 96 well plate was labelled NTA (Nextera XT Tagment Amplicon Plate). 
2.5µl of TD buffer was added to each well used in the assay. Tips were changed 
between samples. 1.25µl of input DNA at 0.2 ng/µl was added to each sample well 
of the NTA plate. 1.25µl of ATM was added to the wells containing input DNA and 
TD buffer. The samples were gently pipetted up and down five times to mix using a 
multichannel pipette. The NTA plate was covered with a microseal and centrifuged 
at 280 ×g at 20°C for 1min. The NTA plate was placed in a thermocycler and 
incubated at 55°C for 5min and then held at 10°C. Once the sample reached 10°C 
NTA was immediately neutralized. 
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2.17.4! NTA Neutralization 
The microseal was removed carefully and 1.25µl of NT Buffer was added to each 
well of the NTA plate. Using a multichannel pipette, samples were pipetted up and 
down five times to mix. The NTA plate was covered with microseal, centrifuged at 
280 ×g at 20°C for 1min and then placed at room temperature for 5 min. 
2.17.5! PCR Amplification 
In this step the tagmented DNA was amplified via a limited cycle PCR program. 
The PCR step also added index 1 (i7) and index 2 (i5) and sequences required for 
cluster formation (Lot no 9855502). The Nextera PCR Master Mix (NPM) and the 
index primers were removed from -20°C storage and thawed on bench at room 
temperature for approximately 20min. Once thawed the tubes were gently inverted 
3-5 times to mix and briefly centrifuged in a microcentrifuge. The index primers 
were arranged in the TruSeq Index Plate Fixture using the following arrangement: 
Index 1 (i7) primer tubes (orange caps) in order horizontally, so that N701 is in 
column 1 and N712 is in column12. Index 2 (i5) primers (white caps) in order 






































Figure 2.4: True Index plate fixture arrangement. (A) Rows A-D Index 2(i5) adapters. 
(B) Column 1-6 Index 1 (i7) adapters. (C) Hard shell PCR plate. (Image taken from 
Nextera XT sample preparation guide)  
2.17.6! Amplify NTA 
The NTA plate was placed in the TruSeq Index Plate Fixture. 3.75µl of NPM was 
added to each well of the NTA plate containing index primers. Tips were changed 
between samples. Using a multichannel pipette 1.25µl of Index 2 primers (white 
caps) was added to each column of the NTA plate. Tips were changed between the 
columns to avoid cross contamination. Using a multichannel pipette 1.25µl of Index 
1 primers (orange caps) were added to each row of the NTA plate. Tips were 
changed again after each row to avoid index cross contamination. Using a 
multichannel pipette, samples were pipetted up and down 3 to 5 times to mix and 
again tips were changed between samples to avoid index and sample cross 
contamination. The plate was sealed with a microseal and centrifuged at 280 ×g at 
20°C for 1min. PCR was performed using the following program on a thermal 
cycler (Table 2.16). 
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2.17.7! PCR Clean Up 
AMPure XP beads were used to purify the library DNA and provide a size selection 
step to remove very short library fragments from the population. All patient samples 
post Nextera amplification was quantified using the picogreen dye as described 
previously in section 2.16.1 patient libraries were pooled together in equal 
concentration. Pooled patient libraries were purified using the Agencourt AMpure 
XP beads as described in section 2.16.3 and quantified again using the picogreen 
dye.  
2.18! MiSeq Amplicon Sequencing 
2.18.1! Preparation of HT1 buffer 
HT1 (Hybridization Buffer) (Lot no 9853711) was used to dilute denatured libraries 
before loading libraries onto the reagent cartridge for sequencing. The tube of HT1 
was removed from -20°C storage and set aside at room temperature to thaw.  
Freshly diluted NaOH was used to dilute libraries for cluster generation on MiSeq. 
A fresh dilution of 0.2N NaOH was prepared by combining 800µl of Laboratory-
grade water with 200µl of 1.0 N NaOH of in a microcentrifuge tube.    







12 95°C 10sec 
55°C 30sec 
72°C 30sec 
 72°C 5min 
Hold at 10°C 
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2.18.2! Denature DNA for 4nM Library 
5µl of 4nM sample DNA and 5µl of freshly prepared 0.2N NaOH were combined in 
a microcentrifuge tube. The rest of the NaOH was used to make a PhiX control (Lot 
no 9702818). The sample solution was vortexed briefly to mix and then centrifuged 
at 280 × g for 1min. The sample was incubated for 5mins at room temperature to 
denature the DNA into single strands. 990µl of pre-chilled HT1 was added to the 
tube containing 10µl denatured DNA. 
The result is a 20pM denatured library in 1mM NaOH. The denatured DNA was 
placed on ice prior to proceeding to the final dilution. The 20pM DNA was diluted 
further to give a final concentration of 11pM in 600µl. The tube was inverted 
several times to mix and then pulse centrifuged. The denatured and diluted DNA 
was placed on ice until ready to load the samples onto MiSeq reagent cartridge (Lot 
No 9853711). 
2.18.3! Preparing PhiX Control 
2µl of 10 nM PhiX library was combined with 3µl of 10mM Tris-Cl pH 8.5 with 
0.1% Tween 20 to dilute PhiX library to 4nM. 5µl of 4nM PhiX was combined with 
5µl 0.2 N NaOH and vortexed briefly to mix the 2nM PhiX library solution. The 
template solution was centrifuged to 280 × g for 1min and was incubated for 5min 
at room temperature to denature the PhiX library into single strands. 10 µl of 
denatured PhiX library and 990µl of pre-chilled HT1 was added to result in a 20pM 
PhiX library. 6µl of denatured and diluted PhiX control was combined with 594µl 
of denatured and diluted sample library. 
2.18.4! Load Sample Libraries 
The foil seal covering the reservoir labelled load samples of the reagent cartridge 
was cleaned using a low lint lab tissue. 600µl of prepared library was pipetted into 
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the load sample reservoir. Using forceps, the flow cell was immersed in a storage 
buffer in a flow cell container and lightly rinsed with laboratory grade water to 
remove excess salts and then dried with a lint free lens cleaning tissue. The flow 
cell glass was cleaned with alcohol wipe to make sure that the glass was free of 
streaks, fingerprints and lint or tissue fibres and was loaded into the flow cell stage. 
The PR2 bottle was removed from 4°C, inverted, the lid removed and was then 
placed in the reagent compartment door. The reagent cartridge was placed in the 
reagent chiller door. After loading, the flow cell, the reagents and the run 
parameters were reviewed and a pre-run check was performed before starting the 
run. When all the items successfully passed the pre-run check, the actual run was 
performed and the run was monitored using sequencing analysis viewer (SAV) in 
BaseSpace. An instrument wash was performed after completion of the sequencing 
run. 
2.18.5! Data Analysis 
The MiSeq data analysis pipeline was used to analyse the data. *.bcl files were 
generated during the sequencing run by the Illumina RNASeq 2000 Real Time 
Analysis (RTA) software. fastqfiles were generated from *.bcl files. Sequence 
alignment to the human target reference genes (NCBI37/Hg19) and variant calling 
for SNPs/Indels was performed via Burrows-Wheelers aligner (BWA) GATK 
pipeline (Li and Durbin, 2009, McKenna et al., 2010).  Illumina Variant studio was 
used to visualize processed VCF and BAM files. Validation was performed on 






3! Chapter Three 






The Myelodysplastic Syndromes are a group of clonal heterogenous disorders 
characterized by inefficient haemopoiesis, hypercellular bone marrow, dysplasia of 
blood cells and peripheral blood cytopenias. High-throughput second generation 
sequencing, (SGS) has elucidated a comprehensive biomarker mutation profile 
leading to an increased diagnostic sensitivity, specificity and improved prognostic 
risk stratification except in the context of CHIP (Clonal hematopoiesis of 
Indeterminate potential) and CCUS (Clonal cytopenia of undetermined 
significance) where sensitivity of this technique is not clear. These entities are not 
specific disorders per se rather, they are general terms that can be used to describe 
patients without a specific diagnosis in whom cytopenias or clonal mutations 
represent a possible sign of disease that may manifest more clearly in the future. 
Infinitely deep sequencing will detect acquired mutations in every adult so 
proposals have been made to distinguish between the above terms on the basis of 
variant allele frequency (VAF). VAF is the proportion of sequencing reads with a 
mutation which in the absence of a copy number variant is roughly parallel to the 
size of the clone bearing the mutation. With good natural history studies, we may 
learn that specific mutations and variant allele frequencies have a similar natural 
history to MDS diagnosed by conventional means, thus allowing diagnosis of MDS 
without the morphologic dysplasia that is currently required for the diagnosis in the 
absence of karyotypic abnormalities. 
 
DNA sequencing has come a long way since the days of two dimensional 
chromatography in the 1970s (www.Illumina.com). Genome sequencing has been 
revolutionised since the completion of the human genome project (HGP) and has 
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moved away from first generation sequencing approaches to whole-genome 
sequencing (WGS) with changes in the accompanying software for denovo 
assembly of large scale sequencing data. Highly streamlined sample preparation 
steps prior to DNA sequencing in second generation sequencing (SGS) offers 
significantly increased time saving and a minimal requirement for associated 
equipment in comparison to the highly automated multistep pipelines necessary for 
first generation sequencing (Table 3.1). Instead of sequencing a single DNA 
fragment SGS extends this process across millions of fragments in a massively 
parallel fashion. The sequencing library is prepared by random fragmentation of 
DNA followed by 5’ and 3’adapter ligation followed by PCR amplification. These 
universal adapters are specific to each sequencing platform that can be used to 
polymerase amplify the fragments during specific steps of the protocol. Each 
fragment is then amplified into distinct clonal clusters. During clonal cluster 
formation the sequencing template is immobilized on a proprietary flow cell surface 
(Illumina sequencing) or a bead (454 Next generation sequencing) designed to 
present DNA in a manner that facilitates easy access to enzyme while ensuring high 
stability of surface bound template and low non specific binding of fluorescently 
labelled nucleotides and resulting in thousands of identical copies of each single 
template molecule in close approximation. During each cycle the nucleotides are 
identified by fluorophore excitation through the incorporation of fluorescently 
labelled deoxynucleotide triphosphates (dNTPs) into a DNA template strand during 




Table 3.1: Advantages of SGS. Advantages and mechanism of first and second 














Read length (bp) 
 (No of bases sequenced) 
Depends on the MiSeq kit 
used 
2×250bp using MiSeq Reagent Kit 
v2 
2×300bp using MiSeq Reagent Kit 
v3 
700bp 400-900 bp 
Accuracy Error rate below 0.4% 99.9% 99.999% 
Reads 15 million reads  1million - 
Output data/run 120 Mb-1.5 Gb 0.7 Gb 1.9 ~84 Kb 
Time/run 4 hrs to 55 hrs depending 
on the number of cycles 
performed 
24 hrs 20 min ~ 3 
hrs 
Advantage Moderate cost instrument 
and runs. Low cost per Mb 
for a small platform. Fastest 
Illumina run times and 
longest Illumina read length 




Disadvantage Major concentrate in 
flowcell surface size, insert 
sizes, and how to pack 
cluster in tighter 
Error rate with 
polybase more 







Large scale genomic sequencing has identified mutations in cohesin complex in a 
large variety of myeloid malignancies particularly in AML (10-20%) (Lindsley et 
al., 2015, Thol et al., 2014, Thota et al., 2014). Mutations have also been reported in 
various types of solid cancers Ewing’s sarcoma (20%) bladder cancer (20%), 
(Balbas-Martinez et al., 2013, Guo et al., 2013, Solomon et al., 2013, Solomon et 
al., 2011) Apart from somatic mutations germline mutations in cohesin complex has 
also been associated with developmental disorders like Cornelia de Lange 
Syndrome (CdLS) and Roberts syndrome characterized by developmental disorders, 
intellectual disability. (Mannini et al., 2013). 
Mutations in cohesin complex fall into two categories (1) nonsense and frameshift 
mutations are found in STAG2 and RAD21 genes (2) missense mutations are mostly 
observed in SMC1A and SMC3 genes (Kon et al., 2013). Mutations in different 
members of the cohesin complex appear to be mutually exclusive which 
disapproves functional redundancy between these proteins however how these 
mutations contribute towards pathogenesis of disease is still undermined. To 
unravel the role of cohesin mutations in myelodysplastic syndrome second-
generation sequencing was carried out in a cohort of 154 MDS patients. The main 
aim was to 
(1) Determine the prevalence and allele burden of mutations affecting the cohesin 
complex in MDS patients. 
(2) Correlate cohesin mutations with other mutations, response to therapy, survival 





Table 3.2: Demographics, Clinical characteristics and therapy in 154 MDS patients. 
Cytogenetic failed in 3 patients † denotes other treatments which include; 
lenalidomide, thalidomide, cyclosporine and Anti-thymocyte globulin * includes 13 
patients who had HSCT (Haematopoietic stem cell transplant) after receiving 5-
azacitidine. [n- Represents number of patients] % Represents percentage of the 
patients. 
 
Patient Characteristics Overall 
Total Patients 154 




Male [n (%)] 104 (67%) 
Female [n (%)] 50 (32.4%) 
WHO category*  
RA/RCMD [n (%)] 40 (26%) 
RARS/RCMD-RS [n (%)] 24 (16%) 
RAEB1/2 [n (%)] 49 (32%) 
sAML [n (%)] 15 (10%) 
tMDS/AML [n (%)] 12 (8%) 
CMML & MPD/MDS-U [n (%)] 14 (9%) 
Bone Marrow Blasts  
Median (%) 5 
Range 0-80 




Median follow up (months) 21.4 
Transfusion dependency  
Yes 80 (51%) 
Progression to AML  
Yes 44 (28%) 
Treatments  
5-Azacytidine 66 
Other Treatments † 14 
HSCT* 35 




3.2.1! Testing for STAG2 gene 
REPLI-g Midi Kits from Qiagen (refer to section 2.14.1 for more details) was used 
to amplify patient DNA isolated from bone marrow total nucleated cells to increase 
the yield of DNA as cell number were low. Unamplified patient gDNA was used for 
mutation confirmation in an independent experiment. The amplified DNA was 
diluted using TE buffer and 2µl was run on a 1.8% agarose gel to check for 
amplification. However, bands were detected in the negative control (water instead 
of DNA was used as negative control) (Fig 3.1a). Although the Go Taq Polymerase 
used to perform the PCR reaction is a high fidelity polymerase but despite that there 
is still a low rate of misincorporation of nucleotides that might have been the reason 
for the amplification product observed in the negative control. To check whether the 
amplified products were real or artifactual, PCR was performed for two positive and 
three negative controls for amplicon 1 of STAG2 gene and then were run on a 1.8% 
TAE agarose gel. No bands for the negative samples were found. PCR was again 
performed with two negatives and two positive samples for all the amplicons of 
STAG2 gene and again run on 1.8% TAE gel.  Bands for amplicon 9 in one negative 
sample and amplicon 10 in another negative sample for STAG2 gene were detected. 
Primers for amplicons 9 and 10 were thus redesigned using the 
http://bioinfo.ut.ee/primer3/ software and PCR reactions were re-performed with 
the newly designed primers. No bands were detected in the negative control (Fig 
3.1b). 
In order to determine the primer efficiency PCR reactions were initially performed 
using 5µM of primer and 2µl of 10ng/µl of unamplified control genomic DNA. Two 
PCR runs were performed using all the STAG2 primers and then the PCR products 
were loaded on 1.5% TAE agarose gels. Due to PCR non amplification of the 
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amplicons primers 8, 10, 14 did not amplify a PCR product (Fig 3.1c) thus a 
gradient PCR for each primer at three different annealing temperatures 56°C, 58°C 
and 60°C was performed (Fig 3.1d). Upon altering the annealing temperatures PCR 
products were obtained at the correct sizes at all temperatures and thus an annealing 
temperature of 60°C was selected in all reactions. The PCR product bands were of 







































Figure 3.1: DNA amplification of STAG2 using Qiagen REPLI-g kit and Primer 
Optimization. (a) Lane 1-5 amplified DNA, Lane 6-8 negative controls. (b) Newly 
designed primers for amplicon 9 and 10. Row 1-3 two positive and one negative 
samples tested with newly designed primer for amplicon 9.  Lane 4-6 two positive and 
one negative sample tested with newly designed primer for amplicon 10. No bands 
were detected in the negative control. (c) The primers were tested twice on 
unamplified genomic DNA. Row 1a-1b All the 33 primers were tested on unamplified 
genomic DNA. Row 2a-2b PCR was performed again with unamplified DNA for all 
the amplicons. On comparison it was found that primers for amplicons 8, 10 and 14 
had not worked and hence gradient PCR at three different annealing temperatures 
was performed. (d) Gradient PCR was performed using primers 8, 10, 14 and tested 
at three different annealing temperatures 56°C, 58°C and 60°C. Primers worked at all 
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3.2.2! Next Generation Sequencing 
Amplified DNA from all the 154 samples was used to identify mutations in the 
STAG2 gene using the Roche 454 GS FLX + second generation sequencing platform 
which offers read length upto 1kb. 1st round of PCR was performed using the 
optimised primers (Refer to section 2.15.1 for more details) and then two random 
patient samples from each amplicon were analysed on 1.8% TAE agarose gel. The 
bands were all of the same intensity and corresponded to the anticipated product 
size Fig (3.2). 0.9 µl of DNA sample from all amplicons were used for the 2nd round 
of PCR (Refer to section 2.15.1 for more details). Again two random samples from 













Figure 3.2: Visualization of two patient samples per amplicon after 1st round of PCR. 
Lane 1-33 upper section represent number of exons while lane 2-67 lower section 














Figure 3.3: Visualization of two patient samples per amplicon after the 2nd round of 
PCR for STAG2. Lane 1-33 upper section represent number of exons while lane 2-67 
lower section represent two patient samples per amplicon. 
 
 
After the second round of PCR all the 33 amplicons were quantified using Quant-iT 
picogreen dsDNA Assay kit on the Rotor–Gene 6000 Multiplexing System. This 
measurement was performed to equalize the concentrations of all the amplicons per 
patient and then all the amplicons for each patient were pooled together. Following 
on picogreen measurement was again performed to quantify patients samples and 
then all patients were pooled together in equimolar concentrations (Refer to section 
2.18.1 for more details). The final mix library was run on a 1.8% agarose gel for 45 
min at 120 V to obtain clear demarcated bands. The band was purified twice using 
QIAquick Gel Extraction Kit and Agencourt AMPure XP magnetic beads 
(Beckman Coulter USA) and then analysed on a 1.8% agarose gel (Fig 3.4). Once 
the library was purified, pooled concentration of STAG2 was determined and was 
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Figure 3.4: Analysis of pooled STAG2 library on agarose gel after gel and bead 
purification. Lane 1: 1-10000kb ladder, Lane 2: Library after gel purification, Lane 3-
4: Library after bead purification. 
3.3! Sequencing of the Library and identification of Mutations 
The library was sequenced on the Roche 454 GS FLX sequencer and the data was 
analysed using Roche Variant Analysis Software. Somatic mutations were 
identified in six patients (4%) with an average mutant allele burden of >15%. The 
mutant allele burden is defined as the ratio between reads contained in the mutant 
allele vs wildtype alleles, which are summarized in (Table 3.3). Average 
sequencing coverage depth (total number of nucleotides from reads that are mapped 
to a given position) across the whole genome was greater than 400X (Fig 3.5 and 
3.6). All the mutations were confirmed by Sanger Sequencing on constitutional 
DNA except for one patient for which no constitutional source was available. 
Somatic nature of the mutation for this patient was confirmed by the absence of 




2               3             4 
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Table 3.3: STAG2 mutations type allele burden and sites. Distribution of STAG2 
mutations found in six MDS patients. The mutations were identified in different exons 

















Figure 3.5: Distribution of generated amplicon sequence reads per patient. For all the 
patients, the read length (x- axis) and number of generated sequence reads (y-axis) is 









1.! 6! CGA>TGA! R110X! 32.98%!
2.! 19! TTG>TAG! L589X! 50.10%!
3.! 20! del TC_ins GGG! F647fsX! 21.05%!
4.! 26! CAG>TAG! Q888X! 34.26%!
5.! 27! AGG>AGC! R908S! 18.27%!
6.! 28! CGA>TGA! R953X! 43.16%!
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3.3.1! Mapping of mutations to different regions of STAG2 protein 
Mutations were located in exons 6, 19, 20, 26, 27, 28. All the mutations were 
heterozygous. Four of the mutations were nonsense mutations, one was a frameshift 
deletion and other was a missense mutation. All the mutations were outside the two 
major SCD (Stromalin conservative domain) and STAG domain found in STAG-2 
protein (Fig 3.6). STAG2 has been associated with gene regulation through the 
formation of loops which involve CTCF (CCTC binding factor). Interaction 
between CTCF and STAG2 has been reported to occur in the region between 162 to 
993 amino acids (Xiao et al., 2011). Five of the mutations were identified in this 
region. 
 
Figure 3.6: Somatic STAG2 mutations in MDS patients. Distribution of mutations 
across STAG2 protein. STAG2 is a 1268 amino acid protein and has two main 
domains STAG2 and Stromalin conservative domain (SCD). Most of the  mutations in 
STAG2 were nonsense mutations resulting in truncation of protein and occurred 
outside the STAG2 and SCD domain. 
 
To investigate the impact of mutations an Insilco 3D model of STAG2 was 
constructed using the Swiss model (Biasini et al., 2014). Although sequence 
homology predicted by software was 100% but the coverage of the protein 
sequence contained residues starting from 83-1207 (Fig 3.7). Crystal structure has  
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been predicted for yeast Zygosaccharomyces rouxii (Zr Scc3) residues 88-1035 
amino acids. Scc3 is an ortholog for human STAG2. As sequence homology among 
Scc3 ortholog stretches throughout the entire Z.rouxii structure most if not all 
features are likely to be shared by orthologs from a wide variety of eukaryote 
including animals. The crystal structure revealed a partly twisted and partly crescent 
shaped structure composed of large number of α helices stacked upon one another 
some of which contained the signature motif Asp19/Arg25 found in HEAT repeats. 
Three HEAT repeat motifs were found between residues 341-450. In addition to a 
pronounced hook at the proteins C-terminal half, a prominent feature was a nose at 
the N terminal part at the tip of which three basic residues KKR (298-300) were 
found. None of the mutations were found in the HEAT domain N terminal part at 













Figure 3.7: 3D structure of STAG2 protein (centre) and detailed structure of mutated codons (right and left). Mutated codons are represented within 
the red circle centre by small structures red and  blue. The square structure represents the HEAT domains   
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3.4! Testing for RAD21, SMC1A and SMC3 Genes 
DNA was extracted using the Qiagen extraction kit (Refer to section 2.14.1 for 
protocol) for 154 patients but was amplified for 72 patients using the amplification 
DNA kit from Qiagen (Refer to section 2.14.3 for more details) due to low cell 
number. 
3.4.1! Primer testing and PCR Optimisation 
All primers were designed using the Primer 3 sofware http://bioinfo.ut.ee/primer3/ 
and tested on 50 ng/µl of genomic DNA (Fig 3.8). While testing for primer 
efficiency, an extra band was observed in amplicon 5 for SMC1A gene and thus a 
gradient PCR for amplicon 5 was performed at three different annealing 
temperatures 62°C, 64°C and 66°C (Fig 3.9). No extra band was detected at these 
temperatures and thus PCR for all the amplicons for all the three genes was 
performed at annealing temperature 62°C apart from amplicon 3 for SMC3 which 
was performed at 60°C as it didn’t work at above three annealing temperatures. All 
PCR reactions were optimized using 4ng/µl of patient DNA and 5µM of primer 
(Refer to section 2.15.1 for more details). Once PCR was performed for all the three 
genes, the same four patients for each gene were run on a 1.5% agarose gel at 120V. 
After adjusting the concentration for all the amplicons for each patient for all the 
three genes, all the amplicons for each patient for each gene were pooled together. 
Gel and bead purification was performed using QIAquick Gel Extraction Kit and 
Agencourt AMPure XP magnetic beads from Beckman Coulter (USA) to purify the 
PCR mixes (Fig 3.10). Two picogreen measurement were performed and then 
















Figure 3.8: Testing for Primer efficiency for RAD21, SMC1A, and SMC3. All the 
amplicons for the three genes were tested on non amplified DNA. Upper PCR panel: 
2-14 amplicons for RAD21, 1-11 amplicons for SMC1A. Middle PCR panel: 12-25 













Figure 3.9: Gradient PCR at three different annealing temperatures for amplicon 5 of 
SMC1A. Gradient PCR worked at all the three different annealing temperatures 


















Figure 3.10: Visualization of all the amplicons for all the three genes from one patient 
sample after 1st round of PCR. Upper PCR panel 2-14 for RAD21 1-10 for SMC1A. 
Middle PCR panel 11-25 for SMC1A, 1-8 for SMC3. Lower bottom two PCR panel for 
SMC3. 
3.4.2! Nextera PCR 
For the Nextera PCR, the input DNA is tagmented (simultaneously tagged and 
fragmented) by the Nextera XT transposome technology. The Nextera XT 
transposome simultaneously fragments the input DNA and adds adaptor sequences 
to the ends allowing amplification by PCR in subsequent steps (Refer to section 
2.20.5 for more details). After the PCR was performed, the plate was kept at -20°C 
for two days, followed by bead purification. Nextera libraries were quantified using 
picogreen assay. Calculations was made in order to achieve a final concentration of 
4nM DNA followed by pooling together of all the patient samples and performing 
another picogreen assay. 
2   3   4   5   6   7   8   9  10  11 12 13 14  1  2    3   4   5   6   7   8   9   10 
 11 12 13 14 15 16 17 18  19 20 21 22 23 24 25 1   2    3   4   5   6   7   8              







3.4.3! MiSeq Amplicon Sequencing and Analysis 
The MiSeq sequencing technology was used to sequence the pooled library which 
was denatured and diluted before being loaded on the flow cell for sequencing 
(Refer to section 20.18.2 for more details) PhiX control was used as an internal 
control. The data was analysed using the variant studio. Since no constitutional 
source was available the mutations were confirmed using independent PCR and also 
checked in various data bases i.e. dbSNP and 1000 genome project to rule out for 
polymorphism. 
3.5! Identifications of Mutations 
Mutations were identified in 3 out of 154 patients (2%). A missense mutation in 
SMC1A was found in one patient and a frameshift insertion in one patient and an 
intronic mutation in 3’ splice site of exon 22 in another patients for SMC3 (Table 
3.4). Mutation was not detected in RAD21 gene. Mutations were detected in the 
coiled coiled domain of both SMC1A and SMC3 protein. Mutations in the 
intermolecular domains have been reported to either disrupt binding of accessory 
proteins to cohesin ring or disrupt the inter or intramolecular interaction of head 
domains (Fig 3.11). 
Table 3.4 Patients with identified SMC1Aand SMC3 mutations  along with the variant 
allele frequency.  Mutations were identified in three patients, one in SMC1A and two 
in SMC3 gene. All the mutations were exclusive of one another. 







1. SMC1A 13 CGG>TGG R>W 12.93% 
2. SMC3 22 
(Intronic) 
A>G SA 3’Exon 22 30.08% 



























Figure 3.11: Mapping of the mutations to various domains of SMC1A and SMC3 
protein.(a) SMC1A and (b) SMC3 are members of the structural maintenance of 
chromosome proteins. SMC1A and SMC3 proteins are 1233 and 1217 amino acids 
long with a molecular weight of 143 and 141 kDa respectively. They have identical 
structure and contain five domains, two ATPase and coiled coil domains and one 
hinge domain.  
 
Second mutation in SMC3 has not been depicted as it was found in the intronic sequence. 
An Insilico 3D model could not be constructed for SMC1A and SMC3 proteins 
using the Swiss model software as no homology sequence was detected by the 
software. 
3.5.1! Correlation between cohesin complex mutations and clinical phenotype. 
Sequencing of the Cohesin complex revealed mutations in 6% of patients (9/154) 
comprising STAG2 4% (6/154), SMC1A and SMC3 2% (3/154). WHO subgroups 
for patients with cohesin mutations included RAEB1 (3/154, 2%), RAEB2 (2/154, 
1.28%), RCMD (2/154, 1.28%), MDS/MPN (1/154) and sAML (1/154) (Table 3.5). 
According the IPSS-R (International Prognostic Scoring System- Revised) cohesin 
mutations were more common in Very High (3/9 33.3%) as compared to Very Low 
(1/9 11.1%) category. Mutations were identified in six males and three females 
patients. The median age of the patients at the time of diagnosis was 74 years. Five 
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out of six aberrations detected in STAG2 gene were nonsense mutations resulting in 
truncation of the protein, a missense mutation was found in SMC1A and a 
frameshift insertion and a mutation in intronic splice site in SMC3. Six of the 
patients showed progression to AML. Four males and one female showed normal 
karyotype by metaphase cytogenetics which was performed at Kings College 
Hospital. Mutations in cohesin complex genes were correlated with coexisting 
mutations in genes involved in various pathways done as a part of study in the same 
cohort of patients using a 22-gene panel by Mian et al (Mian et al., 2013). 
Coexisting mutations were found in genes involved in epigenetic, splicing factor, 
cell signalling pathway and transcriptional regulation (Table 3.5). Mutations in gene 
encoding epigenetic factor ASXL1 (Additional sex comb like protein 1) and splicing 
factor SRSF2 (Serine arginine splicing factor 2) were the most common aberrations 
found in patients with cohesin patients. All the mutations identified in ASXL1 were 
nonsense mutations resulting in truncation of protein while hotspot mutation (P95) 
was found in most of the SRSF2 mutated patients. In three of the patients ASXL1 
mutations co-existed with SRSF2 mutation. WHO subgroups for patients with 
ASXL1 included three with RAEB1 and one with RAEB2 while for SRSF2 two 
RAEB1 and one each of RAEB2 and RCMD patients were found. Further 
according to the IPSS-R scoring system only one of the three patients with cohesin 







All the patients with cohesin mutations showed a shorter progression free survival 
as compared to cohesin wildtype patients (p=. 001) with a median free survival of 
8.5 months. Median overall survival of 32 months with cohesin mutations as 
compared to 33 months without mutations (p=0.86). (Fig 3.13)                             
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STAG2 R110X 69 M 2 RCMD Very Low 46,XY 32.98%  TET2 C1193W 49% 
EZH2 R690H 70% 
 No 
STAG2 R908S 75 F 23 sAML Very High trisomy6 and 21 
del11q(q25:q21) 
18.27%     
STAG2 L589X 69 M 9 RAEB1 Intermediate 46,XY 50.10% SRSF2 P95L 41% ASXL1 Q760X 37% RUNX1 SA 3’Exon 4 
32% 
Yes 
STAG2 F647fsX 79 F 19 RAEB2 Very High 46,XX,t(7;21),der19 21.05% SRSF2 P95L 45% ASXL1 R693X 26% FLT3-ITD R595-dup5%, 
NRAS Q61R 11% 
Yes 
STAG2 R953X 67 M 13 RAEB2 Very High 46,XY 43.16%     
STAG2 Q888X 82 F 9 RAEB1 Low 46,XX 34.26% SRSF2 P95L 50% ASXL1 G646WfsX12 
22% 
 Yes 





SMC3 Splice site 73 M 0 RCMD Low trisomy19, trisomy8 30.08% SRSF2 Y93fsX121 24%   Yes 
SMC3 K936-E93 
insK 





46,XY 9.4%  EZH2 SA 5’Exon 19 
























Figure 3.12: Progression free survival in 154 patients with MDS/secondary AML. 
Kaplan - Meier plot for progression free survival for patients with cohesin mutation 
(n=9) as compared to wildtype patients (n=145) p = .001. Median progression free 






























Figure 3.13 Overall survival in 154 patients with MDS/secondary AML. Kaplan - 
Meier plot for overall survival for patients with cohesin mutation (n=9) as compared 
to wildtype patients (n=145). Median overall survival 32 months vs 33 months p= 0.86. 
Median overall survival 34 months vs 32 months if the data is censored for 

























A broad spectrum of diseases arise due to germline mutations in cohesin complex 
genes and are termed as cohesinopathies which include Cornelia de Lange 
Syndrome (CdLS), Roberts syndrome/SC- Phocomelia and Warsaw breakage 
syndrome. Patients with germline cohesin mutations show a constellation of 
phenotypes including craniofacial, heart, gastrointestinal defects, poor growth, 
developmental delay and intellectual disability. 
We identified a total of 9 patients (6%) with somatic mutations in one of the 
cohesin genes. Six of the mutations were in STAG2, one in SMC1A and two in 
SMC3. No aberrations were found in RAD21. All the mutations in our study were 
mutually exclusive of one another. Four of the patients with cohesin mutations 
progressed to AML. Patients with cohesin mutations also showed a significantly 
shorter progression free survival (p= .001) as compared to those without mutations. 
According to IPPSS-R scoring system three of the patients with cohesin mutations 
were found in very high subgroup. Cohesin mutations fall into two categories, 
truncation and frameshift mutations reported in STAG2 and RAD21 and missense 
mutations reported in SMC1A and SMC3 (Kon et al., 2013). 
STAG2 is located on chromosome X q25 and is mutated in 6/154 (4%) patients in 
our cohort, four males and two females. Four of these mutations were nonsense 
mutations suggestive of C terminal truncation of the protein, the other two were 
missense and frameshift mutation. One of the nonsense mutation arginine to a stop 
codon (R110X) has been reported in two different studies. Kon et al reported this 
mutation in two patients with Chronic Myeloid Leukaemia in blast crisis (CML) 
and Chronic Myelomonocytic Leukaemia (CMML) (Kon et al., 2013) while Thota 
et al reported this mutation in patient with Refractory cytopenia with multilineage 
dysplasia (RCMD) (Thota et al., 2014). In both the studies, the reported patients 
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were males and showed normal karyotype, except in the CMML patient where the 
karyotype was undetermined. Although the position of the reported mutation was 
different in all the patients, the mutation would have resulted in premature 
truncation and reduced expression of protein. All the STAG2 mutations identified in 
our study were located outside the two main domains found in STAG2 protein, the 
SCD (Stromalin Conservative Domain) and STAG2 domain. Five of the mutations 
were located in the region between (162-993) amino acids which could have 
affected interaction of STAG2 with CTCF. STAG2 has been reported to interact 
with CTCF in this region (Xiao et al., 2011). CTCF a 11 zinc finger DNA binding 
protein is the only insulator protein reported in vertebrates which can block 
enhancer function in plasmids and native DNA context. Interaction of STAG2 with 
CTCF is reported to be crucial for the expression of imprinted Igf2/H19 genes and 
insulation activity of CTCF. Also direct contact between CTCF and cohesin has 
been found to occur via STAG2. Phosphorylation sites have been identified in 
STAG2 at residues S1058, S1064, S1065 in the C terminal region that is important 
for the dissociation of cohesin from chromosome arm during mitosis. 
Phosphorylation of STAG2 might also be important for recruiting cohesin unloading 
factors to chromatin that can then enable dissociation of cohesin from chromosomes 
(Hauf et al., 2005). As truncated proteins would have been the end product of all the 
non-sense mutations in our study this could have an impact on sister chromatid 
separation due to loss of phosphorylation sites. 
SMC1A gene is located on chromosome Xp11.2. One patient in our cohort had a 
missense mutation (R711W) in SMC1A gene. The patient was a male. This 
mutation which is associated with a Cornelia de Lange phenotype (CdLs) was 
found to be somatic residing in the coiled coil domain. By use of the Coils program 
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which predicts the probability of a protein to form a coiled-coil Deadorff et al 
reported that this mutation had a small likelihood of disrupting the coiled-coil arms. 
However, the alterations caused by this mutation might affect the angulation of the 
coiled-coil resulting in impaired intra or intermolecular approximation of the SMC 
head domains or disrupt binding of accessory proteins to the cohesin ring 
(Deardorff et al., 2007).  
SMC3 gene is localised on chromosome 10 q25.2. Two patients in our cohort had 
mutations in SMC3 gene, one was a frameshift insertion in the coiled coiled domain 
of exon 24 and the other was in the 3’splice intronic acceptor site of exon 22. 
Studies have shown that mutations occurring in the bases at the beginning of the 
exon-intron junction have an impact on the splicing of the intron and  result in the 
production of defective protein (Raben et al., 1992). Both the patients were males 
and showed progression to AML. 
All the truncating mutations in cohesin complex were identified in STAG2 gene. 
Solomon et al identified a diverse range of tumors harbouring deletions or 
inactivating mutations of STAG2 and correlated aneuploidy with mutational 
inactivation of STAG2. As the presence of p53 mutations is characterised by gross 
chromosomal instability, it is interesting that none of the cohesin mutated patients 
had a p53 mutation. A number of papers have documented mutations in cohesin 
complex are not to be associated with chromosomal instability (Taylor et al., 2013, 
Welch et al., 2012) These result suggest that either loss of cohesin is not associated 
with chromosomal instability in the background of wildtype p53 or there might be a 
compensatory mechanism that compensates for the loss of cohesin complex genes 
and hence survival of cohesin deficient tumour cells. STAG1 is a paralog of STAG2 
primarily involved in telomere replication. Solomon et al and other groups could not 
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detect an upregulation of STAG1 expression in STAG2 deficient cells. In contrast, 
Kon et al reported compensatory upregulation of STAG1 or STAG2 in SA1/SA2 
deficient HeLa cells. Bailey et al also showed an increase in STAG1 containing 
complexes in STAG2 mutated glioblastoma cell line following immunoprecipitation 
with RAD21 (Bailey et al., 2013). Interestingly a recent study carried out by Kim et 
al showed that chromosomal instability is not the phenotype of all cohesin 
mutations and different mutations have either different mechanisms by which they 
cause cancer or the mechanism is unknown (Kim et al., 2016). In this study all the 
missense mutations tested retained wildtype cohesion, mitotic integrity and 
euploidy also the truncating mutations which despite showing defects in sister 
chromatid cohesion and a subset showing increase in lagging chromosome didn’t 
show any change in modal chromosome number. Further they demonstrated that 
truncating mutations in STAG2 had no influence on its interaction with other 
members of the cohesin complex and supported this hypothesis with the recently 
published crystal structure of STAG2 which showed that missense mutations didn’t 
have any influence on interaction of STAG2 with members of the cohesin complex. 
 as STAG2 interacts with cohesin via an extensive interface with RAD21 spanning 
the entire length of STAG2 (Hara et al., 2014). Further correction of endogenous 
STAG2 mutant allele in two isogenic glioblastoma cell lines by somatic cell gene 
targeting did not disrupt the ability of SMC3 to co-immunoprecipitate SMC1A, 
SMC3 and RAD21 subunits suggesting that STAG2 is not required for assembly of 
cohesin subunits .The results from this study could support our findings that despite 
truncating mutations in STAG2 no influence on chromosomal instability was 
observed as STAG2 is not responsible for formation of the ring. 
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In five of our patients, cohesin mutations were found to co-occur with mutations in 
SRSF2 (ribosome pre-mRNA splicing factor) and ASXL1 (polycomb repressive 
transcriptional factor mutations) genes. SRSF2 (Serine/ arginine rich splicing factor 
2) is a member of serine /arginine- rich (SR) protein family that contributes to both 
constitutive and alternate splicing by binding to exonic splicing enhancer (ESE) 
sequences within the pre-mRNA through its RNA recognition motif domain 
(RRM). Most of the splicesome mutations are heterozygous, mutually exclusive and 
are associated with adverse outcomes among MDS and acute myeloid leukemia 
(AML) patients. Kim et al associated hot spot mutations (P95H/L/R) in SRSF2 to be 
responsible for alterations in splicing of major haematopoietic transcriptional 
regulators like EZH2. A change in the conformation of the termini of SRSF2 RRM 
caused retention of poison exon cassette in EZH2 resulting in nonsense mediated 
decay (NMD) of EZH2. Mutations in SRSF2 were identified in four of the cohesin 
mutated patients with three patients carrying hot spot (P95H and P95L) mutations 
in SRSF2. In most of the cases in our cohort aberrations in SRSF2 coexisted with 
nonsense mutations in cohesin complex. Impaired SRSF2 could have resulted in 
altered splicing of cohesin subunits subsequently leading to nonsense mediated 
decay however this effect could not be ascertained at a protein level due to 
unavailability of cells from these patients (Kim et al., 2015). This hypothesis can 
further be supported by a study carried out by Sundermoorthy et al where using a 
functional genomic approach an association between pre mRNA splicing factors 
and sister chromatid cohesion was unveiled. Loss of a multitude of splicing factors 
including SF3B1 (one of the genes of the splicesome machinery) was found to 
cause a loss of sister chromatid cohesion upon mitotic entry. Compromised splicing 
produced a non functional truncated sororin (a protein required for stable 
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association of cohesin with chromatin) due to retention of intron 1 in sororins 
mRNA. Reduced levels of sororin were detected in cells depleted of splicing 
factors. Expression of an intronless version of sororin and depletion of WAPL 
whose activity is antagonized by sororin was able to restore sister chromatid 
cohesion (Sundaramoorthy et al., 2014). Reported findings from the two studies 
predict that mutations in components of splicing machinery can result in 
compromised splicing of cohesin members which could alter the turnover of 
cohesin on chromatin hence affecting chromosomal stability and gene regulation. 
Mutations in additional sex -combs like-1’ ASXL1 gene have been also found in 
cohesin mutated patients. ASXL1 encodes a chromatin binding protein involved in 
epigenetic regulation and is responsible for recruiting polycomb and trithorax 
complexes to specific loci. Mutations in cohesin complex have been reported as 
coexisting passenger mutations along with ASXL1 mutations that exist as drivers of 
clonal evolution (Thota et al., 2014). Clonal dominance at the time of 
transformation to more aggressive disease and strong association with ASXL1 
indicated synergism between epigenetic dysregulation and mechanism of action 
exerted by cohesin haploinsufficiency. Further mutations in ASXL1 were thought to 
promote myeloid transformation through loss of PRC2 mediated myeloid repression 
suggesting that ASXL1 might act as a scaffold for recruitment of PRC2 complex to 
specific loci in haematopoietic cells. Results emerging from gene expression and 
chromatin state data from this study identified HOXA cluster including HOXA9 to 
be altered in the setting of ASXL1 mutation (Abdel-Wahab et al., 2012, Fisher et al., 
2016). Similar findings have also been reported with regards to mutations in 
cohesin complex by other studies. Fisher et al supported a model in which RAD21 
was found to be responsible for recruitment of PRC2 to its targets i.e. HOXA7 and 
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HOXA9. Loss of RAD21 increased haematopoietic stem cell renewal due to 
deficiency of H3K27me3 at the promoters of HOXA7 and HOXA9. As MDS is a 
myeloid malignancy in which multiple mutations co-operate in the progression of 
disease, association between mutations in ASXL1 and cohesin complex by having 
an additive effect on altering the expression of Hox genes could lead to disease 
progression. 
In summary mutations in cohesin complex have been identified in MDS and AML 
but how these mutations contribute to disease progression needs to be unravelled. 
What is the nature of these mutations whether they exist as driver or passenger 
mutations, how these mutations provide a growth advantage to the cancer cell needs 
to be determined and further can these mutations be exploited therapeutically to be 
used in a clinical setting. 
In order to explore contributions of cohesin complex mutations in myeloid 
malignancies my next part of thesis would be to determine the functional 














4! Chapter Four 
FUNCTIONAL CONSEQUENCES OF KNOCKDOWN OF 
STAG2 IN MYELOID CELL LINE            
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4.1! RNA Interference 
The advent of RNA Interference (RNAi) technology has become a powerful tool to 
gain insight into critical biological processes like gene regulation and to identify 
novel therapeutic targets, (Bantounas et al., 2004, Leung and Whittaker, 2005, 




























Figure 4.1: Schematic representation of RNA interference in a mammalian cell.1. The 
dsRNA is initially recognized by an RNase III nuclease enzyme Dicer and is cleaved 
into 21-23 base pairs small double stranded molecules termed siRNA. 2. siRNAs are 
loaded onto a multiprotein complex with RNase activity called RNA Induced Silencing 
Complex leading to degradation of passenger strand while the guide strand remains 
attached to RISC as a template in the silencing reaction. 3. The guide strand 
assembles into a functional siRNA-RISC and attaches to the complimentary strand. 4. 
The target mRNA is degraded and dissociated from the complex and the siRNA-RISC 







One of the drawbacks of using siRNA is the generation of off target effects that can 
be elicited through different mechanisms (Birmingham et al., 2006, Jackson et al., 
2003, Jackson et al., 2006, Lin et al., 2005).  An elicitation of an anti-viral 
interferon response (IR) through introduction of long dsRNA leads to widespread 
consequences on cellular processes such as protein synthesis, cell cycle and 
apoptosis. The use of synthetic siRNAs 21-23 nucleotides in length however is 
thought to resolve this problem (Bantounas et al., 2004). Off target effects can fall 
into two categories, they can be sequence dependent specific to siRNAs or sequence 
independent and caused by siRNA in general. Some of the off target effects can be 
avoided by reducing the concentration of siRNA, however most of the off targets 
effects are sequence dependent (Jackson and Linsley, 2004, Lin et al., 2005) 
Complimentarity to a 7 nucleotide region at 5’ end of siRNA (between position 2-8) 
is not only important but sufficient enough to elicit an RNAi response (Birmingham 
et al., 2006, Jackson et al., 2006, Lin et al., 2005). Off target effects however do not 
always cause transcript cleavage but may inhibit translation as a method of 
suppression instead, behaving much like miRNAs (Zeng et al., 2003). Unavoidable 
sequence homology to a 7nt siRNA seed region else were in the genome is 
unavoidable making sequence specific off targets effects almost inevitable and 
difficult to predict. However, these off target effects are generally less efficient and 
much weaker by comparison to the targeted effect on the intended transcript. 
A stable system of gene suppression is required to achieve long term knockdown.  
that can be achieved by adapting the more sustainable short hairpin (shRNA) 
mediated approach. Like siRNAs, shRNAs may be transfected as plasmid vectors 
encoding shRNAs transcribed by RNA pol III or modified pol II promoters, but can 
also be delivered into mammalian cells through infection of the cell with virally 
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produced shRNA. shRNA expression cassette consists of a sense and antisense 
strand separated by a loop. The RNA transcript folds at the loop and self anneals to 
form a dsRNA stem loop structure: a short hairpin RNA. The shRNA is structurally 
related to endogenous miRNAs and is processed accordingly by the RNAi 
machinery to mediate target silencing.    
Conventionally the RNA polymerase III promoters U6 and H1 are used for shRNA 
expression, generating transcripts lacking a long poly (A) tail that may hinder 
subsequent RNAi processing machinery. However, RNA polymerase II promoters 
such as the CMV promoter have been used. RNA interference is an effective 
technique to knock down gene expression in order to study protein function in a 
wide range of cell types as long as off target effects are circumvented. The use of 
























•!  Establishment of a transient or stable STAG2 knockdown in a myeloid cell 
line in order to delineate the functional consequences of STAG2 knockdown 
in myeloid malignancies 
•! Consequences of STAG2 knockdown on the expression of other members of 
the cohesin complex. 
•! To determine whether sensitivity to poly-ADP ribose polymerase inhibitors 
(PARPi) is attributable to defects in the cohesin complex using the 
Homologous Recombination assay (HR assay). The aim is to exploit cohesin 
mutations therapeutically, which could aid in the development of new drugs 
specifically targeting cohesin mutations.  
•! To study the effect of PARPi on proliferation and cell cycle in shRNA 


































4.3.1! Establishment of a transient cell line 
Two predesigned siRNA oligonucleotides, one from Dharmacon™ and the other 
from Santa Cruz™ were used to transiently silence STAG2 expression using 
electroporation (Refer to section 2.10.1 for more details). A negative control (a 
scrambled oligonucleotide) was used to distinguish sequence specific silencing 
from non-specific effects. To exclude any variations caused as a result of the 
technique mock-transfected cells were used. Cell lines i.e. K-562, NB4, U-937, 
MCF-7 were tested for knockdown efficiency using different concentrations of 
siRNA. Samples were collected at 24, 48 and 72hr timepoints. and maximum 
knockdown efficiency was achieved at 48hr timepoint in U-937 cell line using 











Figure 4.2: Detection of maximum STAG2 knockdown efficiency in U-937 cell line 
using different concentrations of Dharmacon siRNA. In order to attain maximal 
knockdown efficiency of STAG, U-937 cells were electroporated with different 
concentrations of Dharmacon siRNA and maximum knockdown efficiency was 
achieved using a concentration of 100nM of siRNA at 48hr timepoint determined by 
qRT-PCR. GAPDH and TUBULIN (data not shown) were used as endogenous 
controls. The results are expressed as STAG2 mRNA fold difference compared to that 
measured in mock treated control ΔΔCT.  
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4.3.2! Transient knockdown of STAG2 using  electroporation method 
The viability and general health of cells prior to transfection is considered to be an 
important source of variability from one transfection to another. Electroporation a 
very harsh technique uses electric impulses to create temporary pores in the cell 
membrane through which substances like nucleic acid can pass. In preliminary 
experiments, a substantial amount of cell death was observed, therefore a starting 
cell density of 2×106 cells/ml was found to be efficient to achieve maximal 
transfection efficiency (Refer to section 2.10.1 for more details). U-937 cells were 
then transfected with 100nM of siRNA and samples were collected at 24, 48 and 












Figure 4.3: Silencing efficiency of Dharmacon siRNA in U-937 cell line. Expression 
level of STAG2 (using 100nM of Dharmacon siRNA) was calculated relative to mock-
infected cells (ΔΔ CT) by q-RT PCR. GAPDH and TUBULIN (data not shown) were 
used as endogenous controls. Maximum knockdown (62%) was achieved at 24hr 
timepoint with a gradual increase in expression at later timepoints. Data presented as 




























Knockdown efficiency of around 63% was achieved that was observed at the 24hr 
timepoint with a gradual increase in expression over time. Therefore the 24hr time 
point was considered to be the optimal timepoint to carry out further experiments. 
Expression levels for STAG1, a paralog of STAG2 was also carried out to determine 
whether upregulation of STAG1 occurs upon knockdown of STAG2 as previously 











Figure 4.4: Expression levels of STAG1 in STAG2 si-RNA silenced (Dharmacon). U-
937 cell line determined by qRT-PCR. Expression level of STAG1 in STAG2 
knockdown U-937 cell line (using 100nM siRNA) was calculated relative to mock-
infected cells (ΔΔ CT). GAPDH was used as an endogenous control. No upregulation 
of STAG1 was observed in knockdown samples. Data presented as mean ±SD (n=3). 
 
No significant upregulation of STAG1 was observed in STAG2 silenced U-937 cells 
at 24hr. To confirm that the knockdown by siRNA (Dharmacon) was real and not 
artifactual, another siRNA from Santa Cruz was used at the same concentration of 
100nM using electroporation method (Fig 4.5). 
  

































Figure 4.5: Expression level of STAG2 in U-937 cell line transfected with siRNA 
(Santa Cruz) and determined by qRT-PCR. Expression of STAG2 in U-937 using 
100nM of si-RNA from Santa Cruz was calculated relative to mock-transfected cells 
(ΔΔ CT). GAPDH and TUBULIN (data not shown) were used as endogenous controls. 
Maximum knockdown was achieved at 24hr similar to Dharmacon siRNA. Data 
presented as mean ±SD (n=3). 
 
Similar knockdown efficiency i.e. 63% was achieved using the Santa Cruz siRNA 
at 24hr timepoint confirming the results achieved using Dharmacon siRNA. The 
expression level of STAG1 was also determined to confirm the results obtained by 














Figure 4.6: Expression levels of STAG1 in U-937 using 100nM siRNA(Santa Cruz). 
Upregulation of STAG1 was determined relative to mock-infected cells ΔΔ CT using 
qRT-PCR. GAPDH and TUBULIN (data not shown) were used as endogenous 
controls. No significant upregulation of STAG1 was observed in STAG2 knockdown 
U-937 cell line. Data presented as mean ±SD (n=3). 
 













































No effect on the levels of STAG1 was observed with downregulation of STAG2, 
using 100nM of Santa Cruz siRNA thus confirming the Dharmacon 100nM siRNA 
results.  
4.3.3! Cell cycle analysis 
STAG2 forms a part of the cohesin complex which holds sister chromatids together 
and several papers have reported downregulation of STAG2 to be associated with 
chromosomal instability (Solomon et al., 2011). To correlate the association 
between chromosomal instability and STAG2 knockdown, U-937 cells were 
transfected with 100nM of Dharmacon siRNA and samples were collected at 
various time points up to 96 hours. Cell cycle kinetics analysis was performed using 
flow cytometry (Refer to section 2.5.2 for more details) to determine a change in 





Figure 4.7: Effect of transient knockdown of STAG2 on cell cycle kinetics. Samples 
were collected upto 96 hrs (data only shown for 48 hrs (upper panel) and 72 hrs 
(lower panel) treated with propidium iodide (for DNA content) and fluorescein 
isothiocyanate (for protein content) and then analyzed for cell cycle distribution using 
flow cytometry. The histogram was plotted using the flow jo software. The software 
predicted the percentage of cells in different phases of cell cycle. No significant 
difference was observed between the percentage of cells in different phases of cell 
cycle G0, G1, S and G2/M between the siRNA versus mock transfected cells. The result 
is representative of three independent experiments. 
 
No significant differences could be determined between the scrambled, knockdown 
and mock transfected cells in various phases of cell cycle especially (apoptotic) 
G0/sub G1 phase. As inhibition of target by siRNA is transient, this could be one of 
the reasons behind the non-significant effect on cell cycle. This issue can be 
circumvented by the establishment of a STAG2 downregulated stable cell line using 
short hairpin RNAs (shRNAs). 
  
Scrambled 48hr Knockdown 48hr 
Scrambled 72hr Knockdown 72hr Wildtype 72hr 
Wildtype 48hr 
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4.4! Stable knockdown of STAG2 using shRNA in Retroviral system 
Four independent retroviral shRNA expression vectors targeting STAG2 were 
obtained from Origene (Rockville US) and were amplified by transforming E.coli. 
(Fig 4.8). Concentration of 1µg, 4µg of each individual shRNAs as well as 10 µg of 
pooled shRNAs were used, to transfect U-937 cells by electroporation, however cell 
death was observed after puromycin selection. After several unsuccessful attempts 
lentiviral approach was initiated to establish a stable cell line. 
 
 











           
                     
 Figure 4.8: Map of shRNA cloning vector pGFP-V-RS. pGFP-V-RS is a plasmid 
vector used for cloning shRNA expression cassettes. The cassette consists of a 29 
nucleotide target-gene-specific sequence, a 7 nt loop, and another 29 nucleotide 
reverse complementary sequence, all under the control of the human U6 promoter. A 
termination sequence (TTTTTT) is located immediately downstream of the second 29 
nt reverse complementary sequence to terminate the transcription by RNA Pol III.  A 
puromycin-N-acetyl transferase gene is located downstream of the SV40 early 








4.5! Stable knockdown of STAG2 using a shRNA Lentiviral system 
4.5.1! shRNA (Thermo Fisher) 
Four independent shRNA were purchased from Thermo Fisher (Dharmacon) and 
virus was generated using lentivirus system (Refer to section 2.11 for more details). 
Cells were transduced with the virus and 48hours later transduced cells were 
subjected to puromycin (2µg/ml) selection. Samples were collected at day 7 and 
knockdown was determined using qRT-PCR, however no efficient knockdown was 
observed with any of the shRNA so another batch of shRNA from Addgene was 
obtained. 
 
4.5.2! shRNA (Addgene) 
Two shRNAs and a scrambled control were purchased from Addgene and lentiviral 
particles were produced (Refer to section 2.11 for more details). The shRNA 
vectors did not possess a fluorescent marker i.e. GFP, therefore, virus titre was 
roughly calculated by transfecting Hela cells with different concentration of virus 
and then counting the colonies. U-937 cells were transduced with 12 µl of virus for 
each shRNA as well as scrambled (control). Puromycin (2µg/ml) was added after 
48 hrs and positive cells were collected for western and q-PCR after 14 days (Fig 




























Figure 4.9: STAG2 expression in STAG2 lentiviral shRNA treated U-937. STAG2 
expression was determined using qRT-PCR. GAPDH and TUBULIN (data not shown) 
were used as endogenous controls. A knockdown efficiency of 72% and 76% using 
shRNA1 and shRNA2 respectively was achieved. Expression levels were calculated 
relative to wild type STAG2 (ΔΔ CT). Error bars represent mean of standard 
deviation of three independent experiments. **p<.01, ***p<.001. 
 
A knockdown efficiency of 72% and 76% was achieved using shRNA1 and 
shRNA2 respectively at day 14 after post selection by puromycin. The knockdown 
for both shRNAs was found to be significant when compared with scrambled 
(control) with p <0.1 for shRNA1 and p< .01 for shRNA2. 
4.5.3! Western Blot Analysis 
Reduction in STAG2 expression at the protein level was also confirmed by western 
blotting (Fig 4.10). To correlate the impact of STAG2 knockdown, western blotting 
was also carried out on other members of the cohesin complex RAD21 (Fig 4.10 a), 
SMC1A and SMC3 (Fig 4.10b).  
  
**              *** 



































Figure 4.10: Western Blot analysis for depletion of STAG2 in lenti- virus treated U-
937. Immunoblot analysis of whole cell extracts from U-937 cell line that were 
previously transduced with STAG2 lentivirus (16 days prior to analysis) (a). β-actin 
was used as a loading control (b) Western blot was also carried out on other members 
of cohesin complex RAD21 (Fig 4.9a), SMC1A and SMC3 however no decrease in 
expression level was observed. The result is representative of five independent 
experiments. 
Results from western blot correlated with qRT-PCR results confirming the down 
regulation of STAG2 although the knockdown efficiency was more pronounced by 
western blot. This discrepancy in the knockdown efficiency at mRNA and protein 
level could not be explained. No difference in the expression levels of other 
members of the cohesin complex was observed although western blot did show a 
reduction in the expression level of RAD21 level but the reduction could be ruled 
out due to unequal loading between the scrambled and knockdown samples and also 




4.5.4! Homologous Recombination Assay 
The phenomenon of Synthetic lethality was first described by Calvin Bridges in 
1992 who noticed that some combinations of mutations in the model 
organism Drosophila melanogaster confer lethality. Synthetic lethality arises when 
a combination of mutations in two or more genes leads to cell death, whereas a 
mutation in only one of these genes does not, and by itself is said to be viable. 
In order to determine synthetic lethality between STAG2 and PARP. 3×105 U-937 
cells with stable knockdown of STAG2 were cultured in a 24 well plate in 1ml of 
RPMI media and 100nM of PARPi, BMN-673 (gifted by Biomarin). In a study 
conducted by Gaymes et al from our group 100nM of BMN-673 was found to be 
the optimal concentration to be used in HR assays as increasing the concentration 
resulted in non specific cell death (Fig 4.11) (Gaymes et al., 2013). After 24hr 
incubation, the cells were collected and cytospun onto poly- lysine coated slides. 
The cells were stained for RAD51 and γH2AXP foci (Refer to section 2.7 for more 
details). RAD51 foci formation is a marker for competent Homologous 
Recombination (HR) an error free DNA DSB repair pathway. In HR, RAD51 is 
recruited to sites of double stranded DNA damage where it is involved in 
complementary strand invasion and formation of a helical nucleoprotein filament 
that is detected in the form of nuclear foci. γH2AXP is a marker for DSB DNA 
damage. Upon phosphorylation at Ser 139, it acts as a mediator of repair factor 
recruitment during DSB DNA damage. The cells were visualised using a 
fluorescence microscope and percentage of RAD51 and γH2AX P positive cells (>5 


























Figure 4.11: Evaluation of the effective drug concentration in leukaemic and 
fibroblast cell lines. (a) Soft agar clonogenic assays were used to determine cell 
survival in leukaemic (P-39, KG-1, Molm-13, FancD2, OCI-AML2) and fibroblastic 
cell lines (DNL and BLM) in response to different concentrations of BMN-673 and 
KU-0058948 (now known as olaparib). Data from cell survival assays were used to 
construct dose response curves. BMN-673 was found to be more cytotoxic than KU 
0058948 at the same concentration. (b) Comparison of cytotoxicity of BMN-673 
(dashed line) with KU-0058948 (solid square) and AG-014699 (solid triangle) in P-39 
































Figure 4.12: Effect of PARP inhibitors on STAG2 knockdown U-937 cell line. 
Immunostaining of STAG2 knockdown U-937 nuclei treated with 100nM BMN-673 
for 24hr. Cells were probed for γH2AX-P foci (green stain) Rad51 foci (red stain) and 
nuclei stained with DAPI (blue) white arrows depicts the foci. The figure shows the 
frequency of cells displaying Rad51 foci (%) (red bars) γH2AX-P (%) (green bars) as 
detected by immunofluorescence following addition of BMN-673. 200 nuclei were 



















































Figure 4.13: Effect of PARP inhibitors on STAG2 knockdown U-937 cell line. 
Immunostaining of STAG2 knockdown U-937 nuclei treated with 100nM BMN-673 
for 24hr. Cells were probed for γH2AX-P foci (green stain) Rad51 foci (red stain) and 
nuclei stained with DAPI (blue) white arrows depict the foci. The figure shows the 
frequency of cells displaying Rad51 foci (%) (red bars) γH2AX-P (%) (green bars) as 
detected by immunofluorescence following addition of BMN-673. 200 nuclei were 


























          
             
 
Figure 4.14: Percentage of cells displaying Rad51 foci (red bars) γH2AX-P (green 
bars) as detected by immunofluorescence following addition of BMN-673. 200 nuclei 
were counted per experiment. n=2.   
 
Increase in phosphorylation of H2AX in the form of foci was observed on addition 
of BMN-673 to knockdown cells as compared to treated scrambled and wildtype 
cells however this increase was not accompained by loss of RAD21 foci. 
 
4.5.5! Effect of PARPi on STAG2 deficient cell viability 
To evaluate the additive effect of PARP inhibition and STAG2 deficiency on cell 
viability. STAG2 shRNA treated U-937 were exposed to BMN-673 and cell counts 
were performed on days 2, 7 and 12 using the trypan blue exclusion method (Fig 
4.15). Trypan blue is a vital stain that distinguishes between live and dead cells. It is 
































































Figure 4.15: Cell survival of STAG2 silenced U-937 treated with BMN-673. STAG2 
silenced. U-937 cell line was exposed to BMN-673 for 12days and cell count was 
determined using trypan blue exclusion analysis. *p<. 05 for both shRNA1 and 
shRNA2 STAG2 deficient cells treated with BMN-673 as compared to control cells 
using trypan blue exclusion method however no cell death was observed.  
 
Significant difference in cell count was observed between treated and untreated 
shRNA1 and shRNA2. STAG2 deficient cells but low cell count was not associated 
with any cell death although increase in phosphorylation of H2AX was observed. 
This result can be supported by the fact that under the influence of drug, treated 
cells need more time to repair as compared to untreated cells hence resulting in 
slower cell growth. 
4.5.6! Cell cycle 
Cell cycle was performed on STAG2 knockdown cells exposed to BMN-673 for 12 
days. Cells were stained with FITC and PI (and cell cycle was performed using flow 
cytometry). The percentage of cells in each phase of the cycle was compared 





















































Figure 4.16: Effect of BMN-673 on cell cycle in shRNA silenced U-937 cell line.   
Knockdown cells were exposed to BMN-673 for 12 days (a) treated and (b) untreated 
cells were stained with fluorescence isothiocyanate (FITC) and propidium iodide and 
then analyzed using flow cytometry. Although a small increase in the percentage of 
cells in the subG1 phase for both treated shRNA1 and shRNA2 could be observed the 
decrease was insignificant. 
 
The cell cycle profile did not vary significantly in different phases of the cell cycle 
between BMN-673 treated and untreated shRNA silenced STAG2 U-937. Moreover, 













































4.5.7! Annexin V assay 
The Annexin V assay was performed at day 12 to support the data from the cell 
viability and cell cycle assays (Refer to section 2.6 for more details). Annexin V 
assay determines the degree of apoptosis via binding of annexin to phosphatidyal 
serine (PS) on the surface of apoptotic cells (Fig 4.17).  
 
Figure 4.17: Annexin V assay on STAG2 shRNA treated U-937 treated with 100nM of 
BMN-673. Annexin V and PI staining of shRNA transduced U-937 cells treated with 
BMN-673 at day 12. Q1 upper left quadrant represents cells + for PI. Q2 upper right 
quadrant represents cells double +ve for Annexin V and PI. Q3 bottom right 
quadrant represents cells +ve for Annexin V and Q4 bottom left quadrant represents 
cells double –ve for Annexin V and PI.  
 
Although increase in apoptotic cells was observed in shRNA1 treated cells this 
increase was not significant as compared to untreated knockdown cells. No 
difference in apoptotic cells was found between treated STAG2 silenced cells as 





Annexin V assay supported the findings from viability and cell cycle assay as no 
difference was found in the percentage of early apoptotic and late apoptotic cells 
between the treated vs untreated shRNA transduced U-937 cells. 
4.6! The UMUC3 cell line 
4.6.1! Evaluation of Expression of STAG2 in STAG2 mutated cell line 
UMUC3 by Western Blotting 
 
UMUC3 is an adherent hypertriploid urinary bladder cell line. It has a single base 
deletion that creates a nonsense mutation at position K983X resulting in no 
expression of STAG2 as shown in (Fig 4.18 a). Loss of the endogenous allele of 
STAG2 formed the basis of selecting this cell line to determine the functional 
consequences of complete loss of STAG2. The effect of the complete loss of 
STAG2 expression on other members of the cohesin complex was also determined 









Figure 4.18: Expression levels of members of cohesin complex in UMUC3 cell line. (a) 
Evaluation of  STAG2 expression in UMUC3 by western blotting, compared with Hela 
and U-937 cell lines used as controls . Loss of expression of STAG2 was confirmed in 
UMUC3 cell line. β -actin was used as a loading control (b) Expression of other 
members of the cohesin complex SMC1A, SMC3, RAD21 and STAG1 in UMUC3* 
and U-937** were also evaluated no difference in expression was observed between 
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β-actin 
(a)                                                     (b) 
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Western blot analysis confirmed complete loss of STAG2 expression in UMUC3 
cell line however the loss in STAG2 expression was not accompanied by 
concomitant decrease in expression of the other members of the cohesin complex. 
4.6.2! Homologous Recombination Assay 
Homologous Recombination assay was performed on UMUC3 to evaluate whether 
complete loss of STAG2 influences HR repair. UMUC3 was exposed to 100nM 
BMN-673 for 24hr and then immunostaining was carried out. UMUC3 cells were 








Figure 4.19: Effect of PARPi on cell line (UMUC3) with no expression of STAG2. 
Immunostaining of UMUC3 nuclei treated with 100nM BMN-673 for 24hr. Cells were 
probed for Rad51 foci (red stain) γH2AX-P foci (green stain) and nuclei stained with 
































Figure 4.20: Percentage of cells displaying Rad51 foci (red bars) γH2AX-P (green 
bars) as detected by immunofluorescence following addition of BMN-673. 200 nuclei 
were counted per experiment. n=3. Significant difference was found in the 
phosphorylation of γH2AX. **p<. 01 between the treated and untreated cells. 
 
Treatment of UMUC3 with 100nM BMN-673 resulted in a significant increase in  
the number of γH2AXP foci but this was not accompanied by any cell death further 
lack of STAG2 expression  had no effect on recruitment of RAD51 foci although 
the number of foci observed were less as compared to that observed in treated 
STAG2 knockdown U-937 cell line.  
To study the effect of BMN-673 on UMUC3 viability cells were treated with BMN-
673 for 12 days and cell counts were performed at fixed time points using trypan 
blue exclusion MCF-7 cell line an adherent breast cancer cell line with expression 





































































Figure 4.21: Cytotoxicity curves of treated UMUC3 cell line. (a) Cell counts were 
performed on day 2, 5, 8 and 12 using the trypan blue exclusion assay. MCF-7 was 
used as a control. Significant difference was found between treated and untreated 
UMUC3 at day 12 and between treated UMUC3 and MCF-7 at day 8 p*<. 05. Data 
presented as mean ±SD (n=3). (b) A separate graphical plot for day 12 between 
treated and untreated UMUC3 cell. 
 
Significant difference in cell count was found between treated and untreated 
UMUC3 cell line on day 8 and between treated UMUC3 and MCF-7 cell line on 
day 12 but this decrease in cell number was not associated with cell death.  
4.6.3! Cell cycle 
To study the impact of BMN673 treatment on UMUC3 cell cycle kinetics, UMUC3 
cells were exposed to 100nM BMN-673 for 12 days. Cells were collected and 





























Figure 4.22: Cell cycle profile of UMUC3 cell line treated with 100nM of BMN-673 for 
12 days. Cells were exposed to increasing concentrations of BMN-673 for 12 days and 
cell cycle kinetics was determined using flow cytometry. No significant difference was 
found in the percentage of cells in different phases of cell cycle.   
 
No effect was observed in any phases of cell cycle after treating UMUC3 cell line 
with increasing concentrations of BMN-673, was in agreement with the data 
obtained from STAG2 shRNA silencing of cell cycle kinectics. 
4.6.4! Annexin V 
Annexin V analysis was performed on UMUC3 exposed to 10 nM and 100 nM of 







Figure 4.23: Annexin V analysis on UMUC3 cell line treated with 10 and 100nM 
BMN-673 continuously for 12 days. At day 12 Annexin V assay was performed. The 
upper left quadrant Q1 represents –ve cells for 7AAD, the upper right quadrant Q2 
represents double + for FITC and 7AAD V, the lower left quadrant represents double 





No difference in early apoptotic and late apoptotic cells was observed in UMUC3  
cells treated with increasing concentrations of BMN-673. Based on the results 
obtained from HR assay, viability, cell cycle and Annexin V one can infer that loss 
of expression of STAG2 has no effect on homologous recombination and further 
STAG2 deficient cells are not sensitive to PARPi. 
4.6.5! Synergistic effect of Cisplatin and Aurora Kinase B with BMN-673 
No enhancement in  cytotoxicity was observed with combined treatment of BMN-
673 with Cisplatin (a DNA damaging agent) and Aurora kinase B after treating the 
cells for 19hr. Aurora kinase B inhibitor  and cisplatin were chosen to determine if 
synergistic inhibition using Aurora kinase B (involved in phosphorylation of 
sororin) or cisplatin with PARPi could enhance the cytotoxicity in STAG2 deficient 
cells. Although treating knockdown cells individually with 1µg/ml cisplatin and 
20nM Aurora kinase B showed cytotoxicity at 19hr but no enhancement in 





Figure 4.24: Synergistic inhibitory effect of Aurora kinase B and Cisplatin with BMN-
673 on STAG2 deficient UMUC3 cell line after 19hrs. UMUC3 cell line was treated 
with BMN-673, Aurora Kinase B and Cisplatin for 19hr. Treated cells were stained 
with PI and FITC and effect on cell cycle kinetics was determined by running the 





Apart from its established role in maintaining the polarity of sister chromatids 
during mitosis, cohesin is also involved in a large number of biological processes 
such as DNA damage repair and gene regulation (Panigrahi and Pati, 2012). A 
major role of cohesin as a tumor suppressor gene has been revealed by genomic and 
clinical analysis, but its link with leukaemogenesis is still undermined. The majority 
of the cohesin mutations in myeloid malignancies such as MDS and AML are 
heterozygous mutations and are mutually exclusive. 
Here, in-vitro analysis was performed to delineate the role of cohesin complex in 
leukaemic progression by silencing STAG2; a subunit of the cohesin complex in 
myeloid and urinary bladder cell lines.  
STAG2 is a gene located on X chromosome and  majority of the mutations are 
nonsense mutations resulting in a truncated protein. U-937 is a malignant cell line 
that was derived first from a pleural effusion of 37 year old Caucasian male with 
diffuse histiocytic lymphoma. It is one of the only few human cell lines still 
expressing many of the monocytic like characteristics exhibited by cells of histiocytic 
origin.  
In order to determine the effects of STAG2 downregulation, we used siRNA from 
Dharmacon and transfected cell samples were collected at various timepoints. Using 
qRT-PCR, maximum silencing was achieved at 24hr timepoint, with 67% 
reduction. Expression levels of STAG1, a paralog of STAG2 involved in telomere 
replication was also evaluated as previous reports have indicated compensatory 
elevation of STAG1 upon knockdown of STAG2. However, no increase in the 
expression level of STAG1 was observed upon knockdown of STAG2 as confirmed 
by qRT-PCR. In order to increase the knockdown efficiency and authenticity of 
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knockdown, another siRNA from Santa Cruz was used. However, there was no 
increase in knockdown efficiency or increase in the level of STAG1 expression. Cell 
cycle samples collected upto 96hr also did not show any significant difference 
between the STAG2 knockdown and control samples.  
A connection between cohesin mutations and cell cycle irregularities has been 
investigated by various groups including work done by Mazumdar et al where the 
role of cohesin mutations was studied in the differentiation and self renewal of 
human haematopoietic stem and progenitor cells  (HSPCs). The group engineered 
human erythroid and AML cell lines to express wildtype or mutant cohesin 
(including missense and nonsense mutations) in all four cohesin components under 
the control of doxycycline -inducible promoter and found no significant changes in 
proliferation or cell death upon knockdown of cohesin sub-units (Mazumdar et al., 
2015). The lack of discernible phenotype is supported by other studies 
demonstrating that during metaphase only a very small fraction of cohesin is 
required to hold the sister chromatids together and as knockdown of STAG2 was not 
100% in our analysis, the residual STAG2 was sufficient to hold sister chromatids 
together and  as such no effect on cell cycle was observed. Also study carried out by 
Kim et al has shown that STAG2 is not involved in ring formation (Kim et al., 
2016). 
The transient nature of siRNA knockdown could be one of the reasons behind the 
results obtained from cell cycle and potentially could be resolved by generating a 
stable knockdown cell line. Unsuccessful attempts to generate a stable knockdown 
cell line using the retroviral expression vectors prompted the application of 
lentiviral mediated knockdown of STAG2. Two pre-designed shRNAs from 
Addgene were used which gave a knockdown efficiency of 72 and 76% that was 
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confirmed at the mRNA level by qRT-PCR and protein level by western blotting. 
Expression levels of other core cohesin subunits was also determined by western 
blotting. No changes in the expression level of other members of the cohesin 
complex were observed upon shRNA knockdown of STAG2. Work done by Bailey 
et al in two glioblastoma cell lines, with an inherent defect in STAG2 also 
demonstrated no increase in the expression level of other cohesin components in 
STAG2 mutated cell lines, further supporting my data (Bailey et al., 2013). 
Conventional chemotherapeutics agents cannot differentiate between the normal 
and cancerous cells resulting in the death of both. Up until now, targeted therapy 
that is selective for the malignant clone has been an unachievable target, however 
the advent of targeted therapeutics in clinical use illustrates the enormous potential 
of this approach. The concept of synthetic lethality originates from work in 
Drosophila where a combination of mutations in two genes is deleterious for the 
cell in contrast to mutations in one gene which restores viability. Changes in the 
genetic makeup of cancer cells has been delineated by a large number of studies 
that make them a target for synthetic lethality approaches. Synthetic lethality 
induced by PARPi has given a renewed enthusiasm since its application in breast 
cancer susceptibility BRCA1 and BRCA2 mutated cancers to develop anticancer 
agents that can target cancer cells while sparing normal tissues (Bryant et al., 2005, 
Farmer et al., 2005). Although different underlying mechanisms have been 
proposed they are mostly attributed to critical functions of PARP in variety of DNA 
processes including as a sensor of single strand breaks (SSBs) in base excision 
repair (BER), acting as a mediator to restart stalled replication forks through HR 
mediated double strand break (DSB) repair and preventing binding of Ku to DNA 
ends in non homologous end joining (NHEJ) (Bryant et al., 2009, Haince et al., 
 191 
2008, Paddock et al., 2011). Double strand DNA damage within the cell is repaired 
by two different pathways, error free homologous recombination (HR) pathway and 
the error prone NHEJ pathway. HR pathway predominates in mid-S and mid-G2 
phase where a sister chromatid is available. Helicases and endonucleases carry out 
extensive resection generating long stretches of ssDNA and interaction of various 
proteins i.e. ATM, MRE11, CtiP, BRCA1 and BRCA2 play an important role in 
repair. One of the most important proteins involved in DSB DNA repair is the 
recombinase RAD51, which forms a nucleofilament on ssDNA that drives strand 
exchange with a homologous template strand. As cohesin is involved in DNA 
damage repair, we hypothesized that cohesin i.e. STAG2 may be involved in HR 
repair and hence treatment with PARPi in the background of STAG2 silencing could 
result in increased cytotoxicity and cell death and the establishment of synthetic 
lethality between STAG2 and PARP.  This hypothesis was supported by work done 
by Gaymes et al who showed that leukaemic cell lines were sensitive to PARPi, PJ-
34, KU-58948 (now known as Olaparib), and EB47. The cell cycle profile of P-39 
showed an increase in number of cells in S phase and G2/M phase indicative of 
stalled replication and increased DNA damage. Immunocytochemical analysis 
showed that the cell lines, P-39, Mutz-3 and primary cells from two AML patients 
showed increased ϒH2AXP foci and decreased RAD51 foci as compare to resistant 
cell lines and primary AML patients suggesting that the sensitivity to PARPi was 
due to a defect in Homologous Recombination in these cells (Gaymes et al., 2009). 
BMN-673 (Talazoparib), a highly potent PARPi was used in my analysis. With an 
IC50 value of 0.57nM it significantly inhibits H2O2-elicited PAR synthesis in vitro 
(Wang et al., 2016).The high potency of BMN673 is perhaps due to its PARP  
trapping capacity at SSB sites. STAG2 knockdown cells treated with the inhibitor 
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showed an increase in ϒH2AXP foci as compared to control but recruitment of 
RAD51 to areas of DNA damage could also be observed. This result suggests that 
STAG2 is not involved in homologous recombination pathway i.e. recruitment of 
RAD51. Studies have also shown that other factors can be responsible for 
suppression of homologous genes and can indirectly confer sensitivity to PARP 
inhibitors. A study carried out by Esposito et al demonstrated that sensitivity of 
repressive transcriptional factors like AML1-ETO (encoded by the fusion oncogene 
RUNX1-RUNX1T1) and PML-RARα fusion oncoproteins (encoded by PML-
RARA) to PARPi is  due to  suppression of homologous repair genes and inhibition 
of recruitment of RAD51 however overexpression of Hoxa9 results in loss of 
sensitivity incontrast tO mixed lineage leukaemia (MLL) which are resistant to 
PARPi is due to Hoxa9 and inhibition of Hoxa9 rescues this phenomena and 
confers MLL sensitivity to PARPi (Esposito et al., 2015). 
The effect of STAG2 knockdown on viability was studied by exposing cells to 
100nM of BMN-673 for 12 days. The knockdown cells treated with 100nM BMN-
673 showed significant decrease in cell count compared to control cells by trypan 
blue exclusion assay but no dead cells were observed during counting. One of the 
reasons for low cell count can be attributed to the fact that treated cells unlike 
untreated require more time to repair the damaged caused by PARP inhibitors hence 
resulting  in slow proliferation and accounting for low cell count 
Cell cycle kinetics was performed on STAG2 silenced U-937 that were exposed 
continuously to PARPi for 12 days. No significant difference in the percentage of 
cells in each phase of the cell cycle was observed. This result is in contrast to results 
obtained by Bailey et al where treatment of glioblastoma cell lines over a wide 
range of olaparib concentration showed a significant decrease in cell count as 
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compared to their knock in counterparts. Treatment of STAG2 mutated cells with 
olaparib showed accumulation of cells in G2 phase, increase in micronuclei, 
chromatin bridges (Bailey et al., 2013). This discrepancy might be due to the fact 
that the shRNA knockdown of U-937 did not result in complete loss of STAG2 
protein in my study in contrast to work done by Bailey et al where both the cell 
lines had complete loss of STAG2 expression. In my study, the residual STAG2 
could be sufficient enough to hold the sister chromatids together as a result of 
which no synthetic lethality was observed between STAG2 and PARPi. In a recent 
study, comparison of karyotypic analysis of c-Kit+ progenitor cells in 
Rad21(shRNA/+) Smc1a(shRNA/+) and Stag2 (shRNA/+) animals demonstrated no gross 
chromosomal instability. The report supported my observation by the fact that 
despite efficient knockdown of Rad21, Smc1a or Stag2, the remaining protein will 
be sufficient to form a functional cohesin complex (Mullenders et al., 2015). 
 UMUC3 is an adherent urinary bladder cell line. It has a single base deletion that 
creates a nonsense mutation at position K983X. This cell line was chosen as it had 
no expression of STAG2.  Loss of STAG2 had no effect on the expression level of 
other subunits of the cohesin complex nor upregulation of STAG1. Treatment with 
100nM of PARPi BMN-673 resulted in increase in phosphorylation of histone 
variant ϒH2A.X at Ser 139. Although recruitment of RAD51 was observed foci 
formation was decreased as compared to STAG2 knockdown U-937 cell line. 
UMUC3 cell line exposed to 100nM PARPi for 12 days showed significant lower 
cell count as compared to untreated UMUC3 as well as treated MCF-7 cell line 
used as a control however decrease in cell number was not accompanied by cell 
death. The observed effect could be due to the fact that treated cells unlike untreated 
cells take more time to repair the damaged caused by the inhibitor than and hence 
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account for slower proliferation while different genetic background  between 
UMUC3 cell line (adherent urinary bladder cell line) and MCF-7 cell line (adherent 
breast cancer cell line) could be the reason for the effect observed between them. 
No effect on cell cycle was observed on treatment of UMUC3 cell line with two 
different concentrations of PARPi for 12 days which was supported by Annexin V 
results. No sensitivity to PARPi was observed in UMUC3 cell line despite having 
no expression of STAG2. The results obtained from UMUC3 adherent cell line as 
well as those obtained from STAG2 silenced U-937 myeloid cell line convey that 
STAG2 in such a setting is not involved in HR pathway and further loss of STAG2 
does not contribute towards sensitivity to PARPi. 
To enhance the cytotoxicity of PARPi BMN-673 UMUC3 cell line was treated with 
DNA damaging agents cisplatin and Aurora Kinase B inhibitor. Cisplatin is a 
chemotherapy drug which is the first member of platinum containing anti-cancer 
agents. Cisplatin binds to DNA causing the DNA strands to cross link which 
ultimately results in cell death. Regulation of cell cycle transit from G2 through 
cytokinesis is regulated by Aurora Kinases. The scattered mitotic spindles formed 
due to mutant Aurora kinase have become a target for anti cancer drug 
development. No enhancement in cytoxicity was observed on combined treatment 
of BMN-673 with cisplatin and aurora kinase B inhibitor.  
Cohesin complex has many roles in different pathways and DNA damage repair is 
among one of them. It can be hypothesized that mutations in cohesin complex can 
indirectly contribute to synthetic lethality by disregulating the function of a large 
number of genes involved in various other pathways like transcriptional regulation 
against which inhibitors can be designed. This can be supported by a study, which 
opened up the intriguing possibility that IDH1/2 mutations contribute to 
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leukemogenesis not only through epigenetic changes but also through dysregulation 
of mithochondrial function where mutations in IDH1/IDH2 result in sensitivity to 
anti-apoptotic genes like BCL. The mechanism behind this sensitivity was the 
accumulation of 2-hydroxyglutarate due to IDH1/IDH2 mutations that inhibits 
enzymatic activity of complex IV of the mitochondria and prevents mitochondrial 
proapoptotic BCL-2 family members BAX and BAF to cause apoptosis by binding 
to BCL2. However inhibition of BCL2 by ABT-199 inhibitor prevents this 
interaction and lead to apoptosis (Chan et al., 2015).  
Recent studies carried out by four different groups have strongly pointed towards a 
dominant and highly specific role of cohesin in regulating cell fate decisions in 
HSCs. The studies provide a solid platform to understand the role of cohesin 
mutations in myeloid malignancies.  
Mazumdar et al showed that introduction of cohesin mutations in an erythoid (TF-
1) and AML cell line (THP-1) and primary cord blood HSPC resulted in 
differentiation block. A similar feature was seen with knockdown of RAD21 both in 
vivo and in vitro. Mutant cohesin lead to increased chromatin accessibility and a 
higher predicted binding at transcription factor binding sites to GATA2, ERG and 
RUNX1 (critical regulators of HSPCs). Knockdown of these transcription factors 
reverted the differentiation block induced by cohesin mutants. The cohesin mutants 
were also shown to impart its differentiation block only on the immature HSCs and 
MPPs (Multi potent progenitors) (Mazumdar et al., 2015).  
Mullenders et al generated a series of shRNA silencing models in which 
endogenous cohesin could be inducibly reduced. The authors showed that silencing 
of cohesin complex members did not have a deleterious effect on cell viability. 
However, an increase in serial cell plating was observed in mouse bone marrow 
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haematopoietic progenitor cells. In vivo, cohesin knockdown had an effect on 
myelopoiesis and homeostasis. Furthermore, knockdown of Stag2 showed an 
increase in chromatin accessibility around genes that were found to be upregulated 
in STAG2 knockdown cells such as Fc- ϒ receptor (Fcgr3, and Fcgr4) and decrease 
in chromatin accessibility around genes that were found to be downregulated such 
as CD74. Increase accessibility in GATA1 locus in Stag2 knockdown LSK cells 
was found. Finally, an aged mouse showed varying degrees of splenomegaly, 
myeloid hyperplasia and promoted a clinical picture consistent with 
myeloproliferative neoplasm (MPN) (Mullenders et al., 2015). 
  
A conditional expression model of SMC3 in vivo was created to delineate the role of 
SMC3 in haematopoietic function. The study showed a dose dependent requirement 
of SMC3 in haematopoiesis. Biallelic loss of SMC3 lead to 100% lethality, whilst 
heterozygous loss of SMC3 tilted the balance towards self-renewal rather than 
lineage commitment. The authors concluded that cohesin mutations were associated 
with gene regulation and transcriptional output of hematopoietic cells rather than 
chromosomal instability. SMC3 haploinsufficient cells also showed an increased 
capacity of serial replating and competitive advantage in bone marrow transplants 
in agreement with an enhancement of self renewal. The transcriptome of SMC3 
haploinsufficient mice showed a downregulation of certain genes such as Pou2af1 
and Gfi1b that are involved in lineage committed cells. Smc3 monoallelic deletion 
cooperated with FLT3-ITD mutation to induce AML in vivo, thus indicating the 
potentiation of Stat5 signalling and increased expression of Stat5 targets. There was 
also a preponderance of multifocal nucleoli seen in Smc3Δ/+/Flt3ITD which 
resembled the nucleolar alteration seen in Roberts syndrome, a cohesinopathy 
caused by mutation in ESCO2 that inactivates an acetyl transferase required to form 
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the cohesive structures. The authors also speculated that leukemogenesis arising due 
to cohesin complex mutations in in addition to disrupted transcription regulation 
may also arise due to defective protein synthesis as Robert syndrome nuclei also 
show disrupted ribosomal RNA expression and ribosome biogenesis (Viny et al 
2015). Galeev et al made use of a genome wide RNAi screen and found members 
of the cohesin complex (SMC3, RAD21, STAG2 and STAG1) among the top 20 
genes whose knockdown maintained the HSC phenotype in culture.  STAG2 
knockdown in vivo showed decreased differentiation and myeloid skewing as 
determined by an increase in CD33/CD15-positive cells. Knockdown of SMC3 
despite showing an increase in undifferentiated cells in vitro failed to demonstrate a 
skewing towards the myeloid lineage despite an increase in engraftment in vivo. 
Although several of the observed effects in cohesin knockdown models showed 
signs of myeloid neoplasms, any signs of malignant diseases in either primary or 
secondary transplanted mice were absent indicating that cohesin deficiency alone 
cannot trigger leukaemia. A number of HSC related genes that have a role in HSC 
regulation were identified in the gene expression profiling for STAG2 or SMC3 and 
included ERG, EGR1, KLF5 and SOCS2.  (Galeev et al., 2016).  
In conclusion work carried out here demonstrate that STAG2 is not involved in HR 
which has been demonstrated in the background setting of two cell line with 
minimal and complete loss of expression of STAG2. Further loss of STAG2 did not 
sensitize cells to PARP inhibitor BMN-673 and also to cisplatin and aurora kinase 
B inhibitor. Recent studies show that mutations in cohesin complex which includes 
STAG2 as well contribute to leukaemogenesis through dysregulation of chromatin 
architecture thereby strengthening its role as a gene regulator or else like IDH1/2 
mutations STAG2 mutations may also confer senstivity to inhibitors by affecting 
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genes involved in other pathways. Such genes need to be identified and inhibitors  

































The landscape of MDS is characterized by aberrations in genes involved in various 
signalling pathway that contribute towards pathogenesis of MDS. Mutations in the 
cohesin complex particularly STAG2 a major component of the cohesin complex has 
been found in 5-15% of MDS cases. Mutations have also been identified in SMC1A, 
SMC3, RAD21 besides various other regulatory subunits. 
Although cohesin mutations tend to occur in myeloid malignancies the exact 
mechanism through which they contribute towards MDS is not clear. Chromosomal 
instability (CIN) is one of the hallmarks of human neoplasms. Despite its widespread 
prevalence, knowledge of the mechanisms and contributions of CIN in cancer has 
been elusive. Earlier studies associated cohesin mutations with chromosomal 
instability and aneuploidy however since then a significant number of publications 
disregard any association between cohesin mutations and aneuploidy and in fact most 
of the aberrations in cohesin mutant tumors are found to be euploid. p53 is considered 
as a marker for chromosomal instability and in concordance with several published 
reports in this study none of the patients with cohesin mutations has a p53 mutation 
and five out of nine patients has normal cytogenetics thus disregarding any 
association with chromosomal instability. 
Most of the mutations in cohesin complex are nonsense and missense mutations. Due 
to the essential role of cohesin complex in sister chromatid cohesion (SCC) complete 
loss of cohesin has been proven to be incompatible with proliferation and cell survival 
and hence all aberrations are found to be monoallelic and never caused by a complete 
loss or multiple heterozygous mutations. Similar alteration in genotypic architecture 
caused by cohesin mutations is reported in my study. Majority of the mutations in my 
cohort are nonsense mutations and none of the cohesin mutations are found to co-exist 
together. The genes coding for SMC1A and STAG2 are located on X chromosome and 
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are expected to have a stronger impact as no wild type is present however it has been 
reported that very little cohesin is required to hold the sister chromatids together due 
to which no effect on proliferation has been reported which is also evident from my 
study as transient as well as stable knockdown of STAG2 has no effect on cell cycle 
kinetics as knockdown is not completely 100%. 
Existence of genetically divergent subclones is a common feature of haematological 
malignancies. Less fit subclones tend to diminish with disease progression and only 
fit subclone dominate or various subclones can persist along with the dominant clones 
and aid in disease progression.  In this study mutations in cohesin complex are found 
to coexist with mutations in epigenetic modifier ASXL1 and splicesome components 
SRSF2. Although cohesin mutations have been reported to occur as subclones in the 
setting of co-occuring genetic and molecular abnormalities like ASXL1 and key 
transcriptional regulators like (RUNX1, Ras family genes) this phenomenon could not 
be determined here as samples from patients were available only at the time of 
diagnosis and no follow up samples could be obtained however studies carried out 
have shown that in an individual setting mutations in ASXL1 and cohesin genes, alter 
expression of Hoxa cluster and as cancer is a disease where mutations in genes 
involved in various pathways co-operate towards leukaemogenesis it can be 
speculated that both ASXL1 and cohesin mutations in their altered state mutually co-
operate to alter the functions of Hoxa gene cluster and hence contribute towards 
cancer progression (Abdel-Wahab et al., 2012, Fisher et al., 2016). Mutations in 
members of the cohesin complex have been found to co-exist with mutation in 
spliceosome component SF3B1. A study carried out demonstrated that mutations in 
splicesome component SF3B1 resulted in missplicing of cohesin components and 
result in nonsense mediated decay linking this with my study it can be postulated that 
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mutation in SRSF2 can result in missplicing of cohesin subunits and result in non-
sense mediated decay however the loss of expression of cohesin subunits could not be 
confirmed at mRNA or protein level due to lack of viable cells from these patients 
(Sundaramoorthy et al., 2014) 
Apart from holding the sister chromatids together cohesin is involved in various other 
functions due to its ability to form loops. Cohesin complex along with CTCF is 
responsible for maintenance of genomic architecture by forming tandem associated 
domains (TAD). Five of the mutations in STAG2 are found in region were STAG2 
interacts with CTCF and loss of this interaction may have an effect on genomic 
architecture. 
Mutations in cohesin complex are linked with various developmental disorders 
collectively called as cohesinopathies. The underlying etiology of these disorders are 
different while Cornelia de Lange Syndrome is caused by alteration in gene 
expression Roberts syndrome is a consequence of defective biogenesis. In this study 
one of the missense mutation found in SMC1A in one of the patient has been 
associated with Cornelia de Lange Syndrome. The mutation has been shown to impair 
intra or intermolecular approximation of the SMC head domains or disrupt binding of 
accessory proteins to the cohesin ring which can ultimately lead to developmental 
disorder (Deardorff et al., 2007). 
The concept of synthetic lethality has been exploited to develop therapeutic agents 
that are specific for the maladaptive genetic changes in the cancer cell. The 
development of PARP inhibitors has accelerated rapidly after patients with heavily 
treated BRCA1 and BRCA2 mutations showed efficacy and feasibility to PARP 
inhibitors. In order to determine if STAG2 has a role in HR a stable knockdown of 
STAG2 was established in U-937 myeloid cell line using two shRNA and treated with 
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100nM of PARPi BMN-673 for 24hr. No effect on recruitment of RAD21 (a 
recombinase and a key marker of HR) has been observed leading to conclusion that 
STAG2 is not involved in HR or the residual STAG2 (as knockdown is not 100%) is 
be sufficient for effective HR. No effect on expression of other members of the 
cohesin complex, cell cycle, cell viability, and apoptosis is observed. The phenotypic 
effect of STAG2 is also confirmed in a urinary bladder cancer line UMUC3 that 
despite having no expression of STAG2 still shows similar functional characteristics. 
A recent study has reported that STAG2 is not involved in the formation of ring and 
absence of STAG2 does not affect the ring formation ability this could be one of the 
reasons for the observed phenotype. Synthetic lethality has been observed between 
PARP and STAG2 in glioblastoma cell line and also between cohesin and replication 
fork mediators. Lack of synthetic lethality between PARP and STAG2 in my study 
can be a cell specific effect as these studies were carried out in glioblastoma and 
cervical cancer cell line. Further no enhancement in cytotoxicity was observed in 
UMUC3 cell line with combinatorial effect of BMN-673 with cisplatin and aurora 
kinase B. It can also be possible that cohesin mutations in a myeloid setting contribute 
towards leukaemogenesis by altering the expression of genes involved in various 
pathways that need to be identified and inhibitors need to be designed against them. 
Four studies undertaken to delineate the functional role of cohesin in murine and 
human haemopoiesis have all shown a similar pattern of preservation of immature 
phenotype of HSCs, impaired or delayed differentiation and skewing towards a 
myeloid lineage as well as deregulated gene expression pattern commonly associated 
with a preserved HSC phenotype and reduced activation of lineage specific 
programme. All these studies pointed out towards alteration in the cis regulatory 
chromatin architecture affecting gene transcription as the primary driver of cohesin 
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deficient architecture. Development of these mouse models will aid in understanding 
the molecular etiology of this complex and its role in human malignancies (Galeev et 
al., 2016, Mazumdar et al., 2015, Mullenders et al., 2015, Viny et al., 2015). 
Although mice models have been created for both mitotic and meiotic specific 
counterparts of cohesin but homozygous deletions of mitotic counterparts is lethal as 
compare to heterozygous knockout mice that shows variable phenotypes. Mutations in 
one copy of RAD21, SMC1α or SMC3 have been associated with cohesinopathies. 
The lethal phenotype of homozygous knockout mice as compared to heterozygous 
mice is presumed to be due to rampant aneuploidy that is incompatible with survival. 
Homozygous knockout of meiotic specific counterparts of cohesin SMC1β, Rad21L, 
REC8 and SA3 are found to be sterile while haploinsufficiency of these counterparts 
has not been reported.  
Elucidation of the role of cohesin especially STAG2 in myeloid malignancies and its 
































































Role of cohesin especially STAG2 in myeloid malignancies raises many questions 
which can be addressed in future studies. Some of which are 
 
Introduction of cohesin mutations found in MDS patients in umblical cord blood cells 
and studying the effect of mutations on various HSC compartments, cell cycle 
kinetics and  cell viability. 
  
Creating a conditional knockout murine model of STAG2 and then determining the 
effect of PARP inhibitors on various haematopoietic stem cell compartments. Further 
conduct a gene expression profiling study on these cells to study changes in gene 
regulation. 
 
Introduce SRSF2 hotspot mutations in a myeloid cell line and study its effect on 
splicing of STAG2. 
 
Study the interaction between CTCF and STAG2 in knockdown cells using recent 
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         Sequence of primers for STAG2, SMC1A, SMC3 and RAD21 


















































































































































































































































shRNA 1 ccactgatgtcttaccgaaatctcgagatttcggtaagacatcagtggt 
shRNA 2 gcagttcttacagctttgtttctcgagaaacaaagctgtaagaactgct 
